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ABSTRACT 
 
NATHAN ALLAN STASKO: Synthesis and Characterization of Dendrimer-Based 
Nitric Oxide Delivery Vehicles 
(Under the direction of Mark H. Schoenfisch) 
 
 
Nitric oxide (NO) has garnered much attention as a therapeutic due to its multifaceted 
role in human physiology.  However, NO is a highly reactive radical, making its chemical 
storage and controlled release extremely challenging.  Although several small molecule NO 
donors have been reported in the literature, the limited NO storage and the inability to target 
NO to a specific site of action have seriously hindered the clinical utility of NO donors.  To 
address these limitations, my research has focused on the synthesis of macromolecular NO-
releasing dendrimers that store large quantities of NO (1–5 µmol NO/mg).  Herein, the 
synthesis and characterization of two systems are presented employing the two most common 
small molecule NO donors: N-bound diazeniumdiolates and S-nitrosothiols.  Decomposition 
of the diazeniumdiolate NO donor was proton initiated under aqueous conditions with the 
NO release being highly influenced by the local dendritic environment.   S-nitrosothiol 
dendrimer conjugates were subject to decomposition by various triggers of NO release (e.g., 
copper and light) and also shown to directly transfer NO to proteins via transnitrosation.  The 
systems described in this thesis represent two of the highest NO-releasing nanoparticle NO 
donors reported to date.  Additionally, studies investigating the cytotoxicity of 
multifunctional dendrimer conjugates and the physiological activity of dendrimer derived 
nitric oxide are presented. 
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Chapter 1 
Macromolecular Nitric Oxide Delivery Systems 
 
1.1 Introduction 
Nitric oxide (NO), a simple diatomic free radical synthesized by the human body, has vast 
potential as a therapeutic agent in medicine.  Since Ignarro, Furchogtt, and Murad’s Nobel 
Prize winning discovery that NO is the vascular endothelial derived relaxation factor 
(VEDRF), an extensive number of physiological pathways that utilize NO and/or are 
regulated by NO have been discovered.1-5  The list of bioregulatory processes includes 
vasodilation,4, 6 angiogenesis,7, 8 neurotransmission,9, 10 macrophage destruction of foreign 
pathogens,11 gastrointestinal motility,12 and muscle contractility.13, 14  Endogenously, NO is 
produced by the enzyme nitric oxide synthase (NOS) which catalyzes the conversion of 
bioavailable L-arginine to L-citrulline and NO.15, 16  Three forms of NOS exist, including the 
two constitutive endothelial (eNOS) and neuronal (nNOS) enzymes, and the inducible 
(iNOS) enzyme which responds to physiological stimuli and produces NO according to 
demand. 17, 18  
Due to its integral role in human physiology, deficiencies in NO biosynthesis or the 
overproduction of NO have been linked to a number of disease states ranging from 
Parkinson’s disease to cancer.19-22 Thus, the pharmacological regulation of NO synthesis has 
become a major target of drug discovery.  Significant strides have been made toward 
developing lead compounds that modulate NOS activity as therapies to mediate disease 
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progression.23, 24  In some cases, utilizing the cellular machinery for NO production is 
insufficient, and higher, more prolonged doses of NO are required.  In response, small-
molecule NO donors have been synthesized.  These compounds effectively store and release 
NO according to donor specific stimuli.  N-bound diazeniumdiolates, S-nitrosothiols, organic 
nitrates, hydroxylamine, and transition metal complexes are representative classes of the NO 
donors recently reviewed (Figure 1.1).5, 25, 26  These synthetic NO-releasing compounds have 
been used to unravel some of the mysteries of NO in physiology and proposed as potential 
therapeutics for disease states requiring NO therapy.  Numerous reports have detailed the 
therapeutic efficacy of NO donors, including their toxicity toward cancerous cells,27, 28 broad 
spectrum antimicrobial activity,29-32 cardioprotective effects during ischemia/reperfusion 
injury,33-35 and use as anti-thrombotic agents.36-41   
Despite the promising therapeutic potential of “small-molecule NO donors,” the inability 
to carefully modulate NO-release at a specific site of action and the rapid systemic clearance 
associated with small drug molecules have seriously hindered the clinical development of 
NO-releasing therapeutics.  In response, macromolecular NO storage and delivery systems 
have been devised to obtain highly tunable NO-release scaffolds and expand the areas for NO 
treatment.  These macromolecules focus on the “delivery” of NO to sites of need and aim to 
eliminate the problems associated with poor biodistribution, limited solubility, lack of tissue 
specific targeting, and undesirable small-molecule NO donor toxicity.  In this Introduction 
chapter, I will set the stage for my research by reviewing the field of NO-releasing 
macromolecules.  Specifically, two classes of NO donor chemistry will be reviewed: N-
diazeniumdiolate and S-nitrosothiol conjugates.  The syntheses of the macromolecular NO 
donors is discussed as it pertains to storing NO.  Obvious challenges arise when preparing 
NO donor conjugates with macromolecular properties due to environmentally sensitive NO 
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donor structures.  For example, the NO-release properties of the macromolecular NO donors 
may exhibit different behaviors than the analogous small molecule NO donors.  A number of 
macromolecular scaffolds have been employed to date including proteins, polymeric 
matrices, and inorganic nanoparticles all of that have led to the evolution of next-generation 
NO-releasing devices. 
1.2 N-Diazeniumdiolate Modified Macromolecules 
1.2.1 Diazeniumdiolate formation and nitric oxide release characteristics 
Diazeniumdiolate NO donors, first reported by Drago and Paulik in the 1960’s, are 
formed via the reaction of amines with high pressures (5 atm) of NO.42, 43  As shown in 
Scheme 1.1, a nucleophilic amine substrate attacks the uncharacteristically electrophilic 
nitrogen atom of NO and the resulting radical species reacts rapidly with an additional NO to 
form a zwitterionic intermediate.  Efficient diazeniumdiolate formation requires the presence 
of a second basic residue, either an unreacted amine substrate or in recent synthetic 
procedures an added alkoxide base to deprotonate the backbone amine forming the stable N-
diazeniumdiolate structure.  Secondary amine substrates are preferred due to the enhanced 
electron density at the backbone nitrogen.  Nevertheless, primary amine adducts have also 
been reported (e.g., isopropylamine diazeniumdiolate, IPA/NO).44  The cation stabilized 
products are particularly attractive as NO donors because they dissociate spontaneously 
under physiological conditions (i.e., 37°C, pH 7.4) to yield two moles of NO per mole of NO 
donor.25  The proton initiated decomposition has been demonstrated to exhibit first-order 
exponential decay for small molecule alkyl secondary amine diazeniumdiolates with rates 
governed by the pH of the solution.45  Keefer and coworkers have reported the synthesis and 
characterization of a multitude of small molecule diazeniumdiolates whereby NO release 
rates are governed by the chemical structure of the amine precursor.25, 45, 46  For example, 
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diazeniumdiolate derivatives of polyamines like diethylenetriamine, DETA/NO, exhibit 
lengthy durations of NO release with a half-life (t1/2) approaching 60 h.  In contrast, the 
diazeniumdiolate adduct of the amino acid proline, PROLI/NO, has a t1/2 of only 5 s.46   
The formation of carcinogenic nitrosamines on the amine backbone following NO 
release47 has hindered the development of diazeniumdiolate NO donors as successful drug 
formulations. In addition to backbone toxicity, the lack of specificity of NO release has 
warranted the creation of macromolecular NO donors that covalently immobilize 
diazeniumdiolates to release NO more locally (at the site of action).  
1.2.2 Polymeric diazeniumdiolate delivery vehicles 
Following the discovery that NO was involved in blood pressure regulation and 
vasodilation, the concept of macromolecules capable of NO release was born via 
incorporating small molecule NO donors into polymeric matrices.  Medical devices coated 
such anti-thrombotic polymers were hypothesized to improve a device’s thromboresistivity 
by reducing platelet adhesion while maintaining device function.48-50  Keefer and co-workers 
have reviewed the three possible methods for incorporating N-diazeniumdiolate NO donors 
into polymers.51  The NO donor may be doped into the polymer matrix, covalently bound to 
the polymer sidechains, or integrated into the polymer backbone.  Each methodology has 
made significant advancements in the field of NO-releasing macromolecules.  Leaching of 
the small molecule diazeniumdiolates from polymer coatings warranted the covalent 
immobilization of the potentially toxic byproducts leading to the synthesis of 
diazeniumdiolate-modified polyethylenimine,52 polyurethane,53, 54 polymethylmethacrylate,55 
silicone rubber,49 and xero-gel56 polymers as scaffolds for NO release.  The capacity for NO 
storage, duration of NO release, and biomedical applications of these polymeric 
macromolecules been reviewed previously.50 
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Organic Nitrates S-nitrosothiols Metal Complexes
N-bound Diazeniumdiolates
(DETA/NO) (PROLI/NO) (MAHMA/NO) 
Figure 1.1  Small-molecule NO donors utilized for discovering the role of NO in 
biology and as therapeutic agents. 
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Scheme 1.1  Formation of N-bound diazeniumdiolate in the presence of NaOMe. 
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Although the majority of the NO-releasing polymers synthesized in the literature have 
been utilized as device coatings, several polymer conjugates have been employed as delivery 
vehicles to release NO in other biomedical areas of unmet need. For example, Pulfer et al. 
incorporated diazeniumdiolated polyethyleneimine microspheres (PEIX/NO) into vascular 
grafts as micron-sized NO storage reservoirs.52  The polyethylenimine microspheres were 
formed using a water-in-oil emulsion and chemically crosslinked via a bis-epoxide.  
Conversion of interior amines to diazeniumdiolates resulted in particles with long NO-release 
half-lives due to the basicity of the local NO donor environment (t1/2 = 66 h).  The 
polydisperse particles (d = 10 – 50 μm) were doped into the pores of Gore-tex vascular grafts 
with a yield of 10 nmol NO/mg graft material. The PEI was also modified with fluorescein 
isothiocyanate (FITC) to allow particle leaching studies from the Gore-tex grafts.  Of note, 
leaching was not observed following NO release and the PEIX/NO microspheres proved 
effective at preventing thrombosis in small diameter prosthetic grafts.  This work represents 
the genesis of NO-releasing particle therapeutics.  Zhou et al. employed a similar strategy 
with amine-modified water-soluble polyethylenimine conjugates to improve the NO-storage 
capacity (up to 4.15 μmol NO/mg) while maintaining the large macromolecular size for use 
in hemodialysis experiments.57  The PEI derivatives remained in the dialysate solution while 
the NO evolved was able to diffuse across the membrane reducing platelet adhesion and the 
risk of thrombosis in the dialysis unit. 
The concept of micron-sized diazeniumdiolate delivery vehicles was expanded by Jeh et 
al. who reported the encapsulation of PROLI/NO in biodegradable microparticles.58  As 
described previously, PROLI/NO decomposes rapidly under aqueous conditions.  Proline is a 
particularly attractive NO donor precursor due to the biocompatibility of the amino acid 
metabolite following NO release.  Indeed, the nitrosamine adduct of proline had negligible 
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toxicity.47  Delivery of NO to the alveolar region of the lungs requires both biocompatibility 
of the NO donor and biodegradability of the delivery vehicle.  Encapsulation of PROLI/NO 
via polyethylene oxide-co-lactic acid (PELA) by double emulsion and solvent evaporation, 
followed by freeze-drying, led to PELA/NO microparticles capable of releasing 123 nmol 
NO/mg (t1/2 = 4.1 min), extending the duration of NO release from PROLI/NO into time 
scales applicable for inhalation therapy.  Of note, poly-lactic-co-glycolic acid (PLGA) 
required the addition of gelatin to the emulsion conditions resulting in PLGA/NO particles 
too large for inhalation therapy (d = 23.5 um).  Although PELA/NO and PLGA/NO delivery 
vehicles possessed the necessary biodegradability, both were characterized by limited 
PROLI/NO encapsulation efficiency (∼50%).  
1.2.3 Proteins 
Since diazeniumdiolate complexes decompose spontaneously at physiological pH, their 
administration in vivo present undesirable side effects at NO-sensitive sites throughout the 
body.  Major challenges exist in both targeting NO to a specific site so that it will affect only 
that target, and in attaching diazeniumdiolates to delivery vehicles that will increase their 
retention in blood (i.e., biodistribution). By taking advantage of the reactivity of the 
diazeniumdiolate functionality, several strategies for preparing tissue-selective drugs have 
been proposed.  For example, the terminal oxygen (O2) of the diazeniumdiolates have been 
protected with environmentally labile protecting groups
 
and are thus referred to as being O2-
protected.59 This “prodrug” approach allows the diazeniumdiolate to move freely throughout 
the circulatory system without spontaneous dissociation until reaching a “site” of interest.  
Vinylated-diazeniumdiolates store NO until passing through the liver where epoxidation and 
hydrolysis of the diazeniumdiolate to NO occurs via catalysis by cytochrome P450 
enzymes.60
 
Further studies on O2-protected diazeniumdiolates have resulted in esterase-
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sensitive NO donors that exhibit in vitro antileukemic activity and peptide diazeniumdiolates 
that are specifically metabolized by prostate specific antigen and may prove useful for the 
selective treatment of prostate cancer.61
 
Unfortunately, the small molecule diazeniumdiolates 
used in these studies have no barrier to renal clearance when administered systemically and 
produce potentially carcinogenic byproducts that have circumvented their clinical 
application.  
Hrabie et al. utilized the pro-drug approach to attach a methoxy methylether (MOM)-
protected piperazine diazeniumdiolate to bovine serum albumin (BSA) (Figure 1.2).62, 63  
Representing the first diazeniumdiolate derivatized protein, the PIPERAZI/NO-BSA 
conjugate possessed an extremely long half life of NO-release (56 h) due to the stability of 
the MOM protecting group that hydrolyzes slowly even under acidic conditions.  The 
derivatization of BSA provides proof-of-concept for “pre-packaging” diazeniumdiolate NO 
donors and attaching them to biologically relevant drug delivery vehicles.  Recent 
improvements in O2-protection chemistries may be utilized in combination with the emerging 
techniques in nanotechnology to result in highly specialized NO-releasing medicines via 
diazeniumdiolate chemistry.47, 64 
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BSA
Lysine Linker MOM-PIPERAZI/NO
Bovine Serum Albumin
Figure 1.2  Diazeniumdiolate-modified bovine serum albumin (BSA) prepared 
from an O2-methoxymethyl-protected diazeniumdiolated piperazine. 
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1.2.4 Nanoparticle-derived diazeniumdiolate NO-donors 
Based on their unique size-dependent physical and chemical properties, nanoparticles 
have the potential to revolutionize the field of medicine.65-69 
 
Indeed, nanoscale materials 
have been under development for a number of biological and medical applications including 
drug and gene delivery,70, 71
 
fluorescent biological labels,26, 72, 73 
 
pathogen and protein 
detectors,74, 75 
 
DNA structure probes,76 
 
tissue engineering,77, 78 and MRI contrast agents.79  
Over the past several years, a number of diazeniumdiolate-modified nanoparticles have been 
created in the Schoenfisch Lab utilizing the drug delivery advantages of nanoparticles to fully 
harness the power of NO.
 
1.2.4.1 Monolayer protected gold clusters 
Monolayer protected gold clusters (MPCs) may represent the most widely studied 
nanoparticles to date.  The synthesis of MPCs ( d = 1 – 5 nm) was first reported by Brust 
using alkanethiol protecting ligands surrounding a 2 nm gold core.80 Since this report, several 
classes of gold MPC nanoparticles have been synthesized with a variety of stabilizing 
ligands, allowing for tunable physical properties and multiple functionalization options.65, 81 
 
As such, MPCs have obvious utility for drug delivery applications.82 
 
Their dense gold core 
allows for simple imaging with transmission electron microscopy (TEM), thus providing a 
built-in method for monitoring their cellular uptake.83, 84 
Rothrock et al. synthesized the first reported nanoparticle-sized diazeniumdiolate 
modified MPC via gold-thiolate chemistry.85   Hydrogen tetrachloroaurate salt was reacted with 
hexanethiol in the presence of sodium borohydride followed by functionalization with bromo-
terminated alkanethiols via the place exchange method.86, 87 
 
The bromine-functionalized gold 
nanoparticles were dissolved in toluene or methylene chloride and reacted with ethylenediamine, 
butylamine, hexanediamine, or diethylenetriamine as NO donor precursors. Transmission 
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electron microscopy images confirmed the core diameter of the nanoparticles to be 2.1 ± 0.9 nm 
with constant size regardless of amine derivatization or diazeniumdiolate formation.  The NO 
release for diazeniumdiolate-modified gold nanoparticles was tunable by varying the number 
and/or the chemical structure of the substituted amine ligands. Increasing the concentration of 
ethylenediamine ligand from 14 to 21%, led to a corresponding increase in total NO (t[NO]) (9.8 
to 19.3 nmol NO/mg MPC) and t
1/2 
(from 15 to 78 min). Increasing the length of the alkyl chain 
separating the amines from two to six methylene units led to an increase in the total amount of 
NO released (19.3 to 87.0 nmol NO/mg MPC for ethylenediamine- and hexanediamine-modified 
MPCs, respectively), but a decrease in the half-life, suggesting a NO release/diazeniumdiolate 
structure relationship. The modest NO release was attributed to inefficient conversion of the 
amine precursors to diazeniumdiolates.  The low NO storage capacity and limited aqueous 
solubility thus restricts the use of alkanethiol MPCs as NO delivery vehicles for 
pharmaceutical applications. 
Polizzi et al. expanded the previous work to impart water solubility and increase the NO-
storage of the gold MPCs.88 Tiopronin-stabilized MPCs89 (d ~3 nm) were functionalized with 
polyamine ligands containing 1, 3, or 4 secondary amine sizes for conversion to 
diazeniumdiolates.  Despite their aqueous solubility, proton-initiated decomposition of the 
diazeniumdiolate-modified polyamine Tio-MPCs resulted in only modest NO-release (0.023 
μmol/mg) for short durations (<1.5 h). To increase the NO storage capacity of gold 
nanoparticles, the tiopronin linker was removed and the polyamines were used to stabilize 
gold clusters via a strategy reported by Schulz-Dobrick et al.90  The polyamine-MPCs (d ~5 
nm) exhibited significantly enhanced NO storage capacity following diazeniumdiolate 
formation (up to 0.386 μmol/mg) with NO release durations exceeding 16 h. The MPCs 
represent the smallest water-soluble NO-releasing nanoparticles to date (d = 3 – 5 nm).  
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Additionally, the polyamine-protected MPCs present a multivalent surface for use in 
subsequent delivery efforts. Functionalization of the nanoparticle exteriors with ligands for 
tissue-specific targeting or molecular probes for imaging may further facilitate the use of 
NO-releasing polyamine-protected MPCs for a wide range of pharmacological applications.  
1.2.4.2 Silica nanospheres 
The use of polyamines to store diazeniumdiolate NO donors originated from the early 
work by Hrabie et al. that demonstrated tunable properties of NO release based on the 
number of amines on the donor backbone as well as the distance between them.45, 46  The 
kinetic differences in rates of NO release observed when using diamines as NO donor 
precursors has been utilized extensively by Schoenfisch and co-workers who have 
synthesized a variety of NO-releasing xerogel films via sol-gel chemistry.56  The 
polymerization of aminoalkoxysilanes (e.g., N-(6-aminohexyl)-3-
aminopropyltrimethoxysilane, AHAP3) with alkylalkoxysilanes (isobutyltrimethoxysilane, 
BTMOS) results in optically transparent films that store and release variable quantities of NO 
based on the type and percentage of aminoalkoxysilane polymerized in the network.  Using a 
similar strategy, Meyerhoff and co-workers reported the synthesis of fumed silica particles 
with aminoalkoxysilanes grafted on the surface as substrates for diazeniumdiolate formation 
(200-300 nm).91      As with the xerogel films, the storage and release of NO were mediated 
by the type of aminosilane grafted.  For example, surface grafted silica particles prepared via 
this method released up to 0.56 μmol NO/mg with a t1/2 = 43 min prepared with pendant 
hexane diamine structure (i.e., Sil-2N[6]-N2O2Na).91 These NO-releasing silica particles 
were initially employed as fillers for preparing NO-releasing polyurethane extracorporeal 
circuits.91  It was further shown that the resulting NO-releasing fumed silica particles could 
be embedded into polymer films to create thromboresistant coatings via the release of NO at 
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fluxes that mimic healthy endothelial cells (EC). For example, a silicone rubber coating 
containing 20 wt% Sil-2N[6]-N2O2Na improved the surface thromboresistivity (compared to 
controls) when used to coat the inner walls of extracorporeal circuits (ECC) employed in a 
rabbit model for extracorporeal blood circulation. 
The NO-releasing silica particles prepared by Zhang et al. solved the previous problem of 
NO-donor backbone leaching from hydrophobic polymer films through the creation of 
macromolecules embedded in the polymer matrix.  The aminosilane-grafted fumed silica also 
released up to several hundred nmol NO/mg, a substantial reservoir for NO exceeding most 
other diazeniumdiolate-modified macromolecular scaffolds reported in the literature.  
However, these larger particles (d = 200-300 nm) only contained diazeniumdiolates grafted 
to the surface, hindering the storage capacity of the entire scaffold.  Shin et al. improved the 
NO-storage on silica particles through direct co-condensation of aminoalkoxysilane and 
alkoxysilanes to uniformly distribute the NO-donor precursors throughout the entire silica 
network.92 The amine functional groups in the silica structure were then converted to 
diazeniumdiolate NO donors via exposure to high pressures of NO (5 atm, 3 d) under basic 
conditions.  The selection of the silane precursors (e.g., type and concentration) and specific 
reaction/processing conditions (e.g., solvent, catalyst, pH, and temperature) allowed for 
tremendous chemical flexibility in creating nanoparticles of diverse sizes and NO release 
properties (e.g., NO payload and kinetics). Changing the aminosilane functionality altered a 
range of NO release characteristics including the total amount of NO released (t[NO]), half-
life of NO release (t1/2), and the maximum value of NO release ([NO]m). 92  The NO 
“payload” and corresponding release rates were easily tuned by varying both the percent 
composition and/or structure of the aminosilane used to prepare nanoparticles.  The variety of 
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NO-releasing nanoparticles available enables a “toolbox” from which to select the desired 
NO-release characteristics for developing anti-infective/wound healing products.  
Another advantage of the silane co-condensation process was the ability to control the 
size of the silica nanoparticle by varying the type and concentration of aminoalkoxysilane 
used.  This property is of incredible importance for the systemic delivery and biodistribution 
of nanoparticle devices.  The drug delivery potential of silica has received a great deal of 
attention because of its non-toxic nature and tunable size and porosity.93, 94.  Indeed, 
mesoporous silica nanoparticles, prepared from silicon dioxide, have been explored 
extensively as carrier systems for drugs,95-99 biocides,100-102 genes,103 and proteins.104, 105 
Recently, Shin et al. reported the synthesis of inorganic/organic hybrid silicia nanoparticles 
whereby the aminoalkoxysilanes are first modified as N-diazeniumdiolates and then co-
condensed with the alkoxysilane backbone in the presence of an ammonia catalyst to form 
NO-releasing silica nanoparticles with unprecedented storage capacity.106  Loading the NO 
donor before nanoparticle synthesis allowed for the incorporation of higher aminosilane 
percentages (10-75 mol%) increasing the diazeniumdiolate storage efficiency.  A range of 
aminosilanes have been employed to synthesize NO delivery silica scaffolds with remarkably 
improved NO storage and release properties, surpassing all macromolecular NO donor 
systems reported to date with respect to NO payload (11.26 μmol NO/mg), maximum NO 
release (357 ppm NO/mg), NO release half-life (253 min), and NO release duration (101 
h).106 
1.3 S-Nitrosothiol Macromolecular NO Donor Systems 
1.3.1 S-nitrosothiol formation and NO-release characteristics 
In contrast to exogenously administered diazeniumdiolates, S-nitrosothiols (RSNO) are 
the endogenous transporters of NO and form the basis of a number of NO signaling 
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cascades.2  It is well known that free NO inhibits platelet aggregation via a guanylyl-cyclase 
dependent mechanism36 but the entire mechanism by which RSNO signaling occurs is more 
complex.107  Transnitrosation, or transfer of the nitroso functional group from a nitrosothiol 
donor to a free thiol, provides a mechanism for direct cellular communication with membrane 
bound proteins.108-111  S-nitrosoglutathione (GSNO), formed either via the reaction of 
glutathione with N2O3 or through a host of redox mechanisms involving metabolites of NO 
and transition metal centers, has shown the capacity to regulate several biological processes 
including vasodilation, platelet activation, neurotransmission, and tissue inflammation.108, 112, 
113  Nitrosated cysteine residues on albumin and other serum proteins account for a large 
portion of the 1.8 μM nitrosothiol concentration in blood, as protein RSNO carriers have 
improved stability compared to low molecular weight thiol derivatives.114, 115 
Aside from the absence/presence of nitrosothiol versus diazeniumdiolate NO donors in 
physiology, several other properties clearly differentiate the two classes of NO donors.  
These properties are summarized in Table 1.1.  Diazeniumdiolate NO donors undergo proton 
initiated NO-release under aqueous conditions.  In contrast, S-nitrosothiols require an added 
trigger to spontaneously generate NO (Figure 1.3). For example, copper intiates RSNO 
decomposition via the Cu+/Cu2+ redox couple or through copper containing enzymatic metal 
centers. Trace thiolate anion in solution reduces Cu2+ to Cu+ which subsequently reduces 
RSNO compounds to initiate NO release.108, 116, 117   Photoinitiated NO-release is another 
well-characterized mechanism of RSNO decomposition.118  Irradiation of RSNO donors 
results in homolytic cleavage of the S-N bond to yield NO and a thiyl radical in a process that 
is approximately first-order.118  Electron paramagnetic resonance spectra of spin-trapped 
thiyl radicals have been reported as concrete evidence for the photo-triggered homolysis of 
the S-N bond.119  The synthetic procedures required for NO donor formation are also quite 
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different.  Diazeniumdiolates are formed on amines under basic conditions and high 
pressures of NO, whereby S-nitrosothiols are formed on thiols in acidified solutions of 
sodium nitrite or through organic nitrite donors.120  The photolytic and thermal stabilities, 
formation conditions, and environmental factors governing NO release must all be 
considered when selecting an appropriate NO donor for a desired biological application.   
Nitrosothiols can also be made synthetically through the conversion of free thiols in 
acidified sodium nitrite solutions to the corresponding S-nitrosothiols.  Donors including S-
nitroso-N-acetyl-DL-penicillamine (SNAP) synthesized via this method have been employed 
as tools to better understand the many complicated roles of NO in regulatory biology.  Their 
activity as anti-platelet agents,36-41 toxicity toward cancerous cells,27, 28 broad spectrum 
antimicrobial activity,29-32 and protective effects in a number of cardiovascular applications 
have garnered nitrosothiol NO donors widespread recognition.33-35  Despite the promising 
therapeutic potential of nitrosothiols, analogous to diazenimdiolate compounds, the inability 
to target NO to a specific site of action and the rapid systemic clearance associated with 
small drug molecules has seriously hindered the clinical development of nitrosothiol 
therapeutics.  Similar to innovations made with N-diazeniumdiolates, a number of 
macromolecular drug delivery vehicles have been developed to circumnavigate the 
challenges associated with successful RSNO-based drugs. 
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Table 1.1 Comparison of N-diazeniumdiolate and S-nitrosothiol NO donors. 
Basic, 
high pressures of NO 
 
 
 
H3O+ 
 
 
Limited (store at -20 °C) 
 
 
 
Highly tunable based on 
pH and lipophilicity 
 
 
 
Yes, 
carcinogenic nitrosamines 
 
 
Yes 
 
 
2 mol NO / mol 2° amine 
 
 
No 
 
 
 
Exogenous 
Formation Conditions 
 
 
 
 
Decomposition Triggers 
 
 
Thermal stability 
 
 
 
NO-release kinetics 
 
 
 
 
Toxicity of Metabolites  
 
 
 
Charged 
 
 
Storage Capacity 
 
 
Light Sensitive 
 
 
 
Nature 
Acidic or 
nitrosative conditions 
 
 
 
Light, Cu2+, thiols 
 
 
Limited (store at -20 °C) 
 
 
 
Dependent on 
Trigger Concentration 
 
 
 
None 
 
 
 
No 
 
 
1 mol NO / mol thiol 
 
 
Yes 
 
 
 
Endogenous 
N-diazeniumdiolates S-nitrosothiols 
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S-nitroso-glutathione 
(GSNO) 
Synthetic Physiological 
RSH + NaNO2 + HCl
MeOH RSNO + NaCl + H2O 
Synthetic
Physiological
N2O3 + GSH GSNO + NO2- + H+
2NO  +  O2 2NO2
. .
+
NO N2O3
Figure 1.3 Representative structures for synthetic and physiological NO donors 
and their pathways for nitrosothiol formation. 
S-nitroso-N-acetylpenacillamine 
(SNAP) 
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Figure 1.4 Mechanisms of S-nitrosothiol decomposition. 
RSNO
RSSR + NO•
RS• NO•
Direct Effects
RSH + NO•
hν R'SH
R'SNO + RSH
Cu+ Cu2+
R'SH
R'SSR + NO-
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1.3.2 Protein-based RSNO delivery vehicles 
Due to the physiological occurrence of protein-SNO adducts, protein-based nitrosothiol 
delivery vehicles have been extensively explored as a strategy to extend the systemic half-
lives of exogenous RSNO donors and to aid in the treatment of circulation disorders.121-124 
Katsumi et al. reacted bovine serum albumin (BSA) with acidified nitrite to yield BSA-NO 
adducts possessing ∼0.2 mol SNO/mol BSA with molecular weights near 67 kDa.122  
Nitrosation caused reversible changes in protein secondary structure and the modifications 
were not confined to cysteine residues as the number of modified amino groups also 
increased with increasing nitrosation conditions (i.e., nitrosamine formation).  When 
administered intravenously to a rat at a dose of 100 mg/kg, BSA-NO induced a transient 
decrease in arterial blood pressure for 3 min and exhibited biodistribution properties similar 
to unmodified BSA.122  Realizing the need for higher NO storage per unit of protein and 
prolonged NO release particularly when injected systemically,  Hashida and co-workers 
synthesized PEG-polySNO-BSA conjugates capable of storing 10 mol NO/mol protein 
delivery vehicle (250 kDa) with half-lives of NO release 11 times longer than unpegylated 
BSA-NO and 108 times longer than small molecule SNAP.123  The use of PEG chains 
decreased the aggregation of proteins formed during the synthesis of previous BSA-NO 
constructs121, 124 and provided added thermal stability to the NO donors through “cage 
effects” reported previously by de Oliveira and co-workers.125 Furthermore, the PEG 
microenvironment created a more compact solution structure increasing the frequency of 
geminate radical pair recombination following thermal decomposition and thus, slowing the 
rates of NO release at room temperature.  As a result of the enhanced stability, the pegylated 
BSA-NO adduct prolonged the decrease in mean arterial blood pressure when compared to 
BSA-NO and classical small molecule NO donors (e.g., SNAP, GSNO). 
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Serum albumin-RSNO conjugates have been recently expanded to include human serum 
albumin (HSA).  Ishima et al. nitrosated a genetic variant of HSA (R410C) possessing an 
additional free cysteine at position 410 to yield 1.25 mol SNO/mol protein.126  Protein 
aggregation was not observed during synthesis and lyophilization, and R410C-SNO had 
excellent physicochemical stability with an approximate half-life of 20.4 min in a mouse.  In 
addition to the cytoprotective effects observed in hepatic ischemia/reperfusion experiments, 
potent bactericidal activity was observed for the nitrosated protein.  The concentration of 
R410C-SNO required reducing cell viability to 50% (IC50) of Salmonella typhimurium was 
0.6 µM compared to the 3300 µM dose required with the GSNO small molecule.  These 
findings suggest that protein-based macromolecular delivery vehicles for nitrosothiols may 
afford unexpected biological activity due to their ability to interact preferentially with 
membrane proteins or other cellular targets for RSNO action. The authors also noted that 
Cys-410 in HSA is surrounded by acidic (Glu) and basic (Lys) residues which may constitute 
the acid-base motif necessary for formation, stability, and reactivity of protein-bound RSNO 
groups suggested by Stamler and colleagues.127  Mechanistic interactions between 
nitrosothiols and other blood proteins (e.g., hemoglobin (Hb)) are currently being explored 
and will likely lead to stabilized structural and functional analogues (e.g., HbSNO) that serve 
as NO sources in the absence of red blood cells.128-134 
1.3.3 Polymeric S-nitrosothiol conjugates 
The documented effects of nitrosothiols on preventing platelet adhesion/aggregation and 
the early stages of thrombus formation have led to the creation of nitrosothiol-modified 
polymers as macromolecular delivery vehicles of NO, similar to diazeniumdiolate based NO 
donors.  A number of hydrogels and liquid/solid polymeric matrices have been developed 
that stabilize small-molecule nitrosothiols and deliver NO at controlled rates for topical drug 
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delivery135-138 and metallic device coatings.139 However, doping nitrosothiols into polymeric 
materials faces two main limitations: 1) the solubility of the NO donor in the polymer matrix 
limits the vehicle’s NO storage capacity; and, 2) diffusion of the donor into tissue is 
uncontrollable if the NO donor is water-soluble and not covalently bound to the polymer 
backbone.138 
 Several polymer conjugates containing covalently immobilized nitrosothiols have been 
synthesized to overcome these limitations and deliver nitrosothiols more effectively for 
cardiovascular and topical wound healing applications.  Duan et al. modified polyurethane 
(PU) and polyethylene terephthalate (PET) polymers to contain cysteine residues as 
precursors for NO storage via RSNOs.140  The polymer backbones were aminated with 
aminopropyltrimethoxysilane or ethylendiamine (PU and PET, respectively), reacted with 
glutaraldehyde to form the Schiffs base, and incubated in buffered cysteine solutions to 
covalently attach the amino acid RSNO precursor.  The surfaces were converted to S-
nitrosothiols following exposure to solutions of BSA-NO with the auspice that these 
polymers could serve as stable reservoirs for NO once implanted into the body after contact 
with the ∼2 μM concentrations of BSA-NO in the blood.  Indeed, the cysteine-modified 
polymers rapidly decreased BSA-NO levels in solution via transnitrosation.  In separate 
experiments, CysNO modified surfaces were capable of reducing platelet aggregation >50% 
compared to glycine modified control PU and PET.  Cysteine incorporation at 5 – 8 
nmol/cm2 was sufficient to provide haemocompatibility in vitro and the delivery of NO via 
transnitrosation from BSA-NO was a novel concept for NO donor formation on surfaces.140 
West and co-workers developed a method to covalently immobilize S-nitrosocysteine 
(CysNO) in photo-polymerized hydrogels as a vehicle for the local delivery of NO after 
lifesaving cardiovascular procedures such as angioplasty and stenting.141  S-nitrosothiols that 
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spontaneously generate NO at the site of vascular injury have been demonstrated to aid in the 
prevention of neointima formation and restenosis.142  The N-hydroxysuccinimide ester of 
poly(ethylene glycol) monoacrylate was coupled to the free amines of cysteine residues and 
converted to PEG-CysNO with an acidified nitrite solution.  The PEG-CysNO were photo-
polymerized with a PEG-diacrylate in aqueous solutions containing 2,2-dimethoxy-2-
phenylacetophenone as a long wavelength photoinitiator of polymerization (solubilized via 
0.15% N-vinyl pyrrolidone).141  The RSNO-loaded hydrogels were formed in the 
perivascular space of a rat heart and delivered NO with a half-life of several hours post–
surgery.  Histological analysis two weeks later revealed significant attenuation of wall 
thickening in arteries treated with the NO-releasing hydrogels. 142   
1.3.4 Surface-grafted silica 
Covalent attachment of nitrosothiols directly into poly(ethylene glycol) hydrogels and 
polyesters that possess amorphous structures has been successful for topical NO delivery.138, 
141, 142  However, this strategy may not be accessible for all biomedical grade polymers 
requiring a high level of structural uniformity for medical device fabrication.  Alterations to 
the polymer backbone may change the chemical and mechanical properties (e.g., solubility, 
hardness, water uptake, permeability) and consequently result in the re-evaluation of these 
parameters and/or poor device performance.  An alternative approach is the incorporation of 
macromoleculear NO donors into the already well-known biomedical grade polymer 
compositions.  Previously, Meyerhoff and co-workers employed diazeniumdiolate-modified 
silica particles as polymer fillers that release NO and increase the biocompatibility of 
silicone rubber and poly(urethane).91  Frost et al. also utilized fumed silica as a scaffold for 
S-nitrosothiol modification creating macromolecular-doped polymers capable of releasing 
NO rapidly when exposed to light.143, 144 In a typical synthesis, the free silanol groups on the 
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surface of the fumed silica were modified with (3-aminopropyl)trimethoxysilane and the 
newly formed amine functionalities were reacted with the self-protected thiolactone of N-
acetyl-DL-penicillamine (NAP).  The thiol-derivatized surface was subsequently converted to 
the corresponding S-nitroso-N-acetyl-DL-penicillamine (SNAP-FS) by reaction with tert-
butylnitrite. These derivatized fumed silica nanoparticles stored 0.138 μmol NO/mg with NO 
release rates precisely controlled through the duration and the intensity of the light used to 
initiate NO release. 
The nanoparticles (d = 7 – 10 nm) served as large reservoirs of NO when incorporated 
into trilayer silicone rubber polymer films, effectively immobilizing the nitrosothiols inside a 
device coating without the leaching issues associated with small molecule dopants.  
Localizing NO release at the polymer/biological sample interface and maintaining photo-
triggered control over the NO-release rates may enable fundamental studies on the minimum 
surface fluxes required to inhibit platelet and bacterial adhesion.  Additionally, the light 
initiated release of NO from nanoparticle devices opens the gateway to utilizing NO as a 
therapeutic in photodynamic therapy treatments of cancerous cells.  Frost et al. proposed 
incorporating the SNAP-FS particles into silicone rubber material at the end of a fiber optic 
probe for direct insertion into a tumor mass.  Upon illumination of the fiber, NO would be 
released in controllable doses based on the duration, intensity, and wavelength of light.144  
Future work enabling the synthesis of nitrosothiol-modified silica in combination with 
photosensitizers used in typical photodynamic therapy treatments145 may lead to devices 
capable of releasing NO with the longer wavelengths of light necessary for effective tissue 
penetration.146 
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1.4 Inorganic/organic Hybrid Systems and Photo-triggered Nitric Oxide Donors 
Since the first report by Rothrock et al. of NO-releasing nanoparticles synthesized from 
diazeniumdiolate-modified gold cores,85 several other inorganic/organic hybrid nanoparticles 
have been synthesized to store and release NO.  These systems do not employ 
diazeniumdiolate or nitrosothiol chemistry but are excellent examples of recent 
advancements in materials science that may lead to the next generation of NO-releasing 
devices.  Morris and co-workers created transition metal-exchanged zeolites that store up to 1 
μmol NO/mg.147  The NO was adsorbed both reversibly or irreversibly to the zeolite 
scaffolds through physisorption or chemisorption.  Water was used as a nucleophile to 
displace the irreversibly adsorbed NO (t1/2 = 340 s of NO-release).  Experiments with human 
platelets confirmed that NO released from cobalt-exchanged zeolite-A reduced platelet 
activation and aggregation illustrating the anti-thrombotic potential of the NO-loaded xeolite 
scaffold.147   Furthermore, the kinetics of NO-release were tunable by controlling the amount 
of water contacting the zeolite through incorporation into mixtures of powdered 
poly(tetrafluoroethylene) (PTFE) or poly(dimethylsiloxane) (PDMS).  Pressed disks made 
from the powdered mixtures resulted in increased half-lives of 509 s and 3076 s (PTFE and 
PDMS, respectively), demonstrating control over NO-release fluxes from the disc surface 
albeit at the expense of NO storage capacity.147  Similar gas adsorption experiments were 
carried out on copper benzene tricarboxylate metal-organic frameworks, HKUST-1.148 The 
metal framework had a large adsorption capacity for NO at 298 K (1 bar), 3 μmol NO/mg, 
but the quantities released when exposed to aqueous physiological conditions plateaued at ∼1 
nmol NO/mg.  Despite the inability to recover all of the adsorbed NO, these low levels of NO 
release were sufficient to reduce platelet aggregation in platelet rich plasma.148 
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Water is a simple trigger that initiates NO release from diazeniumdiolates and zeolite 
complexes, but recent studies have explored using light as a stimulant for site-selective NO 
release from inorganic macromolecules.  As described above, photo-triggered NO release 
provides an attractive avenue for using NO in the photodynamic therapy of cancerous tissue 
and other areas of medicine requiring localized NO therapy.  Caruso et al. reported the 
synthesis of monolayer-protected platinum nanoparticles capable of delivering NO upon 
exposure to visible light (λmax = 386 nm). 149 Water soluble, carboxy-terminated platinum 
nanoparticles were partially modified with a thiol derivatized photoactive NO donor through 
a phase-exchange reaction to yield MPCs containing 6 flutamide derivatives per platinum 
cluster (ca. 1 nm).  Photolysis of the nitroaromatic anticancer drug flutamide leads nitro-to-
nitrite photo-rearrangement followed by rupture of the O-N bond to generate a phenoxy 
radical and NO.150  The platinum MPCs exhibited an on/off triggered release profile 
dependent on the light source with a release rate of 1.5 pmol s-1.   
The phototriggered release of NO from transition metal nitrosyl and nitrito complexes 
incorporated into stable matrix formulations have also been pursued as light-responsive NO 
donors.151-153  Due to low extinction coefficients and absorption maxima residing in the UV-
visible range, metal complexes have seen little utility for in vivo biomedical applications.  
For example, trans-Cr(cyclam)(ONO)2+ (cyclam = 1,4,8,11-tetraazacyclotetradecane) is 
photoactive toward cleavage of the CrO-NO bond to release NO, but the dinitrito complex is 
weakly absorbing at near-UV and visible wavelengths.  Recently, Neuman et al. reported the 
use of CdSe/ZnS core/shell quantum dots as antennas to harness light energy and promote 
electron transfer to the NO donor precursor to initiate NO release.154  Quantum dots were 
prepared by a three-step procedure involving synthesis of the CdSe cores, growth of the ZnS 
shell, and surface ligand exchange with dihydrolipoic acid to impart water solubility. 
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Formation of an electrostatic assembly between the cationic trans-Cr(cyclam)(ONO)2+ 
complex with the negatively charged quantum dot surface resulted in particles with an 
average CdSe core diameter of 3.8 nm.  Excitation with a Hg arc lamp (320-390 nm band-
pass filter) resulted in much faster NO release in the presence of the quantum dot antennas 
than photolysis of the metallic complex alone, indicating indirect photosensitization of the 
chromium complex to spontaneously release NO.   
The works reported by Neuman and Caruso bring the field of nanomedicine one step 
closer to utilizing photoactive transition-metal-based prodrugs for NO delivery.149, 154  
Quantum dots and platinum MPCs hold considerable promise as site-specific agents for the 
photochemical delivery of NO because their surface ligands may be utilized to tether 
additional functionalities to the nanoparticle surface.  These modifications may alter vehicle 
solubility as well as impart specificity to the photo-initiated NO prodrug carrier.  The 
formation of metallic nanoparticles typically yields monodisperse populations but the control 
over ligand coverage and surface modifications can vary widely from batch to batch.  
Scaffolds that have a uniform number of surface groups and less dense core structures may 
result in macromolecular NO donors with enhanced NO storage. 
1.5 Dendrimers as Drug Delivery Vehicles 
The macromolecular NO donors described above have made significant advancements in 
the chemical storage and controlled release of NO for a number of biomedical applications.  
Ultimately, limitations to the quantity of NO on each macromolecular scaffold and the failure 
to deliver NO to a specific cell or tissue of interest has prevented their widespread clinical 
application.5, 26, 155 A particular macromolecular drug delivery scaffold that has received a lot 
of attention in the literature but not yet been integrated with NO donor chemistry is 
dendrimers.  Dendrimers are hyper-branched or “tree-like” polymers that possess precisely 
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defined molecular structures with a multivalent exterior (Figure 1.5). Dendrimers have 
garnered significant attention as a new class of drug delivery vehicles due to their ability to 
achieve high drug payloads per unit of drug carrier.156.  These branched molecules also 
exhibit dynamic solution behavior and adopt globular conformations similar to proteins that 
minimize hydrophobic interactions and separate charge along the dendritic backbone.  A 
number of biocompatible dendrimers have been synthesized based on polyether, 
polyarylether, polyamine, and polypeptide networks.157 The multivalent exterior of 
dendrimers can be used to attach multiple functionalities on one molecular scaffold, making 
them extremely useful for targeting drugs to specific tissue types or for imaging drug 
biodistribution.158  For example, Baker and co-workers have functionalized polyamidoamine 
(PAMAM) dendrimers with multiple copies of the anticancer drug methotrexate, folic acid 
for targeting cancerous tissue, and fluorophores for tracking dendrimer distribution in an 
animal model.159  These multifunctional dendrimer delivery vehicles selectively target 
epithelial cancer in rat animal models with no drug accumulation in healthy tissues.159  
Overall, drug-loaded dendrimers have exhibited enhanced cellular delivery and more rapid 
pharmacological responses than therapeutic agents administered without the hyperbranched 
delivery vehicles.  The improved efficacy of dendrimer-based drugs has lead to their 
widespread application in many areas of bioscience including anti-cancer, antimicrobial, and 
antiviral drug research.156, 157, 160, 161 
1.6 Overview of Dissertation Research 
The goals of my research sought to overcome the obstacles impeding targeted NO 
delivery through the development of NO-releasing dendrimers.  Their highly functionalizable 
exterior and reproducible molecular structure of dendrimers make them attractive as NO 
storage devices.  Commercially available starting materials like polypropylenimine (PPI) and 
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polyamidoamine (PAMAM) dendrimers contain a large number of exterior amine precursors 
which can be modified to then serve as NO donor storage sites (Figure 1.5, 1.6).  The number 
of NO donor precursor sites may be further manipulated by selecting dendrimers with 
different generations of growth.  For example generation 5 dendrimer (DAB-Am-64) has 64 
amines at its exterior compared to just 16 for generation 3 polypropylenimine dendrimer 
(DAB-Am-16).  The capacity to pack a large density of NO donors on a loosely branched 
structure may afford unprecedented storage reservoirs for bioavailable NO.  Extensive 
research has been reported on the derivatization of the amine exteriors with a variety of 
functionalities, ranging from lipophilic groups to enhance the hydrophobicity162, 163 to ligands 
required for targeting dendrimer delivery vehicles to proteins on the surface of cancerous 
cells.159, 164  To date, no chemistry has been elucidated to chemically store NO via either N-
diazeniumdiolate or S-nitrosothiol chemistry on a dendrimer scaffold. The specific aims of 
my research included: 
1) the synthesis and characterization of secondary amine dendrimer conjugates for 
modification with N-diazeniumdiolate NO donors; 
2) the creation of hydrophobic and hydrophilic dendritic exteriors to control 
diazeniumdiolate NO release kinetics; 
3) the successful conjugation of thiols and conversion to S-nitrosothiols on  
polyamidoamine (PAMAM) dendritic scaffolds not amenable to 
diazeniumdiolate chemistry; 
4) the full characterization of nitrosothiol-modified dendrimer NO-release kinetics 
following exposure to copper, light, thermal, ascorbate, and thiol triggered 
mechanisms of decomposition;  
5) the exploration of nitrosothiol modified dendrimers as anti-platelet agents; 
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6) the synthesis of multifunctional dendrimers containing mixed functionalities at 
the dendritic exterior relevant to drug delivery; 
7) the evaluation of dendrimer cytotoxicity in cultured endothelial cells using 
confocal fluorescence microscopy and establishment of a clear structure activity 
relationship between dendrimer surface charge and vehicle toxicity. 
Derivitization to contain the secondary amines necessary for N-diazeniumdiolate 
formation or the thiol groups necessary for conversion to S-nitrosothiols would potentially 
unlock a series of NO-releasing vehicles previously unattained by metallic, ceramic, or 
polymeric macromolecules.  The following chapters explore the synthetic procedures 
necessary to create both diazeniumdiolate- and nitrosothiol-modified dendrimers and fully 
characterize their NO-release properties as a function of the dendritic nanoenvironment. The 
creation of NO-releasing dendrimers presented herein effectively supplements the field of 
NO-releasing macromolecules with a new tool capable of increasing the utility of medical 
device coatings and revolutionizing the efficacy of systemically delivered NO based 
therapeutics. 
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Generation 3 Polypropylenimine Dendrimer 
(DAB-Am-16) 
B 
Generation 1 Polyamidoamine Dendrimer 
(G1 PAMAM) 
A 
Figure 1.5 A) Generation 1 polyamidoamine dendrimer (PAMAM). B) Generation 
3 polypropylenimine dendrimer with a diaminobutane core (DAB) and 
16 surface amines. 
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Generation 5 Polypropylenimine Dendrimer 
(DAB-Am-64) 
Figure 1.6 Generation 5 polypropylenimine dendrimer with a diaminobutane core 
(DAB) and 64 surface amines, illustrating the tremendous storage 
capacity for NO. 
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Chapter 2: 
Diazeniumdiolate-Modified Dendrimers as Scaffolds for Nitric Oxide Release 
 
2.1 Introduction 
Nitric oxide (NO), a diatomic free radical produced in the human body, regulates several 
biological functions in the cardiovascular, respiratory, and nervous systems.1, 2 Nitric oxide is 
also actively involved in the immune system response and mediates macrophage destruction 
of foreign pathogens.3  The complex and wide ranging roles of NO in normal physiological 
function thus demand methods for chemically storing and releasing NO in a controlled 
manner.  Metal complexes, nitrosothiols, nitrosamines, and diazeniumdiolates are all 
examples of molecular structures that have been developed as effective NO donors.4  Such 
“NO donors” facilitate the improved understanding of NO’s function in biological systems 
and may potentially serve as therapeutic agents for a number of disease states.5  
Diazeniumdiolate NO donors are particularly attractive because they dissociate 
spontaneously under physiological conditions (i.e., 37°C, pH 7.4) to yield two moles of NO 
per mole of NO donor.6  N-bound diazeniumdiolates formed from the reaction of amines with 
high pressures of NO were initially reported by Drago and Paulik in the 1960’s.7, 8  The rapid 
discovery of NO’s role in biology has resulted in the resurgence of amine based 
diazeniumdiolate NO donors.  Keefer and coworkers have reported the synthesis and 
characterization of multiple small molecule diazeniumdiolates where NO release rates are 
governed by the chemical structure of the amine precursor.6, 9, 10  For example, 
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diazeniumdiolate derivatives of the polyamine diethylenetriamine (DETA/NO) resulted in 
lengthy durations of NO release with a half-life (t1/2) of 56 h.  In contrast, proli/NO has a t1/2 
of only 5 s.10   
Larger molecular frameworks have also been modified with diazeniumdiolate NO donors 
to produce materials capable of storing large quantities of NO.  Pulfer et al. synthesized 
diazeniumdiolated poly(ethylene imine) microspheres which were embedded into the pores 
of small-diameter prosthetic grafts to prevent thrombosis via the controlled release of NO.11  
Similarly, Meyerhoff and co-workers reported the synthesis of fumed silica particles with 
aminoalkoxysilanes grafted on the surface as substrates for diazeniumdiolate formation.    
The storage of NO was mediated by the type of aminosilane grafted.  The silica particles 
prepared via this method released up to 0.56 μmol NO/mg.12  These NO-releasing silica 
particles were initially employed as fillers for preparing silicone rubber coatings for 
extracorporeal circuits.12  Hrabie et al. synthesized a water soluble macromolecular NO 
donor with a t1/2 of 20 d via covalent attachment of a NO donor piperazine ligand to the 
solvent accessible lysine residues of bovine serum albumin.13  Nitric oxide release was 
initiated via the slow hydrolytic cleavage of the methoxymethyl protecting group.  Proteins 
modified with diazeniumdiolate ligands demonstrate a strategy for increasing the stability 
and systemic half-life of NO donors in vivo. 
  Rothrock et al. reported the synthesis of NO-releasing gold monolayer protected clusters 
(MPCs) through diamine functionalization of bromine thiol ligands followed by subsequent 
amine conversion to diazeniumdiolates.14  Although capable of releasing NO, the NO donor-
modified nanoparticles were characterized by poor amine to diazeniumdiolate conversion 
efficiencies, lack of aqueous solubility, and limited surface functionality.  Such factors 
warrant the development of more efficient, multifunctional nanoparticle NO donor scaffolds.   
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In contrast to gold and silica particles, dendrimers are hyper-branched nanostructures 
possessing a multivalent surface with well defined polymeric structure.15, 16  Dendrimers are 
assembled by one of two general strategies: 1) the divergent method, where repeat monomers 
are branched outward from a central core; or, 2) the convergent method developed by Frechet 
et al.,17 where the synthesis begins at the periphery and grows inward. The resulting 
dendrimer products are monodisperse compared to bulk polymers, and their size (2-20 nm) 
varies with dendrimer type and exterior functionality.18 The structure of a generation 3 
polypropylenimine dendrimer (DAB-Am-16) is shown in Figure 2.1.  Produced via divergent 
synthesis, this dendrimer has become a widely utilized construct due to its multivalent, 
primary amine exterior.16  The multifunctional surface and unique structural properties of 
dendrimers have resulted in their widespread utility as drug delivery agents and medical 
diagnostic tools in the pharmaceutical and nanotechnology industries.18-21  
In this chapter, the development of nanoparticle NO donors that store and release large 
quantities of NO from dendritic scaffolds is described. The primary advantage of NO 
releasing dendrimers over other NO donor systems is the ability to store high concentrations 
of NO on a single molecular framework.  The exterior of NO releasing dendrimers can also 
be manipulated to enable specific functionality (e.g., solubility) producing macromolecular 
NO donors tailored for a desired application.  For example, dendrimer-based NO donors 
possessing lipophilic exteriors may be incorporated into hydrophobic polymers to impart 
thromboresistivity.  Water soluble, hydrophilic dendrimers may allow for the development of 
therapeutic agents capable of delivering NO in vivo.  The synthesis and NO storage capacity 
of several polypropylenimine dendrimer conjugates are presented.  Furthermore, dendritic 
NO release kinetics are explored as a function of dendrimer size, structure of dendrimer 
bound amine precursor, and lipophilicity of the dendritic exterior. 
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2.2 Experimental Section 
2.2.1 General 
All reagents including generation 3 and generation 5 polypropylenimine dendrimers 
(DAB-Am-16 and DAB-Am-64) were purchased from the Aldrich Chemical Company 
(Milwaukee, WI). Methanol was distilled over magnesium prior to use. Water was purified 
with a Millipore Milli-Q gradient A-10 purification system (Bedford, MA).  Spectra/Por® 
Float-A-Lyzers® were purchased from Spectrum Laboratories Inc. (Rancho Dominguez, 
CA). Absorption spectra were recorded on a Perkin Elmer Lambda 40 UV-Vis 
spectrophotometer (Norwalk, CT).  Nuclear magnetic resonance (NMR) spectra were 
collected in CDCl3, CD3OD, or D2O using a 400-MHz Bruker Nuclear Magnetic Resonance 
spectrometer.  Mass spectra were acquired in positive ion mode using a Micromass Quattro 
II triple quadrupole mass spectrometer equipped with a nano-electrospray ionization source.  
Nitric oxide release was measured using a Sievers 280i Chemiluminesce Nitric Oxide 
Analyzer (Boulder, CO).  
2.2.2 Formation of the diazeniumdiolate NO donor 
Parent primary amine dendrimers and the dendrimer conjugates were dissolved in 0.5 M 
NaOMe/MeOH and placed in 5 mL glass vials equipped with a stir bar prior to exposure to 
NO gas.  The vials were placed in a Parr bottle, connected to the NO-reactor, and flushed six 
times with Ar, followed by a series of six longer charge/discharge cycles with Ar (6 x 10 
min) to remove oxygen from the stirring solutions.  The Parr bottle was then filled with 5 atm 
of NO (purified over KOH pellets for 30 min to remove trace NO degradation products) and 
sealed.  After 3 d the NO was expunged using the same Ar procedure described above to 
remove unbound NO from the dendrimer-diazeniumdiolate product solutions. 
2.2.3 Characterization of NO-releasing dendrimers 
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Two methods were employed to characterize the formation of the N-bound 
diazeniumdiolate NO donor species.  First, absorption spectroscopy was used to confirm 
diazeniumdiolate formation.  UV-Vis spectra recorded on a Perkin-Elmer spectrophotometer 
in dilute MeOH solutions displayed the characteristic diazeniumdiolate absorption maximum 
(λmax) between 250-260 nm for diazeniumdiolates in all cases.9  Second, NO released from 
the polypropylenimine dendrimer conjugates was measured upon donor decomposition via 
chemiluminescence.22  Aliquots (10 μL) of the NO exposed dendrimer solution were added 
to 0.01 M phosphate buffered saline (PBS, pH=7.4) at 37 °C to initiate NO release under 
physiological conditions.23 Dendrimer concentrations ranged from 0.2 to 1.0 mM.  The 
chemiluminescence analyzer was calibrated with NO gas (24.1 ppm). A parameter for 
converting the instrument response (ppb) to moles of NO was obtained via the conversion of 
nitrite standards to NO in a 0.1 M KOH/H2SO4 solution (1.19x10-13 moles NO/ppb).  
Chemiluminescence data for the NO-releasing dendrimers were represented in two graphical 
forms or plots: 1) chemiluminescence response in ppb NO/mg dendrimer vs. time; and, 2) the 
total amount of NO-release (t[NO]) vs. time.  The maximum flux of NO release ([NO]m)  and 
the time required to reach that maxima (tm) were obtained from plot 1.  The half-life (t1/2) of 
NO release as well as the t[NO] (μmol NO/mg) can be determined from plot 2. 
2.2.4 Synthesis and characterization of dendrimer conjugates 
2.2.4.1 DAB-C7-16 (3)  (adapted from Pan and Ford24) 
  (A) Heptanoyl chloride (410 mg, 2.75 mmol) was added to a stirring solution of DAB-
Am-16 (200 mg, 0.12 mmol), DMF (5 mL), and triethylamine (343 mg, 3.4 mmol) at 0 °C.  
The ice bath was removed and the solution was stirred under nitrogen at 70 °C for 24 h.  
Water (3.0 mL) was added, the solution was stirred for 10 min and concentrated under 
reduced pressure.  The orange residue was dissolved in CH2Cl2 (20 mL), washed with 1% 
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aqueous K2CO3 (2 x 20 mL), rinsed with brine, dried over K2CO3 and concentrated under 
reduced pressure. 
(B) The residue from procedure A was immediately dissolved in THF (5 mL) and added 
slowly to a stirring suspension of LiAlH4 (10 mmol) in THF (40 mL) under nitrogen at 0 °C.  
The suspension was stirred at reflux for 24 h and transferred slowly into saturated aqueous 
Na2SO4 solution (40 mL) at 5-10 °C.  The THF layer was decanted, and the aqueous layer 
was extracted with ether (3 x 25 mL).  The combined organic phase was washed with 4% 
aqueous K2CO3 (20 mL), dried over K2CO3, and concentrated under reduced pressure.  The 
crude product was purified on an Al2O3 column (80-200 Mesh, Fischer Scientific; 
MeOH/CHCl3, 2:98) to yield 266 mg (63%) of a viscous yellow oil.  1H NMR (CDCl3, δ): 
0.85 (t, CH3), 1.20-1.33 (m, CH2), 1.39-1.72 (m, NCH2CH2CH2N, NCH2CH2CH2), 2.31-2.49 
(m, CH2N(CH2)2), 2.51-2.64 (m, CH2NH). 13C NMR (CDCl3, δ): 13.97 (CH3), 22.42 
(CH2CH3), 24.17 (NCH2CH2CH2N), 28.69 (alkyl CH2), 49.38 (NCH2CH2CH2NH), 51.26 
(NHCH2CH2), 51.7 (NCH2CH2CH2NH), 51.8 (NCH2CH2CH2N). 
2.2.4.2 DAB-C7-64 (4) (adapted from Pan and Ford24) 
(A) Heptanoyl chloride (370 mg, 2.5 mmol) was added to a stirring solution of DAB-Am-
64 (200 mg, 0.028 mmol), DMF (5 mL), and triethylamine (310 mg, 3.1 mmol) at 0 °C.  The 
ice bath was removed and the solution was stirred under nitrogen at 70 °C  for 24 h.  Water 
(3.0 mL) was added, the solution was stirred for 10 min and concentrated under reduced 
pressure.  The dark orange residue was dissolved in CH2Cl2 (20 mL), washed with 1% 
aqueous K2CO3 (2 x 20 mL), rinsed with brine, dried over K2CO3 and concentrated under 
reduced pressure. 
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(B) The residue from procedure A was immediately dissolved in THF (5 mL) and added 
slowly to a stirring suspension of LiAlH4 (10 mmol) in THF (40 mL) under nitrogen at 0 °C.  
The suspension was stirred at reflux for 24 h and transferred slowly into saturated aqueous 
Na2SO4 solution (40 mL) at 5-10 °C.  The THF layer was decanted, and the aqueous layer 
was extracted with ether (3 x 25 mL).  The combined organic phase was washed with 4% 
aqueous K2CO3 (20 mL), dried over K2CO3, and concentrated under reduced pressure.  The 
crude product was purified on an Al2O3 column (80-200 Mesh, Fischer Scientific; 
MeOH/CHCl3, 2:98) to yield 157 mg (42%) of a dark yellow oil.  1H NMR (CDCl3, δ): 0.86 
(t, CH3), 1.19-1.4 (m, CH2), 1.40-1.76 (m, NCH2CH2CH2N, NCH2CH2CH2), 2.30-2.49 (m, 
CH2N(CH2)2), 2.50-2.75 (m, CH2NH). 13C NMR (CDCl3, δ): 14.21 (CH3), 22.69 (CH2CH3), 
24.12 (NCH2CH2CH2N), 30.46 (alkyl CH2), 31.81 (NHCH2CH2), 31.98 (CH2CH2CH3), 
50.92 (CH2CH2NHCH2CH2), 52.41 (NCH2CH2CH2N). 
2.2.4.3 DAB-C16-16 (5) 
(Same procedure as described above for DAB-C7-16 but replacing heptanoyl chloride 
(C7) with palmitoyl chloride (C16) as the acylating reagent. 
2.2.4.4 DAB-PO-64 (6) (adapted from Pantos et al.25) 
280 mg (4.8 mmol) of propylene oxide dissolved in 2 mL of water was added dropwise to 
530 mg (0.074 mmol) of DAB-Am-64 dissolved in 5 mL of water.  The mixture was allowed 
to react for 24 h at room temperature, dialyzed using a Spectra/Por® Float-A-Lyzer® (10 mL, 
5000 MWCO), and lyophilized to yield 305 mg (38%) of an opaque oil. 1H NMR (D2O, δ): 
1.13 (d, NHCH2CH(OH)CH3), 1.27 (t, NCH2CH2CH2CH2N), 1.52-1.74 (m, CH2), 2.33-2.52 
(m, CH2N(CH2)2), 2.54 (t, CH2NHCH2), 2.68 (m, NHCH2CH(OH)CH3), 3.89 (m, 
NHCH2CH(OH)CH3). 13C NMR (CDCl3, δ): 20.47 (NHCH2CH(OH)CH3), 22.13 
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(NCH2CH2CH2CH2N), 23.4 (NCH2CH2CH2N), 25.17 (NCH2CH2CH2NH), 47.1 
(CH2NHCH2CH(OH)CH3), 51.14 (NCH2CH2CH2N), 51.7 (NCH2CH2CH2CH2N),  55.69 
(NHCH2CH(OH)CH3), 65.97 (NHCH2CH(OH)CH3).  MS (ESI) calcd: 10,885.  Found: 
10,537 [1054.7 (M+10H)10+, 980.1 (M+11H)11+]. 
2.2.4.5 DAB-Pro-16 and DAB-Pro-64 (7 and 8) 
(A) 2.565 g (12 mmol) of t-boc-L-proline was dissolved in 30 mL of CH2Cl2 to which 
was added 1.37 g (12 mmol) N-hydroxy succinimide (NHS) and 2.70 g (13 mmol) 
dicyclohexylcarbodiimide (DCC).  The solution was stirred at 0 °C for 24, filtered to 
removed the DCU solid impurity, concentrated under reduced pressure to yield a crude solid.  
The white solid was recrystallized in isopropanol and isolated to yield 3.31 g of NHS-t-boc-
L-proline. 
(B) 0.658g (2.1 mmol) NHS-t-boc-L-proline and 0.293 mL (2.1 mmol)  added to 0.20 g 
(1.9 mmol) of DAB-Am-16 dissolved in 10 mL of CH2Cl2 and stirred for 24 h at room 
temperature.  The solution was washed 3x with H2O, 3x with saturated Na2CO3, dried over 
Na2SO4, and concentrated under reduced pressure to yield a white silky solid.  The white 
solid was immediately dissolved in 4 mL of formic acid and stirred for 16 h at room 
temperature to remove the boc protecting groups.  The formic acid was removed under 
vacuum and the resulting oil was dissolved in 5 mL of H2O, neutralized with 6 M NaOH to 
pH 7, dialyzed in distilled water for 5 d, and lyophilized to yield 15.5 mg of DAB-Pro-16. 
2.2.4.6 DAB-Ac-16 (9) 
Acetic anhydride (340 mg, 3.3 mmol) and triethylamine (370 mg, 3.6 mmol) were added 
to a solution of DAB-Am-16 (290 mg, 0.17 mmol) dissolved in 5 mL of anhydrous MeOH.  
The mixture was stirred for 24 h at room temperature under nitrogen.  The reaction mixture 
was concentrated under reduced pressure and resuspended in 10 mL of ultra pure MilliQ 
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water for dialysis.  The product solution was dialyzed in a Spectra/Por® Float-A-Lyzer® (10 
mL, 1000 MWCO) in 2 L phosphate buffer pH = 8.0 for 24 h.  The buffer was discarded, the 
product solution dialyzed in ultrapure water for 3 d and lyophilized to yield 35 mg (8.5%) of 
a clear solid: 1H NMR (CD3OD, δ): 1.59-1.65 (br, NCH2CH2CH2CH2N), 1.65-1.80 (m, 
NCH2CH2CH2N, NCH2CH2CH2NH), 1.85 (s, CH3), 2.63-2.70 (m, NCH2CH2CH2N), 2.70-
2.79 (m, NCH2CH2CH2NHCO), 3.13 (t, CH2NHCOCH3).  13C NMR (CD3OD, δ):   22.8 
(NHCOCH3), 23.2 (NCH2CH2CH2N), 26.1 (NCH2CH2CH2NHCO), 38.6 (CH2NHCOCH3), 
52.9 (NCH2CH2CH2N), 53.4 (NCH2CH2CH2CH2N),  174 (C=O).  MS (ESI) calcd: 2359.5.  
Found: 2358.9 [1180.4 (M+2H)2+, 787.3 (M+3H)3+, 590.8 (M+4H)4+]. 
2.2.4.5 DAB-Ac-64 (10) 
Acetic anhydride (160 mg, 1.5 mmol) and triethylamine (170 mg, 1.7 mmol) were added 
to a solution of DAB-Am-64 (140 mg, 0.02 mmol) dissolved in 5 mL of anhydrous MeOH.  
The mixture was stirred for 24 h at room temperature under nitrogen.  The reaction mixture 
was then concentrated under reduced pressure and resuspended in 10 mL of ultra pure MilliQ 
water for dialysis.  The product solution was dialyzed in a Spectra/Por® Float-A-Lyzer® (10 
mL, 1000 MWCO) in 2 L phosphate buffer pH = 8.0 for 24 h.  The buffer was discarded, the 
product solution dialyzed in ultrapure water for 3 d, and lyophilized to yield 26 mg (13.1%) 
of a clear sticky solid: 1H NMR (CD3OD, δ): 1.55-1.77 (m, NCH2CH2CH2N, 
NCH2CH2CH2CH2N), 1.86 (s, CH3), 2.47-2.62 (m, NCH2CH2CH2N), 2.66-2.79 (m, 
NCH2CH2CH2NHCO), 3.11 (t, CH2NHCOCH3).  13C NMR (CD3OD, δ):   22.98 
(NHCOCH3), 23.65 (NCH2CH2CH2N), 38.71 (CH2NHCOCH3), 52.5 (NCH2CH2CH2N),  173 
(C=O). MS (ESI) calcd: 9858.75.  Found: 9859 [1233.6 (M+8H)8+, 1096.5 (M+9H)9+, 987.0 
(M+10H)10+]. 
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2.3 Results and Discussion 
2.3.1 Nitric oxide releasing primary amine dendrimers 
Dendrimers provide an attractive scaffold for storing NO because of their multivalent 
exterior.  A dendrimer fully modified with diazeniumdiolates has the potential to store large 
quantities of NO on a single framework, thereby increasing the “payload” of NO per gram of 
substrate.  Previously, polyamines have been shown to convert readily to 
diazeniumdiolates.10  Secondary amines in the polyamine backbone react with NO to form a 
diazeniumdiolate NO donor that is stabilized via neighboring cationic amines.  The 
diazeniumdiolate adduct of diethylenetriamine, a short polyamine, is depicted in Figure 
2.2A.  In addition to increasing the stability of the zwitterionic species, remote amines 
enhance the duration of NO release by providing alternate sites of protonation, thus slowing 
the proton driven dissociation of diazeniumdiolates to NO.9  Polypropylenimine dendrimers 
are large polyamines grown in a divergent fashion, terminated by a multitude of primary 
amines based on the dendrimer generation.  As such, the exterior of a polypropylenimine 
dendrimer has both a large number of nucleophilic amines to react with NO, and a multiple 
of neighboring amine sites for diazeniumdiolate NO donor stabilization (Figure 2.2B).  
Primary amines typically form unstable NO donors and decompose rapidly to NO under 
ambient or aqueous conditions.8  However, the density of primary amines at the exterior and 
the conformational freedom of the dendritic architecture may lead to enhanced 
diazeniumdiolate stability over small molecule primary amine substrates.   
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Figure 2.1  Generation 3 polypropylenimine dendrimer, DAB-Am-16, possessing a 
  diaminobutane core and 16 primary amines where R = H. 
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Figure 2.2 Ammonium cation stabilized diazeniumdiolates: A) diazeniumdiolate 
  of diethylenetriamine, DETA/NO8; and, B) dendrimer bound  
  diazeniumdiolate where n = 8 or 32 (DAB-Am-16 or DAB-Am-64). 
B A 
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Figure 2.3 Real time NO release profiles for 1 (DAB-Am-16) charged in A)  
  MeOH and B) NaOMe/MeOH. 
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Scheme 2.1 Formation of sodium stabilized diazeniumdiolates followed by  
  decomposition under physiological conditions to yield two moles of 
  NO and initial dendrimer conjugate (n=16, 64). 
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To test the ability of primary amine terminated dendrimers to store NO via 
diazeniumdiolate NO donors, generation 3 polypropylenimine dendrimer (DAB-Am-16) was 
selected as an initial substrate for diazeniumdiolate conversion. DAB-Am-16 (1) was 
dissolved in MeOH and exposed to high pressures (5 atm) of NO for 3 d.  Herein, this 
process will be referred to as “charging,” or the introduction of the multiply charged, 
zwitterionic diazeniumdiolate moiety. An aliquot of the charged MeOH solution containing 1 
(200 μM) was added to a reaction flask containing degassed phosphate buffered saline (PBS; 
0.01 M, pH 7.4) and the corresponding NO release was monitored at physiological 
temperature (37 °C) by chemiluminescence.22  Despite an initial burst of NO (Figure 2.3A), 
the polyamine dendrimer failed to yield the lengthy NO release durations of the polyamine 
diazeniumdiolate DETA/NO. 
The conversion efficiency of amine precursor to diazeniumdiolate NO donor was 
calculated to examine the effect of the dendritic structure and amine functionality on NO 
storage capacity.  Assuming the maximum theoretical yield of two moles of NO per one mole 
of amine precursor, the conversion efficiency is defined as the total moles of NO released 
divided by twice the number of dendrimer bound substrate amines (Equation 2.1).  
 
Equation 2.1 
 
The conversion efficiency for 1 exposed to NO under these conditions was poor (<1%).   
Zhang et al. previously reported that the addition of methoxide base during NO exposure 
shifts the reaction equilibrium toward diazeniumdiolate formation by deprotonating the 
amine and stabilizing the diazeniumdiolate via a countercation (e.g., sodium), thereby 
increasing the NO addition efficiency on a macromolecular scaffold.12  Primary amine 
eminamolesx2
releasedNOmolesConversion% =
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dendrimer 1 exposed to NO in 0.5 M NaOMe/MeOH released greater amounts of NO over 
preparation in MeOH alone (Figure 2.3B), with a maximum flux of NO release ([NO]m) of 
6760 ppb/mg.  Control NaOMe/MeOH solutions did not release NO.  Hereafter, all NO 
releasing dendrimer conjugates were prepared under basic conditions as shown in Scheme 
2.1.  
A similar NO release profile was observed for the sodium stabilized primary amine 
diazeniumdiolates of 2 (DAB-Am-64) charged under identical conditions.  As shown in 
Table 2.1, the total NO released (t[NO]) and conversion efficiency were slightly greater for 
DAB-Am-64/NO, suggesting diazeniumdiolate formation in methanolic solution favors the 
larger, more compact globular structure. Also, the abundance of neighboring amine sites on 
the larger dendrimer slowed diazeniumdiolate decomposition, as evidenced by a t1/2 of 29 
min for DAB-Am-64/NO compared to 12 min for the smaller DAB-Am-16/NO. Although 
DAB-Am-16 and DAB-Am-64 primary amine dendrimers released NO at levels similar to 
previously reported macromolecular NO donors,11-13 the conversion efficiencies of the NO 
donor-modified dendrimers were low, failing to harness the anticipated storage capacity 
offered by a dendritic scaffold.  
Studies were also conducted to evaluate whether the dendrimers stored nitroxyl (HNO), 
and the effect of HNO release (in place of NO) on the NO donor conversion efficiencies.  
Nitroxyl has garnered recent attention due to its importance in the pharmacological treatment 
of heart failure.26  Miranda et al. reported that the primary amine diazeniumdiolate adduct of 
isopropylamine (IPA/NO) represents an attractive HNO donor at physiological pH.26  Further 
studies by Dutton et al. have confirmed the pH dependent production of HNO and NO from 
primary amine diazeniumdiolate adducts using computational methods.27  At neutral pH 
(7.4), primary amine adducts are predicted to release HNO, while at lower pH (3), 
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decomposition follows the traditional diazeniumdiolate pathway and generates two 
equivalents of NO.27  Since nitroxyl primary amine adducts release NO at acidic pH, citric 
acid buffer (pH 3) was employed to assess whether HNO formation was responsible for the 
poor NO donor conversion efficiencies observed for DAB-Am-16/NO.  A 67% increase in 
NO was detected at the lower pH, suggesting that HNO is indeed produced.   Studies are 
underway to further quantitate the HNO release from primary amine dendrimer 
diazeniumdiolates and to explore the potential of dendrimers as novel HNO donors.  
2.3.2 Nitric oxide releasing secondary amine dendrimer conjugates 
Secondary amines convert to diazeniumdiolates more readily than primary amines since 
they form more stable adducts.8 The addition of an electron donating substituent, R, serves to 
both enhance the acidity of the amino nitrogen and provide electron density to stabilize the 
zwitterionic diazeniumdiolate product (Scheme 2.2).28  Several secondary amine dendrimer 
conjugates were synthesized to assess the potential for increasing the NO storage on a 
dendritic scaffold.  Modifications to yield both hydrophobic and hydrophilic NO releasing 
dendrimers were explored (Scheme 2.3). 
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Table 2.1 Summary of NO-release properties for dendrimer conjugates 1-10. 
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Scheme 2.2 Mechanism of diazeniumdiolate formation on dendrimer bound amine 
  functionalities under basic conditions.   
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A 
B 
C 
5 (n=16) 
D 
E  9 (n=16
) 
(n=64)
10 
3 (n=16)
 (n=64)4 
6 (n=64) 
7 (n=16)
 (n=64)8 
Scheme 2.3 Synthesis of polypropylenimine dendrimer conjugates. A) DAB-C7-16 
and DAB-C7-64; B) DAB-C16-16, C) DAB-PO-64; D) DAB-Pro-16 
and DAB-Pro-64; and, E) DAB-Ac-16 and DAB-Ac-64. 
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2.3.2.1 Reaction of DAB-Am-16 with alkyl halides 
Alkylation of primary amines via the reaction with primary halides is a straightforward 
nucleophilic substitution reaction that results in secondary amine formation.  However, the 
resulting amine products are also very reactive toward primary halides and will rapidly result 
in tertiary amine formation.  Diazeniumdiolate groups will not form on tertiary amines due to 
the steric hinderance at the donor formation site as well the negligible tertiary amine 
reactivity towards NO.  Initial attempts to react DAB-Am-16 with two separate alkyl 
bromines (1-bromopropane and 1-bromo-isopentane) resulted in a mixture of secondary and 
tertiary exterior amines, limiting the storage capacity of NO and the utility of this approach 
toward dendrimer modification. 
2.3.2.2 DAB-C7-16 (3) 
Generation 3 polypropylenimine dendrimer 1 was acylated with heptanoyl chloride and 
the corresponding amide was reduced with LiAlH4 to produce DAB-C7-16, 3, an alkyl 
terminated dendrimer (Scheme 2.3A).  Following purification on an Al2O3 column, 
confirmation of the seven carbon alkyl secondary amine functionalization was obtained via 
1H and 13C NMR.  The NMR chemical shifts matched those of previously reported octyl (C8) 
functionalizations of other generation polypropyelenimine dendrimers.24  The alkyl 
secondary amine dendrimer was exposed to NO (5 atm, NaOMe/MeOH) to form DAB-C7-
16/NO.  This NO donor-modified dendrimer exhibited high yields of NO release upon 
addition to PBS (pH 7.4, 37 °C) (Figure 2.4A). Indeed, the t[NO] from DAB-C7-16/NO 
corresponded to nearly 40% conversion of secondary amines to diazeniumdiolate NO donors 
(Table 2.1).  The 3.5 μmol NO/mg released for the alkyl secondary amine dendrimer was a 
sizeable increase over the NO released from the primary amine substrates.  Confirmation of 
the diazeniumdiolate functional group was obtained via UV-Vis spectroscopy.  As shown in 
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Figure 2.5, DAB-C7-16/NO exhibits a λmax of 252 nm, characteristic of the diazeniumdiolate 
absorption maximum.10  
Similar to the primary amine dendrimers, the alkyl conjugate was characterized by an 
initial burst of NO release, reaching [NO]m in just minutes.  Subsequently, significant levels 
of NO continued to be released for up to 14 h, albeit at a lesser rate (Figure 2.4B).  Previous 
work by Price et al. indicated that the diazeniumdiolate decomposition rate constant (kobs) 
and half-life for the secondary alkylamine dipropylamine diazeniumdiolate (DPA/NO) were 
4.45x10-3 s-1 and 2.6 min, respectively.29  Since the diazeniumdiolate structures for both 
DPA/NO and the alkyl secondary amine dendrimer NO donors (DAB-C7-16/NO) are nearly 
equivalent (secondary amine diazeniumdiolates bracketed by three alkyl carbons on each 
side), similar NO release would be expected.  However, the surrounding chemical 
environments of the diazeniumdiolates are drastically different.  The dendritic effect on the 
duration of NO release is evident from the lengthy NO release duration of DAB-C7-16/NO 
(t1/2 = 77 min).  The enhanced NO release is attributed to increased local pH upon 
regeneration of free secondary amines.  The effective decrease in proton concentration at or 
near the diazeniumdiolate NO donors results in slower dissociation rates and longer overall 
durations of NO release. 
2.3.2.3 DAB-C7-64 (4)   
The structure of DAB-C7-16 in solution and the hydrophobic packing of the alkyl tails 
may affect both the extent of diazeniumdiolate formation and rates of NO release.  The 
primary amine dendrimer with 64 exterior functionalities, 2, exhibited slightly greater NO 
release properties than 1, the smaller dendrimer.  To probe the size dependence and effects of 
alkyl secondary amine density on NO storage, 4 (DAB-C7-64) was synthesized using 
generation 5 polypropylenimine dendrimer as the substrate. Changing the dendrimer size 
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from generation 3 to 5 showed little effect on the conversion efficiency and t[NO] for DAB-
C7-16/NO and DAB-C7-64/NO (Table 2.1).  The near 40% conversion achieved for both 
dendrimer sizes is attributed to the coulombic repulsion of multiple anionic functional groups 
upon diazeniumdiolate formation.  Additionally, the formation of a zwitterionic species in a 
primarily hydrophobic environment may also contribute to the observed limit of conversion 
efficiency.   
As shown in Figure 2.4, the NO release profiles appeared remarkably similar for both 
alkyl conjugates.  However, DAB-C7-64/NO was characterized by a greater [NO]m and 
longer t1/2.  The dissimilarity of the two release profiles at early times (<30 min) indicates a 
slight size dependent effect on the initial rates of NO release.  At longer times, DAB-C7-
16/NO and DAB-C7-64/NO adopted similar rates of diazeniumdiolate decomposition. 
2.3.2.4 Macromolecular NO release kinetics 
The extended duration of NO release observed for DAB-C7-16/NO and DAB-C7-64/NO 
indicates a likely deviation from pseudo first-order kinetics reported for the dissociation of 
small molecule alkyl secondary amine diazeniumdiolates.  Zhang et al. previously reported a 
method for determining an “apparent” reaction order (n) of diazeniumdiolate dissociation 
from silica-based NO-releasing macromolecules.12  To determine the reaction order for 
dendrimer-bound diazeniumdiolate decomposition, ln υ vs. ln Cd graphs were plotted, where 
υ represents the dissociation rate of the N-diazeniumdiolate moiety (-dCd/dt) and Cd is the N-
diazeniumdiolate content (μmol/mg) of the dendritic NO donors.  The reaction order (n) is 
given by the slope of this plot.12  After the initial burst of NO release, both DAB-C7-16/NO 
and DAB-C7-64/NO shared the same order of reaction (n = 1.89) for diazeniumdiolate 
decomposition.  The relatively high reaction order observed for the dendrimer bound alkyl 
secondary amine diazeniumdiolates (n = 1.89) is comparable with the value reported for the 
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alkyl secondary amine diazeniumdiolates on the surface of fumed silica (n = 1.75 for 1N-
C1).12  These data illustrate the complexity of macromolecular NO release kinetics, and the 
dependence on the pH and lipophilicity of the local chemical environment as well as 
contributions from nanoparticle solution structure. 
2.3.2.5 Proton initiated diazeniumdiolate dissociation 
The sustained duration of NO release observed from the secondary amine dendrimer 
conjugates at extended periods (>12 h) indicates a likely deviation from the first-order 
exponential decay reported for the kinetics of small molecule alkyl secondary amine 
diazeniumdiolates.9  Consistent with the mechanism of decomposition for small molecule 
diazeniumdiolates,9, 28 the buffer pH influenced the kinetics of NO release from the 
dendrimer conjugates.  As expected, NO release from DAB-C7-64/NO was more rapid under 
acidic conditions (pH 3) and slowed drastically at pH>11 (Figure 2.6).  To test the 
contribution of thermal degradation on NO release, decomposition was measured under an 
inert nitrogen atmosphere as a function of temperature.  At 37°C, negligible NO was released 
from the NO donor-modified dendrimer conjugates.  Upon increasing the temperature to 
70°C, NO release was initiated albeit at an extremely low rate (~0.5 ppb/s).  After 60 min, 
degassed PBS buffer was added to the sample, resulting in a rapid release of NO (Figure 2.7).  
Such behavior, combined with the pH dependent dissociation confirms that the dominate 
mechanism of NO release for dendrimer conjugates was proton initiated.  Dendrimers stored 
under basic conditions at -20°C retained 96% (DAB-C7-16/NO) of the stored NO as 
diazeniumdiolate after 3 wks.  Future studies aim to elucidate how diazeniumdiolate 
structure, solvent behavior, and remote amine sites alter the local dendritic environment and 
influence the rate of diazeniumdiolate dissociation.   
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Figure 2.4 A) Real time NO release profile for NO-releasing dendrimer conjugates 
of 3 and 4; and, B) plot of t[NO] vs. time for conjugates of 3 and 4 
depicting values for the t1/2 for DAB-C7-16/NO and long duration of 
NO release. 
3 
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Figure 2.5 UV-Vis spectra collected in MeOH for A) DAB-C7-16 dendrimer  
  conjugate and, B) the diazeniumdiolate functionalized dendrimer DAB-
  C7-16/NO. 
B
A
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Figure 2.6 Real time NO-release curves for DAB-C7-64/NO diazeniumdiolate 
  decomposition as a function of pH and kinetic parameters as a function 
  of pH. 
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Figure 2.7 Real time NO-release curve depicting the minimal thermal degradation 
  observed for DAB-C7-64/NO over the first several hours under a  
  nitrogen atmosphere.  Addition of phosphate buffer resulted in rapid 
  NO donor decomposition. (Inset: Depicts the small flux of NO upon 
  addition of the sample, reflecting the trace amount of NO released  
  during storage.  The temperature was increased from 37°C to 70°C as 
  indicated.   
70°C 
Addition of 
PBS 
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These parameters are essential for predicting NO release kinetics from macromolecular NO 
donors.  Efforts to develop a model for evaluating the structure-activity relationships of 
macromolecules and NO release rates will be of importance for designing NO releasing 
materials bearing therapeutic significance. 
2.3.2.6 DAB-C16-16 (5) 
Synthesis of more lipophilic diazeniumdiolate NO donors has been the goal of other 
studies aimed at developing NO-releasing hydrophobic polymer coatings.30  Such coatings 
have been used to improve the thromboresistivity of intravascular sensors.30  Dendrimers 
possessing alkyl secondary amines represent novel NO releasing macromolecules with 
increased lipophilicity over traditional NO donors, and may elicit similar potential as 
polymer dopants for preparing NO-releasing polymers.  The larger payload of NO and 
increased duration of NO release from a dendritic scaffold may prove advantageous in 
formulating NO release coatings with extended NO release properties.  To increase the 
lipophilicity of the diazeniumdiolate dendrimer conjugates, amine terminated generation 3 
and 5 polypropylenimine dendrimer starting materials were reacted with palmitoyl chloride 
as described above for the shorter heptanoyl chlorides.  The sixteen carbon tailed derivatives, 
DAB-C16-16 and DAB-C16-64, were extremely difficult to isolate following acylation due 
to their micelle like nature and partitioning into both organic and aqueous phases (Figure 
2.8).  Of note, only DAB-C16-16 was able to be recovered after LiAlH4 reduction of the 
amides to secondary amines. 
Following conversion to DAB-C16-16/NO, the NO-release properties for palmitoyl 
conjugate were very similar to the previous C7 dendrimer conjugates (Table 2.1).  The half 
lives for DAB-C16-16/NO and DAB-C7-16/NO were 77 and 78 min, respectively.  
However, the more lipophilic dendrimer with the longer alkyl tails showed a much higher 
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[NO]m (36,800 ppb/mg for C16 and 11,100 ppb/mg for the C7 conjugate, Figure 2.9), likely 
due to a solution conformation that exposes diazeniumdiolates in polar environments (Figure 
2.8B).  Overall, the 3 alkyl conjugates exhibited similar t1/2, % conversion, and total NO-
released (μmol NO/ μmol amine) regardless of core size or alkyl chain length. 
2.3.2.7 DAB-PO-64 (6) 
The therapeutic implications of NO are well understood,4, 31, 32 but failure to deliver NO 
to a specific cell or tissue type of interest has limited the use of NO donors as therapeutic 
entities.  Dendrimers offer a solution to traditional drug delivery problems because of their 
tailored solubility, globular solution behavior, and highly functionalizable exterior.  The 
biocompatibility of several dendritic structures, including polyester dendrimers synthesized 
by Frechet and co-workers possessing primary alcohols at the exterior, have been reported as 
acceptable for drug delivery applications.21  
A water-soluble, hydrophilic dendrimer with terminal hydroxyl groups and secondary 
amines required for efficient storage of NO was synthesized to demonstrate the potential 
delivery vehicle for the controlled release of NO in vivo.  Generation 5 polypropylenimine 
dendrimer 2 was reacted with propylene oxide under aqueous conditions to yield 6 (DAB-
PO-64) (Scheme 2.3C).25  Functionalization was confirmed via 1H, 13C NMR, and ESI/MS.  
Notably, the NO releasing conjugate DAB-PO-64/NO displayed the largest t[NO] of the 
dendrimer conjugates synthesized to date (5.6 μmol NO/mg, 46% conversion) (Figure 2.10).  
The enhanced storage capacity of the hydrophilic dendrimer is likely attributed to a fully 
extended solution structure of the dendrimer in the polar methanol solvent used during NO 
exposure.  Indeed, the structure of polypropylenimine dendrimers are known to be responsive 
to solvent,33 thereby affecting changes in globular solution behavior.  Compared to the more 
lipophilic dendrimer of similar size (DAB-C7-64/NO), DAB-PO-64/NO was characterized 
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by a greater [NO]m (53,100 versus 15,600 ppb/mg).  DAB-PO-64/NO also exhibited 
prolonged NO release for up to 16 h.  As was the case with the alkyl secondary amine 
dendrimers, the dendrimer bound diazeniumdiolates seem to adopt a slower rate of 
dissociation at longer times.  The reaction order for DAB-PO-64/NO decomposition was 
calculated to be 1.71.  The slight shift toward first order kinetics is attributed to the 
hydrophilic nature of DAB-PO-64/NO and NO donor dissociation closer to that of small 
molecule diazeniumdiolates.  
2.3.2.8 DAB-Pro-16 and DAB-Pro-64 (7 and 8). 
Additional hydrophilic dendrimer conjugates were synthesized via the reaction of NHS-
activated t-boc-L-proline with primary amine containing dendrimers 1 and 2. Following 
amide coupling the t-boc group was removed via formic acid to yield dendrimer conjugates 
terminated with proline residues, each containing a single secondary amine site for 
diazeniumdiolate conversion (Scheme 2.3D).  The small molecule diazeniumdiolate 
PROLI/NO has received much attention due to its short NO-release half life (t1/2 <8 s) and its 
biocompatible amino acid metabolites.  Upon exposing the proline dendrimer conjugates to 
NO, the NO-release kinetics observed were prolonged compared to the small molecule 
analogue (e.g., t1/2 = 150 min for DAB-Pro-16).  However, the total NO release values for the 
proline dendrimer conjugates resulted in >300% conversion based on only 2 moles of NO 
possible per mol of covalently attached proline.  Re-examination of the 1H-NMR spectra 
revealed a number of un-interpretable peaks after dialysis.  These conjugates warrant further 
experimentation due to their incredibly high storage potential and straightforward synthetic 
procedure.  Subsequently, amide dendrimer conjugates with no secondary amines were 
synthesized as described below to check for possible amide reaction with NO.
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Figure 2.8 A) 2-D structure of DAB-C16-16 after LiAlH4 reduction depicting the 
  “uni-molecular micelle” like behavior of the lipophilic dendrimer 
conjugate.  B) Illustration showing how DAB-C16-16 is fully extended 
in organic solvents but upon exposure to water may adopt a solution 
conformation exposing the polar interior and presenting easy access for 
proton initiated diazeniumdiolate decomposition. 
Polar core swells,
hydrophobic chains
packed towards the interior
Polar head group with
hydrophobic chains
packed linearly
H
2 O
H 2O
CH2Cl2
A 
B 
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Figure 2.9 Real-time NO release curves for DAB-C16-16/NO and DAB-C7-
16/NO  demonstrating the difference in the [NO]m for the two 
dendrimer conjugates.     
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Figure 2.10 Total NO release profiles for NO-releasing dendrimer conjugates 1-6.
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3 
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2.3.3 Amide functionalized dendrimers DAB-Ac-16 and DAB-Ac-64 (9 and 10) 
To demonstrate control over the NO storage potential of multivalent dendrimers, 
acetamide functionalities were introduced via the reaction of primary amines with acetic 
anhydride in the presence of triethylamine (Scheme 2.3E).  The functionalization was 
confirmed by 1H, 13C NMR and ESI/MS analysis.  The absence of a nucleophilic amine 
required for diazeniumdiolate formation makes amides an unfavorable moiety for storing 
NO.  Following NO charging, both acetamide dendrimers (9 and 10) exhibited low NO 
release and a short half life (t1/2 < 3 min) (Table 2.1).  The trace amount of NO observed 
(<0.2 % conversion) is attributed to NO donor formation at residual primary amine sites 
(from incomplete acetamide functionalization) and/or loosely associated NO within the 
tertiary amine backbone structure.  The lack of amide reactivity towards NO suggests that the 
acetamide functionality may prove useful in future applications for stoichiometrically 
limiting the number of NO donor functional groups.  Acetamide modifications have been 
used previously to control functionality for other dendrimer constructs.34, 35  In addition to 
tuning the storage capacity of NO, the amide exterior may enable increased water solubility 
and eliminate the toxicity of primary amine dendrimer constructs.34, 36 
2.4 Conclusion 
 A new class of NO-releasing macromolecules was prepared from primary and secondary 
amine functionalized dendrimers.  The total NO released from secondary amine conjugates 
was significantly greater than from the primary amine parent dendrimers due to the enhanced 
stability of secondary amine diazeniumdiolates.  The level of NO released (3-6 μmol NO/mg) 
for the secondary amine dendrimers represents the greatest “payload” of an NO-releasing 
macromolecule to date.  Kinetic data confirmed that the mechanism of diazeniumdiolate 
dissociation was proton initiated.  In addition to the increased storage capacity of the 
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dendritic architecture, the dendrimer bound NO donor half-lives greatly exceed those for 
small molecule equivalents, thereby illustrating a “dendritic effect” on diazeniumdiolate 
decomposition.    
Expansion of the current work to introduce multiple functionalities on the dendritic 
exterior may enable the use of NO-releasing dendrimers as a vehicle for further 
understanding NO’s role in physiological systems of interest.  For example, dendrimers 
equipped with targeting ligands (e.g., folic acid) to deliver NO selectively to cancer cells 
may potentially help elucidate the mechanistic effects of NO on tumor cell biology.  
Fluorescent probes and/or (poly)ethyleneglycol chains  may also be added to produce fully 
biocompatible nanoparticles capable of harnessing the therapeutic potential of NO.  Such 
studies are currently underway. 
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Chapter 3 
S-Nitrosothiol-Modified Dendrimers as Nitric Oxide Delivery Vehicles 
 
3.1 Introduction 
S-nitrosothiols (RSNO) are ubiquitous in human physiology and involved in a multitude 
of cell signaling cascades.1  Endogenously, nitrosothiols are formed either via the reaction of 
free thiols with N2O3, the reactive nitrogen species formed following the auto-oxidation of 
nitric oxide (NO), or through a host of redox mechanisms involving metabolites of NO and 
transition metal centers.1  Nitrosation of cysteine residues on serum albumin and the 
nitrosation/nitrosylation of deoxyhemoglobin account for a large portion of the 1.8 μM 
nitrosothiol concentration in blood.2, 3  As the main carriers of NO in vivo, nitrosothiols 
regulate several biological processes including vasodilation, platelet activation, 
neurotransmission, and tissue inflammation.1, 4, 5    Synthetic nitrosothiol NO donors such as 
S-nitroso-N-acetyl-DL-penicillamine (SNAP) have been employed to better understand the 
many complicated roles of NO in regulatory biology, with the most notable instance 
including the discovery by Ignarro and co-workers that NO is the vascular endothelial 
derived relaxation factor.6 
Numerous reports have outlined the therapeutic potential of nitrosothiol adducts, 
including their toxicity toward cancerous cells,7, 8 antimicrobial activity,9-12 and 
cardioprotective effects during ischemia/reperfusion injury.13-15  Perhaps the most well 
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documented clinical application of S-nitrosothiols is as anti-platelet agents, whereby RSNOs 
inhibit platelet aggregation without affecting vascular tone.16-21  Despite the promising 
therapeutic potential of nitrosothiols, the inability to target NO to a specific site of action and 
the rapid systemic clearance associated with small drug molecules has seriously hindered the 
clinical development of nitrosothiol therapeutics.  In response, several macromolecular 
nitrosothiol NO donors have been synthesized to store NO and expand RSNO delivery 
options.  For example, S-nitrosocysteine polymer conjugates have been utilized as materials 
to aid in the prevention of thrombosis/restenosis22, 23  and for the delivery of RSNOs in 
topical biomedical applications.24  Meyerhoff and co-workers have employed nitrosothiol-
modified fumed silica particles as polymer dopants and demonstrated tunable NO-release 
from hydrophobic polymers as a function of light.25  Protein-based nitrosothiol delivery 
vehicles have also been explored as a strategy to extend the systemic half-lives of exogenous 
RSNO donors and to aid in the treatment of circulation disorders.26-29  
The use of polymeric and protein drug conjugates have led to significant strides in NO 
delivery.  Unfortunately, the NO storage capacity (pmol – nmol NO·mg-1) and/or the number 
of sites for covalent attachment of additional functionalities remain limited.  Previous work 
from our laboratory has described the synthesis of diazeniumdiolate-modified 
polypropylenimine dendrimer conjugates as macromolecular NO donors capable of storing 
up to 5.6 μmol NO·mg-1 with NO-release kinetics dependent on dendrimer structure.30   
Dendrimers represent attractive vehicles for NO loading because of their multivalent exterior 
and its ability to not only to store large amounts of NO, but its capacity for additional 
functionalities for increasing drug specifity .30 31, 32  In this chapter, the synthesis and 
characterization of two thiol-derivatized generation 4 polyamidoamine (PAMAM) 
dendrimers capable of storing up to 2 μmol NO·mg-1 dendrimer when converted to the 
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corresponding nitrosothiol NO donors (Figure 3.1) are reported. S-nitrosothiols have 
received considerable attention as the primary NO carriers in blood and their decomposition 
mechanisms represent alternative strategies for controlled NO-release, albeit under 
conditions distinct from diazeniumdiolates.31  The effect of SNAP-modified G4 dendrimer on 
platelet aggregation is explored and compared to SNAP, the analogous small molecule 
nitrosothiol, to confirm the retention of biological activity of dendrimer bound RSNOs. 
3.2 Experimental Section 
3.2.1 General 
Generation 4 polyamidoamine dendrimer (G4-PAMAM), N-acetyl-L-cysteine, trityl 
chloride, triphenylmethanol, boron trifluoride diethyl etherate (BF3-etherate), 
isopentylnitrite, L-glutathione, ethylenediamine tetraacetate (EDTA), N-hydroxy 
succinimide, dicyclohexylcarbodiimide, 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB), and 
triethylamine were purchased from the Aldrich Chemical Company (Milwaukee, WI). N-
acetyl-D,L-penicillamine and anhydrous sodium bisulfate were purchased from Fluka.  
Sodium nitrite and anhydrous pyridine were purchase from Acros Organic.  All other 
common laboratory salts and solvents were purchased from Fisher Scientific.  Water was 
purified using a Millipore Milli-Q gradient A-10 purification system (Bedford, MA).  
Spectra/Por® Float-A-Lyzers® were purchased from Spectrum Laboratories Inc. (Rancho 
Dominguez, CA). Absorption spectra were recorded on a Perkin Elmer Lambda 40 UV-Vis 
spectrophotometer (Norwalk, CT).  Nuclear magnetic resonance (NMR) spectra were 
collected in CDCl3 and D2O (Sigma-Aldrich) using a 400-MHz Bruker Nuclear Magnetic 
Resonance spectrometer.  Mass spectra were acquired on a Kratos MALDI AXIMA CFR 
plus instrument in linear mode (2 GHz), power 160.  Dendrimer samples for mass analysis 
were prepared at a concentration of 2 mg/mL in a sinapinic acid matrix, 1:1 
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CH3CN/TFA (0.05%).  Size exclusion chromatography was performed on a Wyatt DAWN 
EOS light scattering instrument interfaced with an Amersham Biosciences Akta FPLC 
system equipped with a Wyatt Optilab refractometer and Wyatt dynamic light scattering 
module. Nitric oxide release was measured using a Sievers 280i Chemiluminesce Nitric 
Oxide Analyzer (Boulder, CO) as described previously.33 
3.2.2 Synthesis and characterization of dendrimer conjugates 
3.2.2.1 3-Acetamido-4,4-dimethylthietan-2-one (1) 
To an ice-cooled solution of N-acetyl-DL-penicillamine (4.0 g, 21 mmol) dissolved in 10 
mL of anhydrous pyridine under N2, acetic anhydride (5.9 mL, 63 mmol) was added 
dropwise over the course of 30 min.  The solution was warmed to room temperature and 
stirred for 18 h.  The stirring mixture was diluted with 150 mL of CHCl3, washed with 0.1 M 
HCl (3 x 50 mL), and the organic layer dried over MgSO4.  The CHCl3 was concentrated 
under reduced pressure and the crude thiolactone product was precipitated and triturated in 
100 mL of petrolatum ether, filtered, rinse with ether, and dried to yield 1.05 g (29%) of 
white crystalline solid.  1H NMR (CDCl3, δ): 1.60 (s, CH3), 1.82 (s, CH3), 2.02 (s, 
NHCOCH3), 5.64 (d, CH), 6.52 (br, NHCOCH3). 13C NMR (CDCl3, δ): 22.46 (NHCOCH3), 
26.13 (C(CH3)2), 30.13 (CH3), 51.04 (CH), 169.34 (NHCOCH3), 191.79 (SCO). 
3.2.2.2 G4-NAP (2) 
Thiolactone (7) (80 mg, 0.46 mmol) was added in slight excess (1.2:1) to the number of 
amines of  G4-PAMAM dendrimer (81 mg, 5.7 μmol) dissolved in a stirring solution of 
CH2Cl2.  The mixture was stirred for 5 h under N2 at room temperature, concentrated under 
reduced pressure, resuspended in 10 mL of ultrapure water, and dialyzed for 3 d against 
ultrapure water (3 x 3 L, 5,000 MW co).  The thiol modified dendrimer was lyophilized to 
yield 129 mg (89%) of white powder.  NMR (D2O, δ): 1.30 (d, R(CH3)2SH), 1.97 (s, 
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NHCOCH3), 2.25-2.40 (br, R2NCH2CH2CO), 2.48-2.59 (br, NHCH2CH2NR2), 2.67-2.83 (br, 
R2NCH2CH2CO), 3.12-3.30 (br, NHCH2CH2NR2, NHCH2CH2NHCO), 4.30 (s, 
NHCOCHC(CH3)2SH). 13C NMR (D2O, δ): 21.86 (NHCOCH3), 32.46 (C(CH3)2), 36.54 
(CH3), 51.30 (CH), 169.34 (NHCOCH3), 191.79 (SCO)23.25 (CH3), 25.97 (COCH2CH2CO), 
33.66 (CH2), 49.96 (CH), 67.97 (SC(Ph)3), 127.4 (C4), 128.5 (C3), 129.92 (C2) ,144.48 (C1) , 
166.9 (OCOCH), 168.8 (COCH2CH2CO), 171.04 (NHCOCH3). MWtheoretical: 25,300 g/mol, 
MWMALDI: 23,000 g/mol, MWSEC: 23,700 g/mol. 
3.2.2.3 G4-SNAP (3) 
G4-NAP dendrimer (23 mg, 1 μmol) was added to 2 mL of stirring MeOH on ice, 
followed by the addition of 1 mL of 1M HCl and the dropwise addition of a 2.2 molar excess 
of NaNO2 (9.6 mg, 0.14 mmol) to free thiols dissolved in 1 mL of H2O.  The solution was 
stirred at 0 °C in the dark for 30 min and concentrated under reduced pressure (water bath <5 
°C) to yield a crystalline green glassy solid on the walls of the vessel.  The green product was 
reconstituted in 2 mL of cold EtOH, the salt byproducts were removed via a 0.2 μm syringe 
filter, and filtrate was placed under vacuum to remove the EtOH to yield 22.8 mg (92%) of 
10 (G4-SNAP). 
3.2.2.4 S-Trityl-N-acetyl-L-cysteine (4) 
N-acetyl-L-cysteine (7.0 g, 43.7 mmol) was dissolved in 30 mL of concentrated acetic 
acid followed by the addition of triphenylmethanol (11.4 g, 44 mmol) and BF3-etherate (8.2 
mL, 65 mmol) and the solution was stirred for 3 h at 25 °C.  The solution was treated with 
150 mL of water and 80 mL of a saturated sodium acetate solution, chilled on ice, and 
filtered to yield a white slurry.  The slurry was extracted with diethyl ether, concentrated 
under reduced pressure, and dried overnight to yield 15.02 g (85%) of a white solid. 1H NMR 
(CDCl3, δ): 1.88 (s, NHCOCH3), 2.67 (m, CH2S-Trt), 4.35 (q, CH), 6.2 (d, NHCOCH3), 7.18 
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(t, aromatic, H4), 7.26 (t, aromatic, H3), 7.38 (d, aromatic, H2) . 13C NMR (CDCl3, δ): 23.26 
(CH3), 33.59 (CH2), 55.29 (CH), 67.49 (SC(Ph)3), 127.36 (C4), 128.49 (C3), 129.92 (C2) 
,144.7 (C1) , 171.77 (NHCOCH3), 174.33 (COOH). 
3.2.2.5 N-Succinimidyl-S-trityl-N-acetyl-L-cysteine ester (5) 
2 (4.0 g, 10 mmol) and N-hydroxy succinimide (1.15 g, 10 mmol) were dissolved in 50 
mL CH2Cl2 under N2, cooled to 0 °C, and stirred for 5 min.  Dicyclohexylcarbodiimide 
(DCC) (2.26 g, 11 mmol) was added and the stirring solution was allowed to warm to 25 °C 
and stirred for 18 h.  The white solid DCU byproduct was removed via filtration and the 
CH2Cl2 filtrate was concentrated under reduced pressure to yield 4.13 g (84%) of the white 
solid activated ester.  1H NMR (CDCl3, δ): 1.94 (s, NHCOCH3), 2.79 (m, CH2S-Trt), 2.82 (s, 
COCH2CH2CO), 4.71 (q, CH), 5.81 (d, NHCOCH3), 7.22 (t, aromatic, H4), 7.30 (t, aromatic, 
H3), 7.49 (d, aromatic, H2) . 13C NMR (CDCl3, δ): 23.25 (CH3), 25.97 (COCH2CH2CO), 
33.66 (CH2), 49.96 (CH), 67.97 (SC(Ph)3), 127.4 (C4), 128.5 (C3), 129.92 (C2) ,144.48 (C1) , 
166.9 (OCOCH), 168.8 (COCH2CH2CO), 170.0 (NHCOCH3). 
3.2.2.6 G4-Cys (6) 
1.23 mL of a 10% G4-PAMAM/MeOH solution (100 mg, 7 µmol dendrimer) was added 
to 10 mL of stirring CH2Cl2 under N2.  Triethylamine (Et3N) (75 mg, 740 µmol) and 
activated ester 3 (328 mg, 675 µmol) were then added and the solution was stirred overnight 
at 25 °C.  The CH2Cl2 product solution was washed twice with a saturated sodium carbonate 
solution (2 x 30 mL) and once with saturated sodium bisulfate (pH ∼ 0.2), dried over MgSO4, 
filtered, and concentrated under reduced pressure to yield a clear glassy solid.  The trityl 
protecting group was immediately removed via the addition of 10 mL of a TFA solution 
(95% TFA, 2.5% TIPS, 2.5% H2O) on ice.  The TFA/product solution was stirred for 1 h at 0 
°C, treated with 25 mL of H2O, and washed with diethyl ether (3 x 50 mL).  The aqueous 
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layer was frozen and lyophilized to yield 110 mg of a white flaky solid (67%).  1H NMR 
(D2O, δ): 1.95 (s, NHCOCH3), 2.64-2.71 (br, R2NCH2CH2CO), 2.79 (m, CH2SH), 3.12-3.33 
(br, NHCH2CH2NR2, NHCH2CH2NHCO), 3.35-3.5 (br, R2NCH2CH2CO), 3.51-3.63 (br, 
R2NCH2CH2CO), 4.30 (s, NHCOCHCH2SH). 13C NMR (D2O, δ): 23.25 (CH3), 25.97 
(COCH2CH2CO), 33.66 (CH2), 49.96 (CH), 67.97 (SC(Ph)3), 127.4 (C4), 128.5 (C3), 129.92 
(C2) ,144.48 (C1) , 166.9 (OCOCH), 168.8 (COCH2CH2CO), 170.0 (NHCOCH3). 
MWtheoretical: 23,500 g/mol, MWMALDI: 21,200 g/mol, MWSEC: 20,630 g/mol. 
3.2.2.7 G4-CysNO (7) 
G4-Cys dendrimer (110 mg, 5.2 μmol) was dissolved in 10 mL of a MeOH/H2O mixture 
(9:1) and added to 90 mL of rapidly stirring toluene.  The inhomogeneous mixture was then 
treated with excess isopentyl nitrite (10 mL, 69 mmol) to convert the free thiols to S-
nitrosothiol NO donors.  After the solution was stirred under Ar for 2 h at room temperature 
and in the dark, the pink precipitate on the walls of the reaction flask was removed and dried 
under vacuum at 0 °C for 24 h to yield 88 mg (75%) of  7 (G4-CysNO). 
3.2.3 Ellman’s assay for quantification of free thiols 
39.6 mg (0.1 mmol) of 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) was dissolved in 50 
mL of a 50 mM sodium acetate solution and refrigerated until use.  Dendrimer samples were 
dissolved in water (0.4 mg/mL) and diluted into 3 different dilutions (1:5, 1:10, 1:20) for 
reaction with the DTNB.  For the assay, 1 mL quartz cuvets were filled with 840 µL of 
ultrapure H2O, 50 µL of the DTNB sodium acetate solution, 100 µL of Tris buffer (1M, pH = 
8.0), and 10 µL of the thiol terminated dendrimer sample.  The cuvets were incubated at 37 
°C for 5 min and the optical density was measured at 412 nm.  The absorbance values for 
each dendrimer dilution were divided by the extinction coefficient of the DTNB mixed 
disulfide complex (13,600 M-1cm-1) resulting in a concentration of thiols in solution.  Thiol 
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concentration was divided by moles of dendrimer in solution to obtain moles of thiol/mol 
dendrimer. (n=3 dilutions, values are represented as standard deviation of the mean) 
3.2.4 NO-release testing of nitrosothiol containing dendrimers 
Chemiluminescence34 was employed to quantify the NO released from the S-nitrosothiol 
dendrimer conjugates upon exposure to various triggers previously identified to initiate 
nitrosothiol decomposition in the literature (e.g., copper, light, ascorbate and temperature).  
Total NO release (t[NO], μmol NO/mg) was used to quantify storage efficiency of the thiol-
modified dendrimers. The percent yield values in Table 1 were calculated based on 64 
theoretical amines on the dendrimer starting material, the successful conversion of these 
amines to 64 surface thiols, and their modification to 64 S-nitrosothiol moieties.  Aliquots 
(10 μL) of the dendrimer products in 5 mM EDTA in water for G4-CysNO or EtOH for G4-
SNAP were added to a reaction flask containing 10 mM phosphate buffered saline (PBS, 
pH=7.4) with 5 mM EDTA to chelate trace copper in the media.  A large excess of EDTA 
was required to completely remove initial bursts of NO-release attributed to Cu2+ ion 
impurities in solution.  A chelator was not employed during Cu2+-mediated NO-release 
testing. All NO-release testing was conducted at physiological temperature (37 °C) except 
when testing the rates of thermal decomposition.  Dendrimer concentrations in the 30 mL 
reaction flask ranged from 300-700 nM.  The chemiluminescence analyzer was calibrated 
with NO gas (24.1 ppm). The value for converting instrument response (ppb) to moles of NO 
was obtained via the conversion of known concentrations of nitrite standards to NO in a 0.1 
M KOH/H2SO4 solution (1.34 x 10-13 moles NO/ppb).  During photo-initiated NO release 
experiments 60, 100, or 200 W bulbs were employed (Crystal Clear, General Electric).  The 
light source was positioned ∼5 inches from the sample.  Copper solutions were prepared by 
dissolving CuBr2 in the running buffer (200 -1000 μM) prior to degassing the sample. 
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Chemiluminescence data for the NO-releasing dendrimers were represented in two 
graphical forms or plots: 1) chemiluminescence response in ppb NO/mg dendrimer versus 
time; and, 2) the total amount of NO-release (t[NO], μmol NO/mg) versus time.  Kinetic 
parameters including the maximum flux of NO release ([NO]m) and the time required to 
reach that maxima (tm) were obtained from plot 1 while the half-life (t1/2) of NO release was 
determined from plot 2.   
3.2.5 Platelet rich plasma isolation 
Fresh platelets were prepared from venous blood drawn from healthy volunteers in 
accordance with institutional guidelines. Whole blood (42.5 ml blood to 7.5 ml 
anticoagulant) was drawn into a syringe containing citrate (3.2% by weight, pH = 7.4). 
Platelet rich plasma (PRP) was obtained by centrifugation (200 x g, 20 min) at 25 °C.  The 
platelet rich plasma was centrifuged at 1000 x g for 10 min at room temperature to obtain a 
platelet pellet. The platelet pellet was suspended in the original volume of Tyrode’s buffer 
(without divalent cations, 137 mM NaCl, 3 mM KCl, 3 mM sodium phosphate, 2 mM 
sodium bicarbonate, 5 mM glucose, 10 mM Hepes) and centrifuged as in the last step. The 
final pellet was suspended in Tyrode’s buffer at 200,000 platelets/μL, as measured with a 
Heska hematological analyzer. 
3.2.6 Aggregation studies 
Aliquots of platelets in Tyrode’s buffer at 200,000 platelets/μl were placed in the optical 
cuvettes in the aggregometer (Chrono-Log Whole Blood Aggregometer) and equilibrated to 
37 oC while stirring. DMSO stocks of NO donor compounds (or neat DMSO as a carrier 
control) were diluted 1/100 into the stirred platelet suspensions and allowed to incubate for 
15 min. Aggregation reactions were initiated by adding 100 x stocks of CaCl2 for a final 
calcium concentration of 10 mM and 100 NIH unit/ml stocks of human α-thrombin for a 
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final concentration of 1 NIH unit/ml.  The degree to which test agents inhibited thrombin-
mediated platelet aggregation was estimated from the final extent of aggregation (turbidity 
change) at 25 min. The turbidity changes of each sample were normalized to the turbidity 
observed for the DMSO carrier.  Dose response curves represent the average of two 
independent sets of measurements on different days with different blood donors tested n=3 
times each. The error bars represent standard error of the mean between the two sets of 
measurements. 
3.3 Results and Discussion 
3.3.1 Synthesis of thiol modified dendrimers 
3.3.1.1 G4-NAP (2) 
Previously, Wang and co-workers  developed a strategy toward increasing the cellular 
uptake of S-nitrosothiols in human prostate cancer cells by first reacting amino sugars with 
the cyclized thiol, 3-acetamido-4,4-dimethylthietan-2-one.8, 35  Utilizing a similar approach to 
modify the exterior amines of a generation 4 PAMAM dendrimer, N-acetyl-D,L-penicillamine 
was cyclized in low yields (29%) to 1 (3-acetamido-4,4-dimethylthietan-2-one) with acetic 
anhydride and pyridine.36  The G4-PAMAM dendrimer was then modified with thiol in one 
step via the reaction of the surface primary amines with thiolactone (1) (Scheme 3.1).  
Following dialysis and lyophilization, the extent of G4-NAP (2) modification was assessed 
via 1H NMR and the Ellman’s assay37, 38 to quantify the number of free thiols attached to the 
dendrimer scaffold.  The integrated intensity of the protons on the geminal methyl 
substituents adjacent to the terminal thiols (C(CH3)SH) was compared to the interior 
methylene protons inside the dendrimer to confirm attachment of the N-acetyl-D,L-
penicillamine groups (Figure 3.2 and 3.3).  The number of immobilized thiol groups was 
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calculated to be 63 (Equation 3.1), correlating well with number of free thiols assayed on the 
dendrimer surface 62.1 ± 2.2 (Ellman’s assay).   
 
Equation 3.1  ( )
( )A
aCOCH
Intensity
sH
x
Intensity '
3
3 =  Where  x = number of NAP groups 
   
xx 4124
978.0
3
491.0
+=         60.88 = 0.97x      x = 62.76  
 
Size exclusion chromatography (SEC) was employed to assess both the molecular weight 
and purity of the dendrimer conjugate.  SEC revealed negligible low molecular weight 
impurities following the synthesis and isolation of product.  However, a significant 
population of high molecular weight species was observed (Figure 3.4A).  Although the N-
acetyl-D,L-penicillamine-modified dendrimer contained 20% multimer by weight, the 
majority of the sample was the fully reduced 23,700 MW G4-NAP.  Multimer formation was 
attributed to the presence of intra- and/or inter-dendrimer disulfide crosslinks but dendrimer 
conjugates were not stored/prepared under reducing conditions as such chemistry proved 
incompatible with subsequent S-nitrosothiol formation.  High resolution MALDI-TOF mass 
spectrometry of 2 prepared in a sinapinic acid matrix indicated that the molecular weight of 
G4-NAP was 23,000 g/mol, further validating the SEC data.  A summary of dendrimer 
characterization data is provided in Table 3.1. 
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Figure 3.1 Generation 4 polyamidoamine (PAMAM) dendrimer containing a 
completely modified exterior (64 thiols) of S-nitroso-N-acetyl-D,L-
penicillamine (G4-SNAP) or S-nitroso-N-acetylcysteine (G4-CysNO). 
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Scheme 3.1 Synthesis of S-nitrosothiol modified generation 4 PAMAM dendrimer, 
G4-SNAP (3). 
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Figure 3.2 Proton assignments for G4-PAMAM dendrimer illustrating the 
difference between unmodified dendrimer branches (primary amines) 
and modified branches where R = CH3 (G4-NAP), H (G4-Cys). 
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Figure 3.3 1H NMR spectrum of G4-NAP (2) dendrimer in D2O with proton 
assignments referenced in Figure 3.2. 
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Figure 3.4 Size exclusion chromatographs of A) G4-Cys and B) G4-NAP thiol 
modified dendrimers illustrating the distribution between the higher 
molecular weight multimers (1) and the dominant single molecular 
weight dendrimer (2). 
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# thiols / mol Molecular Weight NO Storage Efficiency
 
Ellman’s 1H NMR MALDI SEC % multimer Mw/Mn μmol NO·mg-1 % yield
         
G4-NAP 62 ± 2 63 23,000 23,700 20% 1.03 ± 0.15 1.7 ± 0.2 79% 
         
G4-Cys 49 ± 4 58 21,200 20,630 16% 1.04 ± 0.11 2.1 ± 0.2 87% 
 
Table 3.1  Characterization data for generation 4 PAMAM thiol conjugates G4-
NAP and G4-Cys and NO storage efficiency once converted to the 
corresponding S-nitrosothiol NO donors.
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3.3.1.2 G4-Cys (6) 
Although the synthetic procedure described above yields G4-NAP thiol-modified 
dendrimer in two steps, this straightforward approach may not be useful when other 
functionalities need to be appended to the dendrimer scaffold.  The opening of the 
thiolactone ring results in the formation of highly reactive thiols which may 
interfere/compete with remaining dendrimer amines during conjugation of additional 
moieties.  Thus, protected S-trityl-N-acetyl-L-cysteine was employed as a precursor to 
nitrosothiol formation allowing for future orthogonal coupling to the dendritic exterior.  A 
similar approach was described previously to synthesize cysteine-modified 
poly(propyleneimine) dendrimers to allow native chemical ligation of both oligopeptides and 
recombinant proteins.39  N-acetyl-L-cysteine was trityl-protected using a mixture of triphenyl 
methanol and BF3-etherate in concentrated acetic acid (Scheme 3.2).25    Upon neutralization 
with saturated sodium acetate and extraction in ether, the white solid 4 was isolated (85% 
yield).  Following activation to the succinimidyl ester 5, the S-trityl-N-acetyl-L-cysteine-
protected thiol was coupled to G4 PAMAM by reaction with the dendrimer’s exterior 
amines.  The trityl protected dendrimer conjugate was then treated with trifluoroacetic acid to 
remove the trityl protecting groups. The dendrimer product was dissolved in water, washed 
with ether, and lyophilized to yield 6 (G4-Cys) as a white flaky solid (67%).  The number of 
free thiols attached to the dendrimer exterior for the Cys conjugate was calculated to be 58 
(Equation 3.2) as confirmed by 1H NMR spectroscopy (Figure 3.5). 
Equation 3.2  ( )
( )C
cCOCH
Intensity
sH
x
Intensity '
3
3 =  Where  x = number of Cys groups 
                
xx 2124
38.1
3
0.1
+=            124 = 2.14x      x = 57.86  
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Size exclusion chromatography (SEC) of G4-Cys resulted in similar chromatograms as 
described above for G4-NAP, whereby 16% high molecular weight species was detected 
arising from dendrimers crosslinked via disulfide bridges (Figure 3.4B).  The molecular 
weight of the higher molecular weight impurity calculated from light scattering data was 
44,550 g/mol, approximately double the mass of the dominate G4-Cys single dendrimer 
(20,630 g/mol), suggesting dimer formation.  MALDI-TOF mass spectrometry confirmed 
that the molecular weight of the prominent G4-Cys species was 21,200 g/mol consistent with 
the molecular weight observed in SEC.  The protection/deprotection strategy employed 
herein may be useful in the future synthesis of multifunctional NO-releasing dendrimers 
since it allows for orthogonal coupling of multiple agents to the dendrimer scaffold without 
interfering with the thiol structure. 
3.3.2 Conversion to S-nitrosothiol dendrimers 
To convert the thiols to S-nitrosothiols, acidified nitrite solutions were employed.  When 
compared to their alkyl nitrite counterparts, such solutions are faster and more efficient at 
nitrosothiol formation.40  The tertiary thiol (G4-NAP) and primary thiol (G4-Cys) dendrimers 
provide macromolecules with different thiol stabilities and chemical properties when 
converted to the corresponding NO donors.  Dendrimer 2 (G4-NAP) was dissolved in a 50:50 
mixture of MeOH / 1M HCl and treated with NaNO2 on ice.  The acidified nitrite solution 
rapidly turned green indicating S-nitroso-N-acetyl-D,L-penicillamine (SNAP) formation.  
Following removal of the solvent under reduced pressure at 0 °C, the nitrosothiol-modified 
dendrimer was reconstituted in cold ethanol and removed from the salt byproducts via 
filtration.  The ethanol was again removed at 0 °C to yield 3 as a green polymer film in 92% 
yield.  Low temperatures and shielding from light were maintained throughout the isolation 
procedure to prevent NO release and the formation of insoluble aggregates. 
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Primary nitrosothiol adducts (e.g., S-nitroso-cysteine) have been historically difficult to 
isolate following nitrosothiol formation due to poor RSNO stability.41 Similarly, the acidified 
nitrite approach described above proved troublesome when working with the G4-Cys 
dendrimer.  Removal of the solvent led to an insoluble polymerized network of thiol 
dendrimers.  As an alternative strategy to convert free thiols of 6 to S-nitrosothiol NO 
donors, the dendrimer was dissolved in a methanol/water solution, added to 200 mL of 
stirring toluene, and treated with isopentyl nitrite.25  After reaction with the organic nitrite 
source for 2 h, a pink precipitate was observed on the walls of the flask.  The precipitate was 
removed via filtration and dried under vacuum to yield 7 (G4-CysNO, 75%).  As S-
nitrosothiol dendrimer conjugates proved susceptible to thermal decomposition, low 
temperatures were employed during all isolation steps to minimize NO donor degradation 
and prevent dendrimer disulfide cross linking. 
G4-SNAP and G4-CysNO nitrosothiol dendrimer conjugates possessed characteristic 
absorption maxima governed by the tertiary or primary thiol structures (Figure 3.6).  The G4-
SNAP dendrimer had an intense broad band at 341 nm (π→ π*) and a weaker absorption 
maxima at 596 nm (n→π*) giving the anti conformer of the tertiary thiol its greenish color.42, 
43  The G4-CysNO conjugate had a similar π→ π* transition at 320 nm and a blue shifted 
n→π* transition at 545 nm.  
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Scheme 3.2  Synthesis of G4-CysNO, S-nitrosothiol modified generation 4 PAMAM 
dendrimer. 
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Figure 3.5 1H NMR spectrum of G4-Cys (6) dendrimer in D2O with proton 
assignments referenced in Figure 3.2. 
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Figure 3.6  UV-Vis absorption spectra of G4-SNAP and G4-CysNO dendrimer 
conjugates (2 mg/mL in EtOH solutions). 
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Scheme 3.3 Mechanisms of nitrosothiol decomposition and NO release from G4-
RSNO dendrimer conjugates. 
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3.3.3 Characterization of NO storage through RSNO decomposition  
3.3.3.1 Copper mediated NO-release 
A major mechanism of S-nitrosothiol decomposition is mediated via the Cu+/Cu2+ redox 
couple and copper containing enzymatic metal centers.5, 43, 44  Previous work has confirmed 
that the breakdown reaction proceeds via the reduction of Cu2+ by trace thiolate anion in 
solution to yield Cu+ that subsequently reduces RSNO compounds to initiate NO release 
(Scheme 3.3A).44  An aqueous solution containing copper bromide (CuBr2) was utilized to 
decompose the S-nitrosothiol dendrimer conjugates to NO and corresponding dendritic 
disulfides.  All copper mediated NO-release testing was performed in phosphate buffered 
saline (PBS, pH = 7.4) at physiological temperature (37 °C) and in the dark.   
The real-time NO-release profiles for copper initiated NO release from G4-SNAP (3) and 
G4-CysNO (7) are shown in Figure 3.7 (A and B).  The tertiary S-nitrosothiols of G4-SNAP 
exhibited a more rapid release of NO as evidenced by the maximum intensity of NO release, 
[NO]m. For example at 1 mM Cu2+, the [NO]m for G4-SNAP was 92,100 ppb/mg  whereas 
the [NO]m for G4-CysNO was only 26,200 ppb/mg.  The kinetics of G4-SNAP dendrimer 
decomposition exhibited small changes as a function of Cu2+ concentration with 0.2 and 0.6 
mM Cu2+ possessing nearly identical NO-release profiles.  However, [NO]m of the primary S-
nitrosothiol terminated dendrimer G4-CysNO scaled with copper concentration (Figure 3.7B, 
Table 3.2) but never reached the same intensity as the G4-SNAP NO-release.  The full set of 
kinetic parameters including the time required to reach the maximum flux (tm) and half life of 
NO-release (t1/2) are given in Table 3.2.     
The difference in copper-initiated NO release is attributed to the S-nitrosothiol structure. 
According to previous reports, primary small molecule nitrosothiols such as S-
nitrosoglutathione (GSNO) are oxidized to the GSSG disulfide in the presence of Cu2+ which 
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effectively chelates remaining Cu2+ in solution and thus slows nitrosothiol decomposition.45  
However, S-nitroso-N-acetyl-D,L-penicillamine (SNAP) does not chelate copper via the 
resulting disulfide and decomposes rapidly to yield NO even at substoichiometric 
quantities.45   In the presence of copper, the macromolecular RSNO donors presented herein 
exhibited the same characteristic NO release behavior as the small molecule analogues 
reported in the literature.  This phenomenon is best indicated by the total NO-release curves 
shown in Figure 3.7C.  At 0.2 mM Cu2+, only 12 min were required for the G4-SNAP 
dendrimer (3) to achieve complete NO release, whereas the G4-CysNO dendrimer (7) slowly 
decomposed to NO over a period of 15 h.  Despite the variable NO-release kinetics, the same 
level of total NO released (t[NO], Table 3.1) was achieved regardless of the copper 
concentration corresponding to 79%  NO-storage efficiency for the synthesis of the G4-
SNAP dendrimer and 87% for G4-CysNO. 
In the development of S-nitrosothiol therapeutics, copper-mediated NO-release holds 
minimal promise due the lack of free-circulating Cu2+.  Ascorbate has often been mistaken as 
another trigger to initiate S-nitrosothiol decomposition as its concentration in the blood is 
appreciable (81 μM).46  However, ascorbate mediates NO release only through the reduction 
of trace metal ions in solution which then promote NO release.47  In the presence of EDTA, 
the dendritic nitrosothiols exhibited no increase in the rate of NO release upon exposure to 
concentrations of ascorbate up to 2 mM, suggesting that ascorbate is not a viable initiator of 
S-nitrosothiol dendrimer decomposition (data not shown). Of note, this does not rule out the 
possibility of other agents capable of facilitating the one-electron reduction to release NO for 
future therapeutic applications.5 
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Figure 3.7  A) NO-released from 3 (G4-SNAP) exposed to 200 μM (---), 600 μM 
(…...), and 1 mM (—) Cu2+ in PBS buffer at 37 °C.  B) NO-released from 
7 (G4-CysNO) exposed to 200 μM (---), 600 μM (…...), and 1 mM (—) 
Cu2+ in PBS buffer at 37 °C. C) Total NO-release curves of G4-SNAP 
and G4-CysNO illustrating the kinetic difference between tertiary and 
primary nitrosothiol decomposition at 200 M Cu2+.  (Data is truncated 
at 12 h, despite the increase of G4-CysNO-release for up to 15 h.) 
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Trigger  G4 
Dendrimer type [conc] 
t1/2 
(min) 
[NO]m 
(ppb/mg) tm 
(min) 
      
G4-SNAP Cu2+ 0.2 mM 2.3 63000 1.1 
  0.6 mM 2.2 58700 1.3 
  1 mM 1.5 92100 0.9 
      
 light 60 W 200 1990 7.5 
  100 W 97 2360 9.5 
  200 W 34 5800 2.0 
      
 37 oC -- ND 158 6.4 
      
      
G4-CysNO Cu2+ 0.2 mM 106  2510 2.6 
  0.6 mM 16 15900 3.1 
  1 mM 7 26200 2.7 
      
 light 60 W 97 1480 10.1 
  100 W 90 1790 24.4 
  200 W 49 2210 27.4 
      
 37 oC -- ND 116 8.8 
      
 
 
Table 3.2 Kinetic parameters for NO-release from generation 4 PAMAM 
nitrosothiol conjugates G4-SNAP and G4-CysNO as a function of 
 decomposition trigger and concentration. 
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Figure 3.8 A) Phototriggered on/off behavior of G4-SNAP dendrimer conjugate (3) 
at 200 W.  Sample was irradiated at 2 min intervals followed by 3 min of 
darkness B) Permanent irradiation of G4-SNAP at 200 W illustrating the 
long first order decay over several hours. The * signifies thermal NO-
release at 37 °C prior to exposing the dendrimer to the light source. 
(Inset: Total NO release curve for G4-SNAP.) 
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3.3.3.2 Photoinitiated NO-release 
Photoinitiated NO-release is another well-characterized mechanism of RSNO 
decomposition.48  Irradiation at either RSNO absorption maximum has been shown to result 
in homolytic cleavage of the S-N bond to yield NO and a thiyl radical in a process that is 
approximately first-order.48  Electron paramagnetic resonance spectra of spin-trapped thiyl 
radicals have been reported as concrete evidence for the phototriggered homolysis of the S-N 
bond.49  Photolysis of dendrimer nitrosothiol conjugates with a broad spectrum white light 
source also yielded a dendritic thiyl radical and NO (Scheme 3.3B).  The reaction is further 
propagated when the resulting thiyl radical reacts with a neighboring RSNO branch to 
produce a disulfide and additional NO (Scheme 3.3B).  Consistent with previously reported 
observations for nitrosothiol decomposition,25 the NO-release from G4-SNAP and G4-
CysNO dendrimers was dependent on light intensity and followed first order decay (Table 
3.2).  The nitrosothiol-modified dendrimers were also extremely responsive to the light 
source and exhibited a clear on/off behavior when the light was removed.  The behavior of 
G4-SNAP exposed to repeat cycles of 2 min light irradiation followed by 3 min of darkness 
is shown in Figure 3.8A.  When the 200 W light source was removed, the signal rapidly 
returned to baseline.  The intensities of [NO]m slowly declined during subsequent 
irradiations, as expected with the depletion of RSNO.  Homolytic cleavage of the S-N bond 
may also result via thermal decomposition of RSNO donors, albeit at a much slower rate.  
The difference between the slow thermal decomposition of G4-SNAP dendimer (9.31 pmol 
NO·mg-1·s-1, indicated by the asterisk) and the rate of NO-release upon exposed to 200 W 
light is shown in Figure 3.8B.   
Overall, G4-SNAP dendrimer was more susceptible to changes in light intensity than G4-
CysNO.  Both dendrimers resulted in similar half-lives and [NO]m at 200W (Table 3.2) but 
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the most significant kinetic variation between the two conjugates was observed at early 
periods (<30 min).  The initial rates of phototriggered decomposition for the G4-CysNO 
dendrimer were also slower than the G4-SNAP conjugate as indicated by the time required to 
reach the maximum flux (tm) (Table 3.2).  This initial delay and lower intensity of G4-
CysNO release is explained by a “cage effect” imposed by the G4-CysNO dendrimer 
conjugate whereby a more compact solution structure results in the increased frequency of 
geminate radical pair recombination and slows the initial rates of NO release.50,51  Indeed, 
Shishido et al. have demonstrated that photogeneration of NO from S-nitroso-N-
acetylcysteine in a PEG matrix resulted in a 22-fold decrease in the intial rate of RSNO 
decomposition when compared to normal aqueous media.51  Additionally, the PEG 
microenvironment reduced the rates of thermal decomposition at room temperature.  The 
increased stability of the macromolecular G4-CysNO structure in this work suggests a 
“dendritic effect” on phototriggered NO release.   This “cage effect” may be manipulated in 
future biomedical applications by increasing dendrimer size (G5-G8) or through the 
attachment of poly(ethylene glycol) functionalities to the dendrimer exterior leading to 
increased storage and handling of S-nitrosothiols. 
3.3.4 S-nitrosothiol inhibition of platelet aggregation 
Free nitric oxide inhibits platelet aggregation via a guanylyl-cyclase dependent 
mechanism.16  However, the signaling actions of RSNOs are not completely dependent on 
the release of free NO and the mechanism by which they deliver NO to platelets is much 
debated.52  Transnitrosation5 between RSNO and membrane bound protein thiols provides a 
mechanism for direct cellular communication and transfer of NO.  Transnitrosation can be 
defined as the transfer of the nitroso functional group from a nitrosothiol donor to a free thiol 
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as shown in Scheme 3.3C.  Indeed, transnitrosation reactions between exogenous NO donors 
and proteins on the platelet surface are well characterized.53-55 
The efficacy of the G4-SNAP dendrimer conjugate at inhibiting thrombin-catalyzed 
platelet aggregation was examined to compare the biological activity of the RSNO-modified 
dendrimers to free small molecule SNAP.  Platelet aggregation as monitored by the loss of 
turbidity in solution using an aggregometer is shown in Figure 3.9 for the small molecule 
SNAP and G4-SNAP dendrimer.  A dose-dependent inhibition of platelet aggregation was 
observed for the SNAP NO donor with 75% inhibition observed at 100 μM SNAP (Figure 
3.9A).  Solutions prepared with equimolar RSNO functionalites on G4-SNAP dendrimer 
(estimated at 64 RSNO per mol dendrimer) exhibited a pronounced inhibition of thrombin-
mediated aggregation regardless of dendrimer concentration (Figure 3.9B).  At 25 μM SNAP 
functionality on the G4-SNAP conjugate (390 nM dendrimer), a 62% reduction in 
aggregation was observed compared to only a 17% inhibition for 25 μM small molecule 
SNAP.  The abundance of RSNO donors localized on the dendritic structure was far more 
effective at inhibiting platelet aggregation compared to small molecule SNAP in solution.  
Control G4-NAP (2) and N-acetyl-D,L-penicillamine without NO were also evaluated at 
concentrations up to 100 μM and showed minimal effects on platelet aggregation.  The 
inactivity of the thiol controls and the absence of SNAP decomposition triggers in these 
experiments (e.g., light, copper, etc.) indicate that the observed inhibition of platelet 
aggregation was mediated via transnitrosation and any resulting nitrogen species derived 
from transnitrosation. 53-55 
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Figure 3.9 Human thrombin-initiated platelet aggregation in the presence of A) 
SNAP small molecule or B) G4-SNAP dendrimer conjugate.  Turbity 
changes of the 0-100 uM RSNO donors were normalized to the DMSO 
signal (100%). C) Normalized percent aggregation for SNAP (gray) and 
G4-SNAP dendrimer (white). Control represents aggregation in 100 μM 
thiol control (N-acetyl-D,L-penicillamine or G4-NAP.  Error is 
represented as standard error of the mean for two independent blood 
samples tested n=3 times each. 
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3.3.5 Glutathione initiated NO-release 
The absence of plasma or blood components in in vitro studies that influence NO 
delivery and transnitrosation is one of the confounding factors that clout the effects of RSNO 
in clinical studies.15  Glutathione (GSH) is present in blood at concentrations near 500 μM 
and plays a key role as an antioxidant and as a reducing agent for thiol containing proteins.  
Moreover, GSH and other thiols have been shown to decompose nitrosothiol donors through 
direct transnitrosation and result in disulfide bond formation (e.g., GSSG) and the liberation 
of  multiple NOx species.49  Previously, Singh et al. studied the transnitrosation process 
between the GSH/SNAP small molecule pair, revealing that the rate of SNAP decomposition 
increased with increasing concentrations of GSH up to 500 μM.49  These experiments, 
performed under aerobic conditions, led to large amounts of nitrite formation (NO2-) and the 
exact quantities of NO released were not determined.  To date, no studies have been 
conducted to directly measure the quantities of NO released from nitrosothiols in the 
presence of physiological concentrations of GSH.   
The NO evolved from G4-SNAP upon exposure to physiologically relevant GSH 
concentrations was measured under anaerobic conditions and the NO generated from G4-
SNAP decomposition was removed from the sample and carried to the detector by a stream 
of N2(g).  The total NO-release versus time for G4-SNAP (13 µM) exposed to GSH (0.5-10 
mM) is shown in Figure 3.10.  The rate of NO-release was the greatest at 500 μM GSH, the 
physiological concentration of GSH in blood, reaching a maximum flux ([NO]m) of 1429 ppb 
NO·mg-1·s-1 (191 pmol NO·mg-1·s-1) after 45 min.  Direct comparison of the NO-release 
curves at 500 μM and zero added GSH, conditions under which the dendrimer only releases 
NO via thermal decomposition at 37 °C, is shown in Figure 3.11.  In the absence of light, 
copper, or free thiol, G4-SNAP failed to generate large quantities of NO.  Increasing the 
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GSH concentration resulted in a dose-dependent decrease in the total NO (t[NO]) observed, 
presumably from GSH scavenging NO at high GSH concentrations.56  All of the glutathione 
experiments resulted in lower t[NO] when compared to the rapid production of NO when G4-
SNAP was exposed to 200 mM Cu2+, yielding 100% percent release of the covalently bound 
NO (Figure 3.10).  A summary of the NO-release properties of G4-SNAP in the presence of 
GSH is provided in Table 3.3.  
As illustrated by the chemiluminescence experiments described above, spontaneous 
generation of NO in 500 μM GSH results in NO donor behavior similar to 
diazeniumdiolates, whereby large concentrations of NO are rapidly released into solution.  
These findings suggest that the effect of GSH and other blood components is critical for 
understanding the translation of nitrosothiol data generated in vitro toward in vivo animal or 
clinical studies.  Indeed, direct transnitrosation reactions between other nitrosothiols and 
GSH have been monitored spectroscopically and favor the production of the more stable 
GSNO adduct.49  Due to the vast excess of GSH over every other thiol in blood, it is likely 
that the transfer of NO will be effectively unidirectional from any S-nitrosothiol to 
glutathione.49  Glutathione represents a sink for the transnitrosation process and the fate of 
GSNO decomposition is of significant importance. Current studies are underway to 
understand the decomposition of GSNO in the presence of GSH in order to further explore 
thiol-initiated mechanisms of NO-release. 
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Figure 3.10 Total NO-release curves of G4-SNAP exposed to variable triggers of 
RSNO donor decomposition.  
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Figure 3.11 Real-time detection of NO-released from DMR-SNAP in the presence 
of 500 μM GSH compared to the slow decomposition of the RSNO 
donor at 37 °C. (Inset: Close-up of the thermally initiated NO-release 
data at 37 °C.) 
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 t[NO] 
(μmol NO·mg-1) 
[NO]m 
(ppb·mg-1) 
tm 
(min) Trigger 
 6 h 16 h   
      
Cu2+ 200 μM 1.89 1.90 63000 1.1 
      
Glutathione 0.5 mM 1.30 1.39 1430 43 
 1 mM 1.01 1.21 990 31 
 2 mM 0.88 1.05 1020 18 
 10 mM 0.38 0.40 570 17 
      
Thermal 37 °C 0.04 NA 30 1.4 
      
 
 
Table 3.3 NO-release properties for G4 DMR-SNAP exposed to various triggers 
for RSNO decomposition.  
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3.4 Conclusion 
The synthesis of thiol-modified G4-PAMAM dendrimers and their conversion to S-
nitrosothiol NO donors represents a new class of NO-releasing dendrimer constructs.  The 
dendrimer scaffold enables the enhanced storage of RSNO donors compared to previously 
reported nitrosothiol delivery vehicles.  For example, G4-PAMAM (MW 14,215 g/mol) has 
64 surface sites for NO loading (Figure 3.1) compared to only 14 for a fully reduced serum 
albumin conjugate (MW ∼66,000g/mol).26  The G4-SNAP and G4-CysNO dendrimers 
effectively stored and released 1.7 ± 0.2 and 2.1 ± 0.2 μmol NO·mg-1, respectively, when 
using known triggers of nitrosothiol decomposition such as Cu2+ and light.  The anti-platelet 
activity of G4-SNAP dendrimer was 45% more effective at preventing platelet aggregation at 
25 μM than the corresponding small molecule NO donor SNAP.  The on/off triggering of 
NO-release and the ability to undergo transnitrosation reactions with biological substrates 
(e.g., platelets) allows for careful control of NO-release previously unattainable with 
diazeniumdiolate-modified dendrimers.30  
Since NO donors are highly reactive, targeting NO to specific tissues or cell types is 
challenging.  An advantage of the dendritic scaffold over other potential RSNO drug delivery 
vehicles is the ease in which multiple surface functionalities may be appended to the 
dendrimer exterior.  For example, Baker and co-workers have synthesized dendrimers 
containing the methotrexate (an anti-cancer drug), fluorescent probes for imaging, and folic 
acid residues for targeting the delivery vehicle to cancerous tissue in vivo.57 Work is 
underway in our laboratory to synthesize multi-functional dendrimer conjugates that 
integrate the recent advancements in nanoparticle drug delivery with the current mechanistic 
understanding of nitrosothiols in physiology to create highly specialized NO-releasing 
therapeutics. 
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Chapter 4: 
Cytotoxicity of Polypropylenimine Dendrimer Conjugates on Cultured 
Endothelial Cells  
 
4.1 Introduction 
As described in Chapter 1, dendrimers represent polymeric drug delivery vehicles that 
possess a well-defined, three-dimensional structure and a multivalent exterior which can be 
modified to contain a multitude of unique surface groups.1, 2 These hyperbranched molecules 
are synthesized either by a divergent method whereby repeat monomers are branched 
outward from a central core, or a convergent method from which the synthesis begins at the 
periphery and is grown inward.3  The dendritic architecture offers a solution to traditional 
drug delivery problems by allowing for the tailored solubility and tissue specific targeting of 
drugs through ligand or antibody immobilization to the multivalent surface.4, 5 Recently, 
dendrimers have been employed as a substrate for delivering a wide range of therapeutic 
agents including water insoluble drugs,6, 7 anti-cancer chemotherapeutics,8-10 and 
oligonucleotides for enhanced gene transfection.11 
Some of the most promising non-viral gene delivery systems are dendritic structures with 
cationic amine exteriors, namely the polyamidoamine (PAMAM) and polypropylenimine 
(PPI) dendrimers.12  These synthetic vector systems form nucleic acid/dendrimer complexes 
through the interaction of cationic dendrimer exteriors with the negatively charged 
phosphates on the DNA backbone.  Since Haensler et al. first reported the use of PAMAM 
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dendrimers to mediate efficient gene transfection in vitro,13 numerous reports have explored 
the use of dendrimers as gene delivery vehicles, carefully detailing transfection efficiency as 
a function of carrier size, surface charge, and exterior functionality.11, 14-17   Although 
cationic amine-terminated dendrimers are suitable carriers to enhance gene transfection, the 
toxicity of these novel delivery vehicles and their unfavorable interactions with cellular 
membranes has slowed their widespread clinical application.11 Indeed, Duncan et al. recently 
reviewed the toxicity of amine containing dendrimers and concluded that amine-terminated 
dendrimers (e.g., PPI, PAMAM) exhibited size dependent cytotoxic effects based on the 
number of free amines at the surface.18  To further elucidate the mechanism of primary amine 
dendrimer toxicity, Hong et al. demonstrated that positively charged amine-terminated 
dendrimers induced the formation of nanoscale holes upon interaction with artificial lipid 
bilayers.19  Possible mechanisms of hole formation include dendrimer-mediated removal of 
lipids from the membrane20 or direct insertion of the amine-terminated dendrimers into the 
membrane.21  Several other studies have been conducted illustrating that both negatively 
charged and neutral dendrimers were non-toxic, clearly demonstrating the structure/toxicity 
relationship that is governed primarily by the functional groups on the dendrimer surface.18, 
22-26 
In this chapter, the cytotoxic effects of model dendritic systems against human umbilical 
vein endothelial cells (HUVEC) are evaluated and provide further mechanistic insight into 
the structure/toxicity relationship of multi-functional polypropylenimine dendrimers.  Time-
dependent changes in the plasma membrane permeability of HUVEC toward propidium 
iodide (PI) and the concomitant release of cytosolic LDH were used to quantify cytotoxicity.  
Laser scanning confocal microscopy was employed to monitor both the interaction of 
fluorescently-labeled dendrimers with the plasma membrane of HUVEC and the effect of 
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dendrimer adhesion on the membrane potential of intracellular mitochondria.  Chemical 
modification of the surface amines on the parent dendrimer and conversion to neutral 
acetamide or poly(ethylene glycol) functionalities reduced both the visible adhesion of 
dendrimers to the plasma membrane of cultured HUVEC and their cytotoxicity, illustrating 
that removal of the cationic charges from the dendrimer’s surface is a necessary step in the 
synthesis of fully biocompatible drug delivery vehicles.  
4.2 Experimental Section 
4.2.1 General 
Tetramethylrhodamine methylester (TMRM) was purchased from Molecular Probes 
(Eugene, OR).  Polypropylenimine dendrimer (DAB-Am-64) starting material, propidium 
iodide (PI), poly(ethylene glycol) monomethyl ether (M-PEG2000), Kaiser test kit, and all 
other reagents were purchased from the Aldrich Chemical Company (Milwaukee, WI). 
Methanol was distilled over magnesium prior to use. Water was purified with a Millipore 
Milli-Q gradient A-10 purification system (Bedford, MA).  Spectra/Por® Float-A-Lyzers® 
were purchased from Spectrum Laboratories Inc. (Rancho Dominguez, CA). Nuclear 
magnetic resonance (NMR) spectra were collected in deuterated water (D2O) using a 400-
MHz Bruker Nuclear Magnetic Resonance spectrometer (Brucker, Germany).  Mass spectra 
were acquired using a Micromass Quattro II triple quadrupole mass spectrometer equipped 
with a nano-electrospray ionization source in positive-ion mode.  Absorption spectra were 
recorded on a Perkin Elmer Lambda 40 UV-vis spectrophotometer (Norwalk, CT). 
Fluorescence measurements were performed using a FluoStar Galaxy plate reader (BMG 
LabTechnologies, Inc., Durham, NC).  Confocal fluorescence microscopy experiments were 
performed using an LSM 510 laser scanning confocal microscope (Carl Zeiss, Thornwood, 
NY). 
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4.2.2 Synthesis and characterization of dendrimer conjugates 
4.2.2.1 DAB-Ac40-FITC2 (1) 
DAB-Am-64 (300 mg, 0.042 mmol) was dissolved in 30 mL of anhydrous methanol 
under an inert argon atmosphere and to the stirring solution was added acetic anhydride (126 
µL, 1.34 mmol) and pyridine (119 µL, 1.47 mmol) to stoichiometrically convert half of the 
primary amines on the dendrimer to acetamide functionalities.  The solution was stirred for 
24 h and then 10 mL of anhydrous methanol containing fluorescein isothiocyanate (FITC) 
(49 mg, 0.126 mmol) was added to stoichiometrically attach 3 fluorescent residues per 
dendrimer.  The solution was stirred for an additional 24 h in the dark and then separated into 
several aliquots for purification or further functionalization.  5 mL of the product solution 
was concentrated under reduced pressure, dissolved in water, and added to a Spectra/Por® 
Float-A-Lyzer® (5 mL, 1000 MWCO) for dialysis in 2 L of 0.5 M NaCl for 24 h, followed by  
dialysis in ultrapure Milli-Q water for 3 d (3 x 2L).  The aqueous sample was frozen and 
lyophilized to yield 21 mg of an orange solid: 1H NMR (D2O, δ): 1.2-1.70 (m, 
NCH2CH2CH2N, NCH2CH2CH2CH2N), 1.80 (s, COCH3), 1.86 (s, COCH3), 2.07-2.54 (m, 
NCH2CH2CH2N, NCH2CH2CH2NH), 2.72 (m, NCH2CH2CH2NH2), 2.91 (m, 
NCH2CH2CH2NHCOCH3), 3.04 (m, NCH2CH2CH2NHCOCH3).  ESI-MS calculated MW: 
9121.4 g/mol, experimental MWavg: 9624.9 g/mol [1190.9 (M+8H)8+, 1386.1 (M+7H)7+, 
1615.4 (M+6H)6+]. UV/Vis (MeOH): λmac= 504 nm. 
4.2.2.2 DAB-Ac59-FITC2 (2)  
Acetic anhydride (32 μL, 0.34 mmol) and pyridine (27 μL, 0.34 mmol) were added to 5 
mL of product solution containing dendrimer 1 to fully acetylate the remaining primary 
amines on the fluorescently labeled dendrimer. The solution was stirred for 24 h in the dark, 
concentrated under reduced pressure, resuspended in water, and dialyzed against 2 L of 0.5 
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M NaCl for 24 h, followed by dialysis in ultrapure Milli-Q water for 3 d (3 x 2L).  The 
aqueous sample was frozen and lyophilized to yield 26 mg of an orange solid: 1H NMR 
(D2O, δ): 1.4-1.70 (m, NCH2CH2CH2N, NCH2CH2CH2CH2N), 1.84 (s, COCH3), 2.2-2.62 
(m, NCH2CH2CH2N, NCH2CH2CH2NH), 3.03 (m, NCH2CH2CH2NHCOCH3).  ESI-MS 
calculated MW: 10,425 g/mol, experimental MWavg: 10,206 g/mol [1702.0 (M+6H)6+, 
2041.9 (M+5H)5+, 2552.7 (M+4H)4+]. UV/Vis (MeOH): λmac= 504 nm. 
4.2.2.3 Synthesis of 4-nitro-phenyl-MPEG (adapted from Kojima et al.)27 
Poly(ethylene glycol) monomethyl ether (M-PEG2000) (10 g, 5 mmol) was dissolved in a 
stirring solution of THF (400 mL) to which 4-nitrophenyl chloroformate (2.01 g, 10 mmol) 
and triethylamine (1.39 mL, 10 mmol) were added.  The solution was stirred for 2 d, the THF 
was removed under reduced pressure, and the crude product was resuspended in toluene (100 
mL).  The salt impurities were removed via filtration and the final product was precipitated 
from toluene with copious amounts of ether.  The white precipitate was dried to yield 4.68 g 
(2.1 mmol, 43%) of activated M-PEG2000 and proton assignments matched those previously 
reported in the literature.  1H NMR (CDCl3, δ): 3.36 (s, OCH3), 3.44 (m, CH2OCH3), 3.52 (m, 
COOCH2CH2O), 3.55-3.75 (br, OCH2CH2O), 3.79 (m, OCH2CH2OCH3), 4.41 (dd, 
COOCH2CH2O), 7.48 (d,  aromatic), 8.25 (d, aromatic). 
4.2.2.4 DAB-Ac40-PEG4-FITC2 (3) 
Activated M-PEG2000 (443 mg, 0.2 mmol) was added to 5 mL of product solution 
containing dendrimer 1 to covalently attach long poly(ethylene glycol) chains to the 
remaining primary amines on the fluorescently labeled dendrimer. The solution was stirred 
for 24 h in the dark, concentrated under reduced pressure, resuspended in water, and dialyzed 
in a Spectra/Por® Float-A-Lyzer® (10 mL, 5000 MWCO) against 2 L of 0.5 M NaCl for 24 h, 
followed by dialysis in ultrapure Milli-Q water for 3 d (3 x 2L).  The aqueous sample was 
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frozen and lyophilized to yield 143 mg of an orange solid: 1H NMR (D2O, δ): 1.39-1.78 (m, 
NCH2CH2CH2N, NCH2CH2CH2CH2N), 1.87 (s, COCH3), 2.2-2.65 (m, NCH2CH2CH2N, 
NCH2CH2CH2NH), 2.84 (m, NCH2CH2CH2NH2), 3.07 (m, NCH2CH2CH2NHCO-PEG), 3.28 
(s, OCH3), 3.41 (m, CH2OCH3), 3.50-3.70 (br, OCH2CH2O), 3.78 (m, OCH2CH2OCH3), 4.09 
(m, NHCOOCH2CH2O), 4.23 (m, NHCOOCH2CH2O). ESI-MS: (unable to resolve a high 
molecular weight species with identical sampling procedure) 
4.2.3 Ninhydrin assay for the detection of free amines  
The following procedure was adapted from Sarin et al. and uses the reagents in a standard 
commercially available Kaiser Test kit.28  Dendrimer samples were diluted to 3 µM in 
absolute EtOH (n=4 dilutions) and 700 uL was added to a quartz cuvet, followed by 50 µL of 
phenol (80% in ethanol), 50 µL KCN in H2O/pyridine, and 25 µL of ninhydrin (6% in 
EtOH).  The solutions were capped, heated at 100 °C for 10 min, and the spectroscopic 
absorption maxima of the Ruhemanns blue chromophore was measured at 570 nm via 
absorption spectroscopy.  Absorbance values for dendrimers 1-3 were averaged (n=4), 
normalized to the absorption maxima of the FITC chromophore (λmax=504 nm) as an internal 
standard, and compared to the ninhydrin response of 3 µM G4-PAMAM possessing 64 
exterior amines at the surface.  Values represent the number of remaining amines per mol 
dendrimer conjugate and are given as the standard deviation of the mean. 1 (DAB-Ac40-
FITC2) = 24.9 ± 4.9,  2 (DAB-Ac59-FITC2) = 3.7 ± 1.5, 3 (DAB-Ac40-PEG4-FITC2) = 21.2 ± 
5.5. 
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4.2.4 Cell culture 
Human umbilical vein endothelial cells (HUVEC) were purchased from Genlantis (Cat. 
#PH200050N, Genlantis Inc., CA) and propagated in Genlantis’s serum containing 
endothelial growth medium (Cat. # PM 211500) according to the manufacturer’s protocol.  
4.2.5 Propidium iodide (PI) viability assay 
HUVEC were plated on 24-well tissue culture treated dishes (BD Bioscience #353047) at 
a density of 3.0 x 105 cells/ml (150 x 103 cells/well) and incubated overnight at 37oC, in 5% 
CO2/95% air for 18-20 h.  For the PI assay, the incubation buffer was aspirated from each of 
the wells and replaced with 500 μL of Krebs-Ringer-HEPES (KRH) buffer containing (mM): 
115 NaCl, 5 KCl, 1 CaCl2, 1 KH2PO4, 1.2 MgSO4, 25 HEPES, pH 7.4, supplemented with 30 
µM of PI [16].  The fluorescence of the cells in the absence and/or presence of 3 µM 
dendrimer conjugates (1, 2 or 3) was monitored using a FluoStar Galaxy plate reader (BMG 
Labtech, Durham, NC) with excitation and emission filters set at 544 and 640 nm, 
respectively. Fluorescence was acquired at 15 min intervals for a total of 150 min.  An 
additional 20 min incubation of cells with 40 µM digitonin was required to completely 
permeabilize not only plasma membrane of HUVEC but also other internal membranes 
(including nuclear envelope) these conditions guarantee full access of PI to intracellular 
nucleic acids for achieving a maximum PI fluorescence. Cell viability was presented as 
increase in PI fluorescence from each well expressed as percentage of maximal obtained in 
cells treated with digitonin (100% cell death). 
4.2.6 Lactate dehydrogenase (LDH) assay 
20 µL aliquots of incubation buffer were removed from the plate used for the PI assay 
and stored at -20oC in black 96-well plates (Greiner, Monroe, NC) for subsequent LDH 
assays. Briefly, 96-well plates containing aliquots of incubation buffer were warmed to 37oC 
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and LDH activity was measured from the rate of NADH production after adding 180 µl of 
the buffer containing (mM): 0.22 NAD+, 11.1 sodium lactate and 11.1 hydrazine, pH 8.0 into 
each well.29 The kinetics of NADH fluorescence was monitored using a FluoStar Galaxy 
plate reader using 340 nm excitation and 460 nm emission filters.  The LDH activity was 
expressed as the rate of relative fluorescence units (RFU) per min per well.  Results were 
normalized to maximal LDH activity in each well obtained from samples treated with 40 µM 
of digitonin for 20 min. 
4.2.7 Imaging with laser scanning confocal microscopy 
For confocal microscopy study HUVEC (3.0 x 105 cells/ml) were plated on round glass 
slides (Fisher Scientific, Pittsburgh, PA) and incubated overnight in 1 mL of Genlantis’ 
growth medium at 37°C, 5%CO2 in a humidified environment.  The cells on the coverslip 
were preloaded with TMRM, a mitochondria specific fluorescent dye (100 nM, for 30 min at 
37oC) and placed into an environmental chamber (37oC, 5 %CO2, 100% humidity) of the 
stage of fluorescent confocal microscope Zeiss LSM 510 (Carl Zeiss, Thornwood, NY). 
Incubation medium was replaced with 1 mL of KRH buffer containing 30 µM PI and 3 µM 
FITC-dendrimer and confocal images of HUVEC were acquired every 5min for 30 min total 
using a 63x N.A. 1.4 planapochromat oil immersion lens with pinholes set to 1.0 Airy units 
in both the red (TMRM) and green (FITC) channels.  Fluorophores were excited with the 
543-nm line of a HeNe laser (TMRM) and the 488-nm line of an Ar laser (FITC), with laser 
intensities attenuated to 0.05%.  Green and red fluorescence were separated by a dichroic 
filter (NFT 545) and recorded in channels 2 and 3 of the LSM 510 using band-pass (BP 500-
530) and long-pass (LP 560) filters, respectively.   (Fluorophore absorption/emission spectra 
provided by manufacturer and dendrimer absorption spectra are shown in Figure 4.1) 
4.2.8 Statistics 
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Differences between the effects of dendrimers on cultured cells were analyzed using one-
way ANOVA with Fisher’s multiple comparisons post hoc test, p < 0.05 as the criterion of 
significance. All experiments were repeated at least three times and results were expressed as 
means ± SEM. When error bars are not shown, they fall within the diameters of the symbols. 
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Figure 4.1  Absorption (dotted) and emission (solid) spectra of all fluorescent dyes 
used in the current work as provided by the manufacturer (Invitrogen). 
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Scheme 4.1 Synthesis of multifunctional dendrimer conjugates. (DAB-Am-64: 
parental unmodified generation 5 polypropylenimine dendrimer; FITC: 
fluorescein isothiocyanate) 
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4.3 Results and Discussion 
4.3.1 Synthesis and characterization of dendrimer conjugates 
Generation 5 polypropylenimine dendrimer (DAB-Am-64) was chosen as the starting 
material due to its previously reported toxicity in drug delivery applications and its capacity 
for a large number of additional functionalities.4, 18  The cytotoxicity of DAB-Am-64 and 
other amine-containing dendrimers is mediated by non-specific interactions of the positively 
charged primary amines with lipid membranes.22  Therefore, we stoichiometrically targeted 
half of the surface positive charges on the parental dendrimer (DAB-Am-64) for conversion 
into acetamides via reaction with acetic anhydride (Scheme 4.1). Previously, amide dendritic 
exteriors have been used to increase water solubility and eliminate the toxicity of primary 
amine dendrimer constructs.19, 30  The partially acetylated product was then fluorescently 
labeled with FITC to produce a fully traceable dendrimer conjugate 1 (Scheme 4.1, DAB-
Ac40-FITC2) for studying the interaction of mixed amine/amide dendrimers with cultured 
cells.  Fluorescent labeling of dendrimer drug delivery scaffolds enables the direct 
monitoring of cellular interactions in vitro and also imparts a molecular probe to study future 
bio-distribution in vivo.10, 31 The modified dendrimer was dialyzed for 96 h, lyophilized, and 
analyzed via nuclear magnetic resonance spectroscopy (1H-NMR) and electrospray 
ionization mass spectrometry (ESI/MS).  The calculation and assignment of all of the protons 
on DAB-Am-64 is shown in Figure 4.2. The extent of amide functionalization (40 of 64 
amines) was calculated from the integration ratio of the protons on the newly formed amide 
(COCH3) to the aliphatic methylene protons of the DAB-Am-64 dendritic interior (Figure 
4.3) according to Equations 4.1 and 4.2:   
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Equation 4.1  
   
( ) ( )EDCOCH Intensity
sHED
Intensity
x
+
+= '3
3
 Where  x = number of acetamide groups 
      
10.2
252
48.1
3 =x  96.3723.6 =x    x= 59.2 acetamide groups 
Equation 4.2 
( ) ( )CBCOCH Intensity
sHCB
Intensity
x
+
+= '3
3
 Where  x = number of acetamide groups 
     
14.3
372
48.1
3 =x  56.55042.9 =x  x= 58.4 acetamide groups 
 
To determine the number of fluorophores attached to the dendrimer scaffold the 
fluorescein dye structure and proton assignments are shown in Figure 4.4.  The integrated 
ratio of the aromatic protons on the fluorophore to the protons alpha to the exterior amine 
(CH2NH2) indicated approximately 2 FITC residues per dendrimer according to Equations 
4.3 and 4.4: 
Equation 4.3 
( )EDed Intensity
sHED
Intensity
x
++
+= '6
)(
  Where  x = number of fluorophores 
            
10.2
252
094.
6 =x   68.236.12 =x   x = 1.88 FITC /dendrimer 
 
Equation 4.4 
( )CBed Intensity
sHCB
Intensity
x
++
+= '6
)(
  Where  x = number of fluorophores 
             
14.3
372
094.
6 =x   97.3484.18 =x  x = 1.85 FITC /dendrimer
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56
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128
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DAB-Am-64
A = protons on 11 = 128 H’s
B = protons on 9 = 128 H’s
C = protons on 2,3,5,6,8 = 244 H’s
D = protons on 4,7,10 = 248 H’s
E = protons on 1 = 4 H’s
Figure 4.2 Proton assignments for the complete hyper-branched structure of DAB-
Am-64 separated in to classes A-E with the corresponding number of 
protons detailed for each class. 
 145
 
 
 
 
 
Figure 4.3 Representative NMR spectra interpretation for A) DAB-Am-64 and B) 
DAB-Ac59-FITC2. 
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B 
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Figure 4.4 Structure of fluorescein isothiocyanate conjugated to an amine terminated 
dendrimer with proton classifications for NMR spectra interpretation. 
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    The remaining exterior amines of the partially acetylated and FITC-labeled dendrimer 1 
(DAB-Ac40-FITC2) were further modified as shown in Scheme 4.1. Dendrimer 1 was reacted 
with either excess acetic anhydride to fully acetylate the dendrimer surface yielding 
dendrimer 2 (DAB-AC59-FITC2) or with 4-nitrophenyl poly(ethylene glycol) 
monomethylether (activated M-PEG2000) following a previously reported procedure27 to yield 
PEG-ylated dendrimer 3 (DAB-Ac40-PEG4-FITC2).  Dendrimer conjugates 1-3 thereby 
provide a unique set of fluorescently labeled macromolecules, comprising defined 
percentages of amine, amide, or PEG modification, from which to study dendrimer induced 
cytotoxicity in vitro.  A quantitative ninhydrin assay was then conducted on the dendrimers 
to determine the number of free amines per molecule of dendrimer.28  Dendrimer 1 retained 
24.9 ± 4.9 primary amines after partial acetylation, dendrimer 2 contained 3.7 ± 1.5 
remaining amines after full acetylation, and PEG modified dendrimer 3 possessed 21.2 ± 5.5 
solvent accessible amines after coupling of the activated PEG moieties, indicating attachment 
of ∼4 hydrophilic PEG chains.  The quantification of amines per dendrimer molecule 
correlated with the number of amines predicted from NMR and ESI-MS data analysis (1 = 22 
NH2; 2 = 3 NH2; 3 = 18 NH2); in all cases the predicted number of remaining amines was 
within the error of the number of amines determined via the colorimetric assay.  
4.3.2 Cytotoxicity of dendrimer conjugates 
The toxicity of amine containing dendrimer constructs has been studied against a range 
of target tissue cell lines from hamster ovarian cells14 to human embryonic kidney cells.32  
However, upon systemic administration of a delivery system, the therapeutic first comes into 
contact with the endothelium which ultimately mediates  the delivery of the drug to other 
tissues.33, 34  The present study evaluates the cytotoxicity of the dendrimer conjugates toward 
cultured human umbilical vein endothelial cells (HUVEC) as a model of the intravascular 
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lining that first interacts with dendrimer delivery vehicles upon intravenous injection.  
Additionally, endothelial cells are a primary target for gene therapies used to treat many 
cardiovascular conditions including restenosis and myocardial ischemia.26   
To assess the cytotoxicity of the various dendrimer conjugates, HUVEC were plated to 
85% confluency in 24-well plates and treated with dendrimer conjugates (3 µM) in KRH 
buffer containing 30 µM propidium iodide (PI).  In cultures possessing healthy cells with 
intact membranes, PI is non-fluorescent and does not enter the cell.  When the plasma 
membrane is compromised, PI diffuses into the cell and binds to nuclear chromatin, 
producing an increase in red fluorescence.35, 36  The viability of HUVEC was calculated from 
the observed PI fluorescence intensity normalized to the maximum values achieved after 
complete permeabilization of the plasma membranes of the entire HUVEC population with 
digitonin (40 µM), a recognized non-ionic detergent that solubilizes membrane-bound 
cholesterol leaving non-selective pores in biological membranes.37 
HUVEC treated with 3 µM dendrimer 1 (DAB-Ac40-FITC2) exhibited rapid changes in 
plasma membrane permeability as evidenced by the sharp increase in PI fluorescence after 
only 30 min (Figure 4.5A).  The rise is indicative of substantial acute toxicity of this agent.  
After 150 min, the fluorescence signal began to plateau and >90% of the cells in culture were 
dead.  The temporal dynamics of plasma membrane disruption by dendrimer 1 was further 
confirmed by measuring the release of LDH, a cytosolic enzyme, from the same cells.  As 
shown in Figure 4.5B, the LDH activity from aliquots of the incubation buffer also increased 
over time after exposure to dendrimer 1 but at a slight delay compared to the passage of the 
smaller PI.  Notably, the PI assay demonstrated more than 50% cell death after 60 min of 
dendrimer exposure, while the LDH release reached only 20% of the maximum.  Therefore, 
the release of LDH initiated by amine-containing dendrimers occurred at longer incubation 
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times than the increase in PI fluorescence from the same cells, indicating that the size of the 
holes in the plasma membrane increased progressively with time; cells first became 
permeable to the 698 Da PI molecules and later to the 140 kDa LDH enzyme. Both assays 
clearly indicate that amine-containing dendrimer 1 caused permeabilization and disruption of 
the plasma membrane integrity in a time-dependent fashion, thus confirming that dendrimers 
with cationic amines at their surfaces are cytotoxic and that partial acetylation is insufficient 
at eliminating the deleterious effects of amine-presenting delivery vehicles.  These data 
provide experimental validation to the molecular dynamics simulations reported by Larson 
and co-workers that suggested pore formation could be induced by 50% acetylated PAMAM 
dendrimers on simulated DPPC bilayers.21 
The viability of HUVEC exposed to 3 μM dendrimers 2 and 3 is also shown in Figure 
4.5.  No observable cytotoxicity was detected for either dendrimer using the PI (Fig. 4.5A) or 
LDH (Fig. 4.5B) assays and there was no statistical differences between the effect of 
dendrimers 2 and 3 (p=NS). After 150 min of incubation of HUVEC, the level of PI labeling 
and LDH release remained unchanged from initial levels, indicating that the fully amidated 
and PEG-modified exteriors did not disrupt the plasma membrane integrity.  These data are 
in accord with the previously observed enhancement of dendrimer’s biocompatibility through 
modification of surface functionalities.14, 22, 32, 38   
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Figure 4.5 Cytotoxicity of dendrimer conjugates in cultured HUVEC. A) Time 
dependent cell killing as evaluated using PI assay: (-■-) dendrimer 1 
(DAB-Ac40-FITC2),      (-●-) dendrimer 2 (DAB-Ac59-FITC2), (-▲-) 
dendrimer 3 (DAB-Ac40-PEG4-FITC2). B) Time dependence of 
dendrimer-mediated release of LDH from cultured HUVEC: (-■-) 
dendrimer 1 (DAB-Ac40-FITC2), (-●-) dendrimer 2 (DAB-Ac59-FITC2), (-
▲-) dendrimer 3 (DAB-Ac40-PEG4-FITC2). The data are means ± SEM of 
three independent experiments.  
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4.3.3 Confocal laser scanning microscopy of dendrimer interactions with HUVEC 
4.3.3.1 Disruption of the plasma membrane integrity by amine containing dendrimers   
The exact mechanism of gene transfection for cationic dendrimers is unknown, but the 
ability to disrupt the plasma membrane and induce hole formation as previously described 
resembles the physical process by which other non-viral transfection agents induce pores to 
deliver DNA cargo (e.g. lipofectamine).39, 40  Interaction of the cationic delivery vehicle with 
the membrane is essential, but large disruptions may cause an influx of extracellular fluid 
and initiate a cascade of apoptotic events including the depolarization of intracellular 
mitochondria. 
To visually monitor the time-dependent changes in membrane permeability, HUVEC 
were cultured onto glass slides in KRH buffer containing 30 μM propidium iodide (PI), 
treated with dendrimer conjugates (3 μM), and imaged via confocal fluorescence 
microscopy.  Fluorescent labeling of the dendrimer conjugates enabled direct visualization of 
the interaction between the dendrimer and the plasma membrane of cultured cells.  Figure 4.6 
depicts HUVEC exposed to the partially modified, amine containing dendrimer 1.  After 30 
min, fluorescently-labeled dendrimer 1 appeared to completely permeate the plasma 
membrane and progressively accumulate within the intracellular compartment, either via 
diffusion through newly formed holes or an endocytotic mechanism proposed previously for 
other dendrimer conjugates.41  A rapid increase in the number of red fluorescent nuclei was 
also observed, visually confirming the kinetics of PI uptake as shown in Figure 4.5.  The 
sequence of images (Fig. 4.6) clearly illustrates that increases in red fluorescence (PI uptake) 
coincide with the increase of the green fluorescence (dendrimer uptake) throughout the entire 
cell population.  In the absence of dendrimers, cells retained their viability for up to 90 min 
and confocal images demonstrated no significant increase in red fluorescence of PI over the 
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time course of the experiment (data not shown).  In similar experimental setup, exposure of 
HUVEC cells to dendrimer conjugate 2 or 3 resulted in no appreciable increase in PI 
fluorescence, consistent with the PI and LDH cytotoxicity assays (Fig. 4.5A and 4.5B).  
4.3.3.2 Cellular adhesion of dendrimers 1-3 and mitochondrial depolarization 
The series of confocal microscopy images shown in Figure 4.7 illustrate the time 
dependent changes in HUVEC viability after addition of the dendrimer conjugates.  Upon 
exposure of cells to FITC-labeled amine-terminated dendrimer 1 for 5 min, a bright, 
punctuated green outline of the cells was observed, indicating adherence of FITC-dendrimer 
to the plasma membrane (Figure 4.7, DMR 1).  Although imaged simultaneously, the origins 
of the PI and TMRM fluorescence are different. Here, imaging of PI and TMRM (both were 
excited using 543 nm laser line and red fluorescence was acquired through LP560 filter) was 
intended to demonstrate that the collapse of mitochondrial membrane potential (punctate 
structures within the cells) occurs before the increased characteristic PI fluorescence 
responsible for nuclear staining (large oval rings filled with fragmented red patches) as 
shown in Fig. 4.8, 30 min. The cellular interactions of fluorescently-labeled dendrimers 2 
and 3 were also examined with the same protocols used for FITC-labeled dendrimer 1, but no 
appreciable accumulation of the green fluorescence was observed on the membrane of 
HUVEC in culture (Figure 4.7, DMR 2 & DMR 3). Thus, chemical conversion of cationic 
amines at the dendrimer surface to amides or sterically shielding the cationic surface via 
attached hydrophilic PEG chains resulted in substantial loss of the polymer’s adhesion to the 
plasma membranes of HUVEC.  Even at longer incubation times (>60 min) no significant 
accumulation at the membrane was observed for either the amide or PEG modified 
dendrimer conjugate. 
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To probe the effects of dendrimers on the membrane potential of intracellular 
mitochondria, cells were loaded with 100 nM TMRM dye prior to imaging. The cationic dye 
is retained in the mitochondria with high membrane potential indicative of cell viability. 
However, compromised cells undergo a characteristic loss of mitochondrial membrane 
potential and a disappearance of red fluorescent staining.42    Confocal images of endothelial 
cells with TMRM-labeled mitochondria exposed to FITC-labeled dendrimers are shown in 
Figure 4.8.  At early time points (5 min) of treatment with any of the dendrimer conjugates 
intracellular mitochondria retain TMRM dye in the matrix.   After 15 min of exposure to 
dendrimer 1, the plasma membrane of cultured cells no longer retained its integrity as 
indicated by the decrease in red mitochondrial fluorescence (white arrows) and a slow influx 
of extracellular PI into the cell nuclei (Fig. 4.8, DMR 1).  Complete loss of TMRM 
fluorescence from mitochondria coincided with the staining of the nuclear envelope (white 
asterisks) and loss cell viability that occurred at 30 min of exposure to dendrimer 1.  In 
control experiments we demonstrated that TMRM, a mitochondria selective fluorescent dye, 
does not bind to cell nuclei, and vice versa, PI does not label mitochondria in cells with 
compromised plasma membranes (Figures 4.9 and 4.10).   
Mitochondrial depolarization may be the result of a dramatic increase in cytosolic Ca2+ 
concentration due to the loss of plasma membrane integrity and influx of extracellular Ca2+.43  
Correspondingly, no visible mitochondrial depolarization or PI staining of the nuclei was 
observed upon exposure of cultured cells to the FITC-labeled dendrimers 2 or 3 (Fig. 4.8, 
DMR 2 & DMR 3).  The TMRM fluorescence appeared to be unchanged over 30 min, 
indicating preservation of the mitochondrial membrane potential and minimal damage to the 
cellular plasma membrane.  Despite the solvent accessible amines still available on 
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dendrimer conjugate 3, the 2,000 MW PEG chains proved to be sufficient to block the 
cationic surface from interacting with the negatively charged membranes of endothelial cells. 
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FITC 
(488 nm) 
PI  
(543 nm) 
5 min 30 min 60 min 90 min 
Figure 4.6 Confocal fluorescence microscopy images of the time dependent 
membrane permeability changes of HUVEC exposed to 3 μM amine 
containing dendrimer 1 in culture media containing 30 μM PI.   
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Figure 4.7 Confocal images of HUVEC treated with 3 µM fluorescent dendrimer 
conjugate (green) co-loaded with TMRM in KRH buffer supplemented 
with 30 μM of PI.  Dendrimer 1 adhered and completely outlined the 
plasma membrane of most cells within 5 min followed by increasing 
green fluorescence over the 30 min of incubation. NO significant 
dendrimer adherence was observed with dendrimers 2 and 3. 
15 min 30 min 5 min 
20 μM 
DMR 2 
DMR 1 
DMR 3 
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Figure 4.8 Confocal images of HUVEC treated with 3 µM fluorescent dendrimer 
conjugate co-loaded with TMRM in KRH buffer supplemented with 30 
μM of PI.  Dendrimer 1 resulted in a progressive loss of mitochondrial 
membrane potential (decrease in TMRM fluorescence, white arrows) and 
entrance of PI into the cells at 15 min and 30 min (white asterisks denote 
typical red fluorescence of PI in the nuclei).   
DMR 2 
DMR 1 
DMR 3 
20 μM 
15 min 30 min 5 min 
* * 
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0 min 
(Pre-Injection) 
5 min 
 
15 min 
 
30 min 
 
Green  
(DAB-Ac40-FITC2) 
Red 
(TMRM dye) 
Figure 4.9 Time dependent mitochondrial depolarization as indicated via the 
diasapearance of TMRM (red) fluorescence.  All cells indicate a 
gradual decrease in TMRM fluorescence over time but the affect is  
most pronounced in the indicated cell at 30 min. (dotted circle). These 
images serve as a control experiment, indicating no dark red staining of 
the nuclei without propidium iodide (PI) added to the incubation media. 
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5 min 
 
15 min 
 
30 min 
 
Green  
(DAB-Ac40-FITC2) 
Red 
(PI dye) 
Figure 4.10 Time dependent membrane permeability toward propidium iodide (PI) 
as indicated via appearance of the bright red stained nuclei (red) 
fluorescence.  The red fluorescence of skirting the nucleus of the cell is 
attributed to fluorescent staining of ribosomal RNA throughout the 
endoplasmic reticulum.  These images serve as a control experiment, 
indicating the affect of dendrimer 2 on cells not previously stained with 
TMRM.   
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Figure 4.11  Illustration of dendrimers interacting with the plasma membrane of 
cultured cells. A) Primary amine containing dendrimer 1 (DAB-Ac40-
FITC2) induces hole formation and allows the transport of dendrimer, PI, 
and LDH across the plasma membrane.  B) Amide/PEG modified 
dendrimer 3 (DAB-Ac40-PEG4-FITC2) exhibits no membrane disruption or 
intracellular accumulation monitored via fluorescence based techniques. 
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4.4 Conclusion 
Figure 4.11 summarizes our results obtained in the fluorescent viability assays and confocal 
microscopy experiments.  Cationic amine residues at the surface of polypropylenimine 
dendrimers induced drastic and time-dependent changes in HUVEC membrane permeability 
toward cytosolic enzymes and PI (Fig. 4.11A).  Rapid cellular uptake of PI, a low molecular 
weight dye, was detected as early as 15 min and the larger cytosolic proteins (e.g. LDH) 
were released from the cells at later time points.  Alteration of amines to amides or covalent 
attachment of PEG resulted in dendrimer conjugates containing mixed functionalities with no 
acute toxicity profiles (Fig. 4.11B). The data presented herein are in agreement with the 
reported cytotoxicity of amine terminated dendrimers and strongly suggests that primary 
amine-terminated dendrimers should be avoided as drug delivery vehicles. In conclusion, the 
cytotoxicity and biocompatibility of dendrimer-vehicles is dependent on the surface 
composition, and it is essential that dendrimer-based drugs formulated for intravenous 
injection be tested for specific cytotoxicity toward endothelial cells. 
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Chapter 5 
Future Applications of Nitric Oxide Releasing Dendrimers 
 
5.1 Introduction 
The development of NO-releasing dendrimers via N-diazeniumdiolate and S-nitrosothiol 
chemistries enables new tools to study the role of NO in biomedical applications.  Thus far 
the synthetic procedures to attach two of the most common organic NO donor functionalities 
to amine terminated dendrimers (e.g., PAMAM) have been established.  Diazeniumdiolates 
and nitrosothiols both retained their characteristic NO-release behavior when attached to the 
dendrimer scaffolds and, in some cases, a “dendritic effect” was observed that may increase 
NO-releasing dendrimer utility.  For example, alkyl diazeniumdiolates on the secondary 
amines of polypropylenimine dendrimers (Chapter 2) exhibited prolonged NO-release half-
lives when compared to analogous diazeniumdiolate small molecules.  The high local 
concentration of amines inside the dendrimer resulted in a dependence on pH and reduced 
proton initiated decomposition.  The creation of the NO donor-modified dendrimers and full 
characterization of dendritic NO-release kinetics has laid the foundation for future 
discoveries. 
As detailed in the previous chapters, dendrimers are attractive delivery vehicles for NO 
because the hyper-branched scaffold may be modified to contain a large number of NO 
donors per molecule.  The most straightforward application of this technology is as polymer 
fillers to confer NO-release to biomedical grade polymers, similar to the strategies reviewed 
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in Chapter 1.  In addition to storing micromolar quantities of NO per mg, the greatest 
attribute of dendrimers as macromolecular NO donors is the multivalent surface that may be 
functionalized with additional ligands.  Expansion of the current work through conjugation 
of moieties capable of tissue specific targeting, attachment of molecular probes for imaging, 
and the synthesis of “pre-packaged” diazeniumdiolates for precise stoichiometric control of 
NO loading are the next steps toward creating multi-functional NO-releasing devices.  As 
depicted in Figure 5.1, the proposed chemistry detailed in this chapter may allow for the 
fabrication of NO-releasing vehicles that may be targeted and tracked thereby harnessing the 
therapeutic potential of NO. 
5.2 Dendrimer Doped Polymers for Wound Healing and other Biomedical Applications 
Extensive research has been conducted on NO-releasing materials that have applications 
across a broad spectrum of medical device industries.  For example, implants coated with 
NO-releasing polymers have been shown to reduce the incidence of infection1 and aid in 
minimizing the foreign body response to implanted materials.2  Sensors with sustained NO 
flux have led to more thromboresistant surfaces and improved sensor longevity.3, 4   The NO-
releasing dendrimers described in this thesis may also be incorporated into polymeric 
matrices.  The ability to tailor the NO-release kinetics based on NO donor structure and 
increase the lipophilicity of the overall macromolecular framework to prevent leaching from 
the polymer, make dendrimers incredibly valuable tools for future sensor membrane 
research.  The primary detriment to NO-releasing polymeric device coatings is that no 
system has an infinite reservoir of NO.  As such, there is a limit to the amount of NO donor 
that may be loaded into the polymer before the polymer loses its desired mechanical 
properties.  Nevertheless, storing large dendrimer-bound quantities of NO may extend NO-
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release durations from days to weeks, and lengthen the experimental timescales for 
examining NO-dependent biological phenomena. 
One setting where NO-releasing dendrimers may make the biggest impact is wound 
repair.  Only recently has it been discovered that NO mediates many of the processes 
involved in wound closure including re-epithelialization, matrix remodeling, and tissue 
granulation.5-7  However, maintaining sufficient levels of NO for prolonged periods at a 
wound site remains a challenge.  Polyurethane barrier membranes have become a popular 
choice for wound closure devices because they facilitate adequate gas transport while 
maintaining a moist wound environment necessary to promote wound healing.  Future 
studies aim to incorporate NO-releasing dendrimers into polyurethane sheets as wound 
dressings to treat infected wounds and promote normal wound healing.  As shown in Figure 
5.2, polyurethane dressings doped with NO-releasing dendrimers release NO gas only at the 
wound site.  After use, the delivery vehicle may be discarded.  In clinical settings where 
topical delivery is required, both diazeniumdiolate and nitrosothiol-modified dendrimers may 
prove useful.  The lipophilicity of diazeniumdiolate-modified dendrimer and the water-
uptake properties of the polymer may be tuned and used to create dressings that upon 
“soaking” exhibit high, rapid amounts of NO-release, or lower prolonged fluxes with 
extended release durations.  Furthermore, polyurethane containing S-nitrosothiol modified 
dendrimers have the inherent ability to turn on and off the NO-release based on exposure to 
light. 
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Figure 5.1  Modification of a generation 3 polypropyleneimine dendrimer (DAB-
Am-16) to possess a diaminobutane core and 16 primary amines 
functionalized with NO donor moieties, a fluorescent label for imaging 
(FITC), and folic acid residues for targeting cancer cells in vivo. 
Folic Acid
NO
NO
NO
NO
NO
NO
NO
NO
NO
NONO
NO
Folic Acid
FITC
NO
NO = NO Donor Ligand
 170
Dermis
Fat
NO NONO NO
Epidermis
Bacterial
Contamination
NO NO NO NONO NO NO
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Figure 5.2 Diagram of a polyurethane wound dressing doped with NO-releasing 
dendrimers capable of delivering NO to infected wounds. 
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5.3 Strategies for Targeted NO Delivery 
In addition to doping NO-donor functionalized dendrimers into polymers, the synthesis 
and use of multifunctional NO-releasing dendrimers may benefit the treatment of disease 
states known to be influenced by NO. The need for site specific delivery to realize the 
potential of NO as treatments for two such applications, cancer and ischemia/reperfusion 
injury, are discussed below. 
5.3.1 Folic acid targeted anti-cancer therapeutics 
Nitric oxide mediates multiple stages of cancer development.  Unfortunately, the exact 
impact of NO on tumor cell biology remains unclear.8-10 Petit et al. hypothesize that low 
levels of NO (pM) may mediate angiogenesis and enhance tumor cell proliferation while 
higher fluxes of NO (µM) may form reactive nitrogen species capable of killing cancer 
cells.11  Several small molecule NO donors have shown efficacy against prostate, colon, and 
human breast cancers in vitro.  Still, elucidating the mechanistic effects of NO on cancerous 
cells in vivo has been problematic due to indiscriminate NO release.8, 12-16  Failure to deliver 
NO to specific cells and/or tissues of interest has limited its clinical development. 17-19  The 
primary obstacles impeding NO delivery to tumor tissue may be overcome through the 
development of multifunctional NO-releasing dendrimers.  
The goal of targeted drug delivery is to maximize the concentration of a drug in specific 
organs or tissues of interest, while minimizing the drug’s systemic distribution and toxicity to 
healthy cells.  Active targeting involves the attachment of a target-specific ligand to the 
carrier system exterior that will interact preferentially with tumor cell surface receptors over 
healthy tissue.20 For example, monoclonal antibodies target specific antigens on tumor cell 
surfaces and have been used to narrow the biodistribution and increase the efficacy of many 
pharmaceutical formulations.21-24 In cancer research, small ligands such as folic acid have 
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been used as a successful method of active drug delivery, targeting the over-expression of 
folate receptors in solid tumors.25-27  Up-regulation of the folate receptor has been observed 
in many human malignancies including ovarian, brain, kidney, endometrial and lung cancers, 
with minimal receptor expression in most normal tissues.25, 28, 29 The over-expression of 
folate receptors on the tumor cell surface is due to the high demand for nutrients in rapidly 
dividing cells. The lack of folate receptors coupled with the high affinity of folate for the 
folate receptor allows folate conjugates to exhibit enhanced, pinpoint selectively for diseased 
tissue. 26, 27, 30 28 The small size, convenient availability, and facile attachment methods to the 
exterior of nanoparticles may make folic acid an ideal ligand for targeted NO-delivery 
systems.  
An attractive feature of folic acid conjugated therapeutics is that folic acid retains its 
receptor binding properties when derivatized via its γ-carboxyl group.25  Several procedures 
have been reported previously for attaching folic acid to nanoparticle constructs.27, 30-32  A 
synthetic procedure modified from the one reported by Baker and co-workers is shown in 
Scheme 5.1.33  The folic acid may first be activated with NHS/DCC in a DMSO solution and 
then added to a suspension of dendrimer in DMSO aiming to stoichiometrically convert 10 of 
the 64 exterior amines.  The cyclized thiolactone of N-acetyl-D,L-penicillamine utilized in 
previous studies may also be added to convert the remaining amines to thiols.  Conversion of 
the thiols to S-nitrosothiols in an acidified nitrite solution may result in the first folate 
targeted NO-releasing dendrimer conjugate.  Direct conjugation of fluorophores for imaging, 
conversion of a portion of the amines to amides to reduce toxicity and increase vehicle 
solubility, or the attachment of poly(ethylene glycol) chains to improve biodistribution 
represent viable options for future conjugation to the dendritic framework (Figure 5.3).  
These chemistries may further unlock the power of dendrimers as NO-delivery vehicles.
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Scheme 5.1  Synthesis of folic acid dendrimer conjugate G4-FA7 and thiolated 
dendrimer conjugate G4-FA7-NAP. 
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PEG Chains
Folic Acid
NO Donor
Figure 5.3 Multifunctional NO-releasing dendrimer delivery vehicle containing 
folate residues for tissue specific targeting and poly(ethylene glycol) 
chains to enhance vehicle biodistribution.  
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5.3.2 Targeted S-nitrosothiol dendrimers to treat ischemia/reperfusion injury 
When an artery is clogged and blood flow through the heart is inhibited, heart tissue 
downstream of the blockage becomes deprived of oxygen and vital nutrients.  This process is 
known as ischemia.  Under such conditions, inflammation and other physiological changes 
occur to damage the heart muscle.  When the blockage is removed through percutaneous 
intervention, the re-establishment of blood-flow and oxygenation leads to oxidative stress 
causing further cell death and an excessive inflammatory response, also known as 
“reperfusion injury.”  Ischemia/reperfusion (I/R) injury is a major complication with 
treatments for heart attack patients as it often results in the loss of heart muscle function and 
reoccurring heart attacks.  To date, clinical trials have not identified an effective therapy for 
salvaging at-risk heart muscle after reperfusion therapy.34  
Since the discovery of NO as the endothelial derived relaxation factor,35  a number of 
studies have attempted to use NO to attenuate ischemia/reperfusion injury.36,37, 38   Nitric 
oxide mediates many of the processes contributing to I/R injury including platelet activation, 
interaction of leukocytes with the vessel wall, inflammatory response, and cardiomyocyte 
apoptosis.39 However, NO exhibits extremely sensitive and concentration dependent effects 
in models of I/R injury and has been reported to be both protective and detrimental, resulting 
in a controversy over the effects of experimental NO therapeutics.34  To further elucidate 
NO’s role in I/R injury, NO-releasing dendrimers with exterior residues for “sticking” the 
delivery vehicles to the vascular wall may be useful for creating a localized dose of NO in 
myocardial tissue.40  Polylysine and PAMAM dendrimers have already been utilized to 
enhance the retention of delivery vehicle to the vessel wall by binding to the extracellular 
matrix after intravascular delivery.41  As discussed in chapter 4, dendrimers like these 
possessing amine containing surfaces are highly cytotoxic toward endothelial cells that line 
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the vascular wall.  Cationic amine terminated vehicles should thus be avoided to create 
vehicles with acceptable toxicity profiles.  Ligands that show excellent specificity for 
targeting the endothelium should be employed like RGD peptide derivatives42, 43 (arginine, 
glycine, aspartate) and sialyl-Lewisx tetrasaccharides.44-46 
Sialyl Lewisx (sLex) oligosaccharides are key ligands expressed on leukocyte and on 
endothelial cell surfaces that are recognized by L-selectin.44  L-selectin belongs to a family 
of transmembrane glycoprotiens responsible for adhesion of leukocytes to the vascular 
endothelium in early cascade events of inflammation.  Dendrimer conjugates of sLex may 
exhibit excellent binding to the endothelium and provide prolonged NO-release during the 
inflammatory period of ischemia/reperfusion injury.  Since synthesis and further 
derivatization of tetrasaccharides is challenging, future studies could make use of classic 
avidin-biotin conjugation to attach sLex to G4-SNAP modified dendrimers to a protein 
delivery vehicle.40  As shown in Scheme 5.2, biotin-N-hydroxysuccinimide could be reacted 
with G4-PAMAM in DMF to biotinylate approximately 25% of the exterior amines (16 of 
64).  Following conversion of the remaining amines to S-nitrosothiols, the biotin modified S-
nitrosothiol dendrimer may be combined with commercially available sLex-biotin 
(Glycotech, Gaithersburg, MD) and 1 equivalent of NeutrAvidin (Pierce, Rockford, IL) to 
create protein-based clusters of RSNO dendrimer and sLex targeting ligand.  The multimeric 
protein would be capable of targeting the endothelium with the pendant sLex ligands and 
release NO via S-nitrosothiol chemistry.   
Dendrimers tailored to specifically interact with the endothelium and accumulate at cell 
surfaces would produce “local” reservoirs of NO.  Once exposed to the levels of glutathione 
present in blood or glutathione that may be added to reperfusion media NO-release will be 
intiated as described in Chapter 3.  This chemistry presents a major advancement over using 
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well dispersed small molecule NO donors (e.g., SNAP) in solution that would not result in 
“dendritic pockets” of NO when stimulated with GSH.   
5.4. Fluorescent Labeling and Near-IR Imaging 
Dendrimers are an isolated class of nanoparticle drug delivery vehicles, but the entire 
field is subject to caution from regulatory agencies and skeptics of nanotechnology.  As 
potential therapeutics that may end up saving human lives, each new drug delivery vehicle 
will be required to have a full exploration of its “nanotoxicology.”  One of the main concerns 
for nanoparticle drug delivery is the fate of the vehicle when it enters the body.  
Achievements made with NO-releasing dendrimers in the therapeutic areas described above 
will also endure the same scrutiny.   Subsequent work will thus require creating vehicles 
containing molecular probes for imaging in combination with the therapeutic doses of NO.  
Fluorescein isothiocyanate (FITC, green) and rhodamine-B-isothiocyante (RITC, red) are 
two commercially available dyes (Sigma-Aldrich or Invitrogen) that possess a handle for 
rapid reaction with amine terminated dendrimers and may prove useful for imaging 
dendrimer in tissue biodistribution experiments with fluorescence microscopy.  
Fluorescently-labeled dendrimers are also vital for understanding cellular interactions in 
vitro as evidenced in Chapter 4.  Near-infrared imaging will allow for imaging the 
biodistribution of IR dye-labeled dendrimers in whole rats, without harvesting individual 
organs.  IRDye® 800 CW is prepared as the NHS-ester for direct covalent attachment with 
proteins and dendrimer based delivery vehicles.  Dendrimers containing amines, amides, 
thiols, alcohols, PEG, or NO donors at the exterior may all be labeled with one or more of the 
dyes depicted in Figure 5.4 to monitor the systemic biodistribution after intravenous 
injection. 
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5.5 O2-protected Diazeniumdiolates 
In the future, O2-protected diazeniumdiolates may be utilized to create stable dendrimer-
NO adducts that exhibit enzymatic or pH triggered NO release. 47, 48  Saavedra and co-
workers have reported a strategy to package protected diazeniumdiolates with a carboxylic 
acid handle for conjugation chemistry.49  When coupling this chemistry to targeted delivery 
vehicles, concerns regarding the kinetics of ligand binding in vivo are paramount when 
deciding which O2-protecting group to use.50 For example, folic acid is metabolized by cells 
for essential cell functions, but the fate of the folate receptor-conjugate complex governs the 
potential therapeutic efficacy of the drug to be released.  For NO-releasing dendrimers, the 
mechanism of NO donor decomposition must compensate for the rate of folate-receptor 
conjugate internalization (kint), the rate of nanoparticle dissociation (knd), and the recycling of 
bound nanoparticle back to the tumor cell surface (kr), requiring that folic acid and other 
ligand receptor targeted nanoparticle conjugates contain an active or “triggered” mechanism 
of NO release. 
Sugar, acetal, vinyl, and photo-triggered protecting groups have all been utilized for the 
potential controlled release of NO from diazeniumdiolates.51, 52     Attaching a protected NO 
donor as a ligand to the dendrimer scaffold has the following advantages: 1) exposure of 
dendrimers to harsh diazeniumdiolate synthesis conditions (i.e., strong base) will be 
eliminated; 2) simple isolation and chromatography of the NO donor–modified dendrimers 
which is currently inaccessible after loading NO; and, 3) greater control over the exact 
quantity of NO loaded on the nanoparticle scaffold. 
5.5.1 Protected diazeniumdiolates with amine and carboxylic acid functionalities 
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Future studies should employ NO donor ligands for covalent modification of  dendrimers 
via either -COOH or -NH2 handles.  The simplest model will contain a secondary amine for 
conversion to a diazeniumdiolate NO donor and a reactive carboxylic acid for NHS coupling 
to an amine terminated exterior of G4-PAMAM.  Proline is an excellent example of such a 
precursor ligand.  However, diazeniumdiolate formation often results in the sodium salt of 
the carboxyl anion that also has reactivity with alkylating agents (e.g, MOM-Cl) (Scheme 
5.3A).  To avoid “blocking” the carboxylic acid that will be used to couple the protected NO 
donor to the dendrimer, prolinol could be used as the starting material.  Following charging 
under basic conditions and subsequent conversion to the MOM-ether, the alcohol could 
undergo a sharpless oxidation in a solution of RuCl3 and NaIO4 (Scheme 5.3B).49 
Alternatively the O2-protected ligand may consist of a polyamine containing one or more 
secondary amines for conversion to N-bound diazeniumdiolates. In this case, the primary 
amine termini could be coupled to carboxylic acid terminated half-generation dendrimers 
(e.g., G3.5 PAMAM).  This approach poses an additional synthetic challenge as early work 
has shown some conversion of primary amines to diazeniumdiolates upon exposure to NO.  
To avoid trace quantities of primary amine diazeniumdiolate, selective protection of the 
primary amines on the polyamine ligands would be necessary before conversion of the 
secondary amines to NO donors.  2-acetyldimedone has been used previously to protect only 
the primary amines of polyamine chains.53 Scheme 5.4 details the synthesis of a 
diethylenetriamine (DETA) functionalized ligand. The bis-N-[1-(4,4-dimiethyl-2,6-
dioxocyclohexylidene)ethyl] (DDE) derivative could be converted to diazeniumdiolate via 
standard diazeniumdiolate formation conditions and protected utilizing previously reported 
strategies.51, 52  The final step would require deprotection of the DDE protecting group with 
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2% hydrazine in DMF to yield the O2-protected DETA/NO ligand for coupling with the 
carboxyl-terminated dendrimers. 
  
 
5.5.2 pH sensitive acetals 
Macromolecular drug formulations containing pH sensitive triggers have shown 
increased cellular delivery of doxorubicin and other anti-cancer therapeutics.54-56 These 
carriers make use of the pH gradient of the endocytic pathway that begins with the 
physiological pH of the cell surface (e.g., pH 7.2-7.4), drops to a lower pH (5.5-6.0) within 
the endosomes, and approaches a relatively acidic pH in the lysosomal compartments 
(~5.0).57 In the future, the chemistry of O2-protected diazeniumdiolates may be expanded to 
provide triggered NO release chemistry utilizing the pH changes of intracellular components. 
Ideally, triggered on/off systems could be developed that turn the NO release “on” at or near 
endosomal pH and “off” at physiological pH. 
 Frechet and co-workers demonstrated that acetals are promising acid-sensitive 
linkages for conjugation to several alcohol functionalized therapeutics. They observed rapid 
hydrolysis and complete drug release at pH 5.0, while measuring minimal hydrolysis (10-
20%) at pH 7.4.58 The remarkable sensitivity of the alcohol protecting group to changes in 
pH makes this an attractive strategy for triggering NO release. Typically, the hydrolysis of 
acetal functionalized alcohols is first order relative to the concentration of hydronium ion 
(H3O+), making the expected rate of hydrolysis ten times faster with each unit of pH 
decrease.59  Several acetal functionalities have also been utilized as O2-protecting groups for 
diazeniumdiolate NO donors but have not been optimized for pH tunable NO-release.51 The 
nucleophilic character of the terminal oxygen in the diazeniumdiolate zwitterion has allowed 
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its straightforward conversion to acetals.  Initially reported by Saavedra et al., the methoxy 
methyl (MOM) protected diazeniumdiolate had a half life of >20 d at pH 7.4 and only 9 h in 
1 M HCl.52 Although this experiment required relatively harsh acidic conditions, it illustrates 
the stability of an NO donor at pH 7.4, but hydrolysis and NO release at a lower pH. 
Synthesis and testing of MOM-protected PYRRO/NO in our lab has confirmed these results 
(Figure 5.5).  Current literature suggests that acetal-protected diazeniumdiolates are 
synthetically accessible. Potential variations of cyclic acetal structures are depicted in Figure 
5.6.  These protecting groups, commonly employed for alcohols, may confer a pH sensitive, 
triggered mechanism of NO release.  Once an acceptable NO donor with the desired “on/off” 
pH behavior is obtained, this chemistry could be applied to dendrimer drug delivery vehicles 
through one of the previously described methods for O2-protected diazeniumdiolate 
dendrimer modification. 
5.6 Conclusion 
The innovation to covalently attach NO to a dendrimer was a logical step in the evolution 
of diazeniumdiolate and nitrosothiol chemistry.  Although previous small molecule NO 
donors have been optimized for desired NO-release kinetics, their therapeutic application 
falls short due to poor pharmacokinetics/biodistribution.  Next generation NO-releasing 
dendrimers may overcome such issues and allow the use of NO as a therapeutic against a 
number of disease states previously unattainable with current techniques (e.g., cancer, 
ischemia/reperfusion injury).  The preliminary data collected on some of the proposed future 
modifications to dendrimer scaffolds suggest that these chemistries are indeed feasible and 
may provide targeted, biocompatible drug delivery vehicles for NO.   
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Fluorescein isothiocyanate 
(FITC) 
Rhodamine-B- isothiocyanate 
(RITC) 
IRDye® 800CW NHS-ester 
Figure 5.4 Molecular probes used for imaging G4-PAMAM conjugates with 
fluorescence and near-IR spectrocscopy.  
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G4-SNAP48-Biotin16 
a 
b,c 
sLex-sp-biotin 
NeutrAvidin 
+ + 
sLex 
sLex 
NO NO
NO
NO
NO
NO
NO
NO
NO
NO
Scheme 5.2 Sialyl-Lewisx targeted NO-releasing protein delivery vehicle made 
from avidin conjugated G4-SNAP-Biotin and sLex-sp-biotin. A) NHS-
biotin, DMF; B) 3-acetamido-4,4-dimethylthietan-2-one, CH2Cl2; C) 1 
M HCl, NaNO2.  
Sialyl-Lewisx Targeted NO-releasing 
Protein Delivery Vehicle 
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A 
B 
Scheme 5.3 A) Diazeniumdiolate formation of PROLI/NO and reaction with 
methoxymethyl chloride (MOM-Cl) to form the doubly protected 
MOM ether which eliminates the carboxylic acid functionality. B) 
Conversion of prolinol to the O2-protected diazeniumdiolate which is 
oxidized up to the desired carboxylic acid residue for future coupling. 
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b
c
d
a
Scheme 5.4 Diazeniumdiolate modified polyamine ligand synthesis. A) 2-
acetyldimedone, DMF; B) 0.1M NaOMe/MeOH, 5 atm NO; C) 
ClCH2OMe, Na2CO3, THF; and d) 2% hydrazine in DMF. 
 186
pH = 7.4 
pH = 2 
pH = 7.4 
A 
B 
Figure 5.5 A) NO-release from PYRRO/NO at pH = 7.4. B) NO-release from O2-
MOM protected PYRRO/NO at pH = 2 and pH = 7.4.  
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Figure 5.6 A) Synthesis of THP-protected PYRRO/NO from the halogenation of 
2,3-dihydropyran to 2-chlorotetrahydropyran and reaction with 
PYRRO/NO diazeniumdioalte in THF/DMSO.  B) The series of acetals 
proposed to study and their pH sensitivity as alcohol protecting groups. 
(H = high, M = medium, L = low)
pH Sensitivity 
4 - 6 6 - 8.5 
L L  
M L  
H L  
A 
B 
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